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ABSTRACT 
Within the herpes simplex virus type 1 particle, a complex compartment termed the tegument 
is sandwiched between the nucleocapsid and envelope. Interactions between tegument 
components and the cytoplasmic tails of viral envelope glycoproteins are thought to play 
some role in the poorly defined process of tegument assembly. Here, virion incorporation of a 
major tegument protein, VP22, and the immediate-early transactivator of gene expression 
ICP0 was studied to improve our understanding of herpesvirus morphogenesis. 
In infected cells VP22 was found to bridge the viral glycoproteins gE and gM to form an 
assembly complex that also incorporates ICP0. VP22 is the major determinant for ICP0 
packaging, although both gE and gM were shown to be required for optimal recruitment of 
ICP0 into the complex and virion. The glycoproteins are redundant for VP22, but not ICP0, 
assembly. A conserved region of VP22, and N-terminal sequences known to facilitate VP22 
oligomerisation, contribute to complex formation. ICP0 domains important for VP22-ICP0 
association and ICP0 assembly include the functionally essential RING finger motif and 
ICP0’s C-terminus. The immediate-early protein ICP27, known to be required for ICP0 
assembly, was shown for the first time to be recruited into virions, independently of VP22 and 
ICP0. A mutant that packages enhanced levels of ICP0 exhibited augmented growth kinetics, 
implying that virion ICP0 performs important functions in infection. 
No impact of VP22 on ICP0 function could be determined, although a new role for VP22 in 
modulating gene expression was identified. Nevertheless, VP22 mutation modified ICP0 
localisation in infected cells. Interestingly, ICP0 was shown to enhance late stages of virus 
replication. ICP0-mediated ubiquitination within putative cytoplasmic assembly domains was 
characterised to further investigate this late function. 
This work significantly improves our understanding of how glycoprotein-tegument interactions 
lead to the formation of multicomponent assemblies involved in herpesvirus morphogenesis. 
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MDV  Marek’s disease virus 
MOPS  3-(N-morpholino)propanesulfonic acid 
mRNA  messenger RNA 
NCS  newborn calf serum 
ND10  nuclear domain 10 
NEDD8 neuronal-precursor-cell-expressed developmentally downregulated protein 8 
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B cells 
NLS  nuclear localisation signal 
ORF  open reading frame 
P300/CBP p300/CREB-binding protein 
PBS  phosphate buffered saline 
PCAF  p300/CBP-associated factor 
PCNA  proliferating cell nuclear antigen 
pfu  plaque-forming unit 
PIAS  protein inhibitor of activated STAT 
PML  promyelocytic leukaemia protein 
PML-NB promyelocytic leukaemia protein nuclear bodies (alternative name for ND10) 
POD  promyelocytic oncogenic domains (alternative name for ND10) 
PRV  pseudorabies virus 
rER  rough endoplasmic reticulum 
REST  repressor element 1-silencing transcription factor 
RING  really interesting novel gene 
RIPA  radioimmunoprecipitation assay (buffer) 
RNA  ribonucleic acid 
RNF8  RING finger protein 8 (and so on for RNF10 and 168) 
rpm  rotations per minute 
SDS  sodium dodecyl sulphate 
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SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SIAH-1 seven in absentia homolog 1 
SIM  SUMO-interacting motif 
siRNA  small interfering RNA 
Sp100  speckled protein of 100 kDa 
STAT  signal transducer and activator of transcription 
SUMO-1 small ubiquitin-related modifier 1 
SV5  simian virus 5 
SV40  simian virus 40 
TAP  tandem affinity purification 
Tas  transcriptional activator of spumaviruses 
TCR  T cell receptor 
TGN  trans-Golgi network 
TK  thymidine kinase 
TRAF6  tumour necrosis factor receptor-associated factor 6 
TRIM  tripartite motif 
Tris  tris(hydroxymethyl)aminomethane 
UBC  ubiquitin-carrier protein 
UBD  ubiquitin-binding domain 
UK  United Kingdom 
USA  United States of America 
USP7  ubiquitin-specific protease 7 
UV  ultraviolet 
VDAC1 voltage-dependent anion channel 1 
vhs  virion host shutoff protein 
VICE  virus-induced chaperone-enriched (domains) 
VP1/2 virion protein 1/2 (and so on for VP5, VP13/14, VP16 etc.) 
VZV  varicella-zoster virus 
YFP  yellow fluorescent protein 
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1.1 HERPES SIMPLEX VIRUSES 
Herpes simplex virus type 1 (HSV-1), formally human herpesvirus 1 (HHV-1) according to the 
International Committee on Taxonomy of Viruses nomenclature, is classified within the family 
Herpesviridae (277). HSV-1 is the prototypic member of the alphaherpesvirus subfamily, 
sharing 82% amino acid homology with herpes simplex virus type 2 (HSV-2), its closest 
relative (10, 277). All herpesviruses have four properties in common: they encode a large 
selection of enzymes involved in DNA synthesis, nucleic acid metabolism and 
posttranslational protein modification; genome replication and capsid assembly take place in 
the nucleus, and virion maturation is completed in the cytoplasm; infected cells are destroyed 
by virus particle production; they establish life-long latency within their host (277). 
1.1.1 TRANSMISSION AND DISEASE 
HSV-1 and HSV-2 share similar epidemiology and clinical manifestations and are transmitted 
readily via close personal contact (277). Primary HSV-1 infection typically occurs in early 
childhood depending on socioeconomic status and geographical location (277, 425, 498). As 
a rule HSV-1 causes asymptomatic or mild disease manifesting as vesicular oropharyngeal 
lesions (cold sores) at the site of infection (277). Latency is established in trigeminal ganglia 
and reactivation occurs throughout the lifetime of the host (277). HSV-1 can also be 
associated with genital lesions usually caused by HSV-2 (277). Serious disease is not 
uncommon, especially in neonates and immunocompromised patients, and HSV-1 is the 
leading cause of sporadic fatal encephalitis and the second most common cause of corneal 
blindness in the United States (277). HSV-1 is distributed globally across all ethnic groups 
(277). At up to 50%, the seroprevalence in the United Kingdom is low (425). 
1.1.2 TREATMENTS AND VACCINES 
The symptoms of HSV-1 and HSV-2 infection can be alleviated with antiviral therapies such 
as acyclovir, although these do not eradicate latent virus (277). There are no licensed 
vaccines against HSV-1 or HSV-2 (211, 563). 
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1.2 THE HERPESVIRUS PARTICLE 
The 152 kilobase linear double-stranded DNA genome of HSV-1 consists of one unique long 
(UL) and one unique short (US) segment, each flanked by inverted repeats (271, 277, 550). 
Gene products are currently named according to the genomic location of the open reading 
frame (ORF) encoding them (e.g. UL49), the relative position of virion proteins on a 
polyacrylamide gel (e.g. VP22), or as numbered infected cell proteins (e.g. ICP0) (277). Viral 
glycoproteins are designated by letters (e.g. gE) (277). 
The relatively large (168 nm diameter) and complex HSV-1 particle incorporates upward of 
forty virus-encoded proteins (201, 336). The linear genome is encased by an icosahedral 
capsid composed of VP5, VP19c, VP23, VP26 and UL6 (figure 1.1) (277). The capsid is 
surrounded by a proteinaceous structure known as the tegument and a host cell-derived 
envelope containing cellular proteins and viral glycoproteins (277, 336). 
1.2.1 THE TEGUMENT 
Mass spectrometry analysis of purified HSV-1 particles placed 54% of all identified peptides 
within the tegument, making this by far the largest virion compartment (336). Up to 23 viral 
tegument constituents have been identified to date (217, 336, 508). VP1/2 and VP16 are 
essential structural components (108, 276, 306, 559). Major tegument proteins include 
VP13/14 and VP22, which, at 1,500 to 2,000 molecules each, respectively represent 5% to 
10% and over 10% of the total protein content of the virion (217, 336). The tegument also 
contains host proteins; one study identified 49 cellular proteins, including cytoskeletal, heat-
shock and Rab proteins, within purified virions (336). Cellular and selected viral mRNAs have 
also been detected within virus particles (482). 
While the tegument, which looks granular with some fibrous elements by electron 
microscopy, is often described as amorphous, its structural integrity does not require the 
capsid or envelope (201, 277, 357). Tegument proteins can be classified as inner or outer 
components based on the strength of their association with the capsid (452, 569). The inner 
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Figure 1.1: The HSV-1 virion. (Adapted from 176). 
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tegument protein VP1/2 binds the capsid to form an icosahedral array, while the outer 
tegument is less ordered (84, 368, 591). Data from our group and others suggest tegument-
glycoprotein interactions facilitate tegument assembly and that, along with tegument-
tegument interactions, these associations bridge the capsid and viral envelope (75, 130, 172, 
178, 200, 305, 346, 365, 367, 387, 518, 548). 
1.3 HSV-1 LIFE CYCLE 
HSV-1 enters the body through damaged epithelia and initiates lytic replication in 
keratinocytes at the inoculation site (187, 218, 427). Following infection of sensory neurones 
innervating the epithelium and retrograde transport to the ganglion, HSV-1 establishes 
latency within the nucleus of a subset of ganglionic neurones (187, 345, 427, 446, 477). 
Reactivation from latency occurs throughout the lifetime of the host in response to stress, 
including exposure to ultraviolet (UV) light, anxiety and malnutrition (551). Transmission 
occurs during lytic replication in neurones and adjacent epithelial cells, or through 
asymptomatic shedding (10, 277). At the molecular level the life cycles of HSV-1 and HSV-2 
are similar, and many aspects of HSV-2 replication have been inferred from HSV-1 (551). 
1.3.1 ATTACHMENT AND ENTRY 
In tissue culture HSV-1 has been shown to enter cells via fusion at the plasma membrane or 
by atypical endocytosis depending upon cell type (10, 80). The glycoproteins gB, gD, gH and 
gL are essential for attachment and fusion, while gC performs an accessory role (63, 493, 
507). Initially gD binds one of its receptors nectins-1 and -2, herpesvirus entry mediator 
(HVEM) or 3-O sulphated heparan sulphate (10, 492, 507). Recruitment of gB, gC and the 
gH-gL heterodimer facilitates fusion of the viral and host membranes; this process may 
involve coreceptors reportedly targeted by gB, gC and/or gH (10, 18, 168, 423, 428, 476). 
Entry may be assisted by actin microfilaments and is accompanied by phosphorylation of 
host proteins (187, 449). Phosphorylation of tegument components by viral and cellular 
kinases is thought to promote tegument dissociation (377). At least a proportion of the 
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tegument remains attached to the membrane following viral entry (354). Inner tegument 
components remain capsid-associated and recruit the cellular microtubule motor dynein and 
its cofactor dynactin to facilitate microtubule-dependent capsid transport to the nucleus (115, 
269, 340, 452, 503, 569). The tegument proteins VP1/2 and UL14 have been implicated in 
nuclear targeting of capsids, and VP1/2 may also anchor the capsid to the nuclear pore 
complex (27, 86, 412, 577). The viral genome is injected into the nucleus through the nuclear 
pore complex in a process that, in vitro, is dependent upon importin-β (412). 
1.3.2 GENE EXPRESSION 
HSV-1 genes are expressed as three temporally regulated classes, immediate-early, early 
and late (277). Following dissociation from the tegument, the major viral transactivator VP16 
is transported to the nucleus independently of the capsid (28, 442). Along with cellular 
cofactors, VP16 promotes immediate-early gene expression (64, 191, 442, 512). The 
immediate-early proteins ICP0, ICP4, ICP22, ICP27 and US1.5 then coordinate to stimulate 
expression of the early genes required for viral genome replication (277). Late gene products 
accumulate after DNA replication has commenced and can be segregated into ‘leaky’ or 
‘true’ late proteins based on their requirement for genome replication (193, 277). 
1.3.3 LATENCY 
Latency is established when viral gene expression is not initiated, which may result from 
impaired VP16 function due to altered expression and/or localisation of its cellular cofactors 
in neurones (216, 290, 404, 427, 551). During latency the chromatin-associated HSV-1 
genome is silenced through hypoacetylation of lytic gene promoters (109, 292, 555). Only the 
region encoding the latency-associated transcripts (LATs) remains active (173, 511, 513). 
The stable nontranslated LATs are speculated to inhibit apoptosis and promote latency by 
enhancing heterochromatin assembly and histone methylation at viral promoters and/or by 
preventing translation from the LAT-antisense mRNA encoding the gene transactivator ICP0 
(56, 429, 523, 540, 555). Whether reactivation occurs at the level of immediate-early gene 
expression or viral DNA replication remains contested (61, 256, 286, 309, 427, 431). 
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1.3.4 GENOME REPLICATION AND CAPSID ASSEMBLY 
Upon infection, or following reactivation from latency, viral and host factors facilitate viral 
DNA replication via a rolling circle mechanism within a globular replication compartment that 
fills the nucleus (67, 97, 242, 320, 451, 505, 527, 572). Cellular chromatin becomes 
condensed and is marginalised to the nuclear periphery (376, 481). Autocatalytic capsid 
assembly and genome encapsidation occur in the replication compartment with the aid of 
viral scaffolding proteins (77, 98, 396, 397, 410, 524, 531, 532). Nucleocapsids acquire a 
primary envelope by budding through the inner nuclear membrane in a process involving 
UL31, UL34 and US3 (366, 367, 460-462). 
1.3.5 TEGUMENT ACQUISITION, ENVELOPMENT AND EGRESS 
The final steps in herpesvirus morphogenesis remain somewhat contentious (366-368). In 
one model, particles formed during budding at the inner nuclear membrane transit through 
the endoplasmic reticulum (ER) and Golgi and are released via the secretory pathway (311). 
It has also been reported that nuclear pores are altered during HSV-1 infection, although this 
remains contested (228, 367, 368, 565). In a second model, these structural changes 
facilitate capsid egress, with envelopment occurring at the outer nuclear membrane or within 
the secretory pathway (311). 
Finally, the widely accepted deenvelopment–reenvelopment model proposes that capsids 
enter the cytoplasm via deenvelopment of primary enveloped particles at the outer nuclear 
membrane (figure 1.2) (248, 366-368, 496). Secondary envelopment occurs by budding of 
inner tegument-coated capsids through membrane-associated outer tegument-glycoprotein 
structures (248, 366-368, 496). While final virion maturation is commonly stated as taking 
place within the trans-Golgi network (TGN) (248, 364, 367, 368), recent unpublished data 
from our group suggest secondary envelopment occurs at endocytic tubules (data not 
shown). Mature virions exit the cell via the secretory pathway (251, 366, 368). 
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In favour of the deenvelopment-reenvelopment model, the lipid content of mature HSV-1 
particles reflects the composition of Golgi- and plasma membrane-derived vesicles, not the 
nuclear membrane (543). Furthermore, the tegument proteins UL31 and UL34 are present 
only in nuclear particles, while VP13/14, VP16 and VP22 are found only in mature virions 
(55, 346, 372, 391, 452, 462, 569). These observations argue against mature particle 
formation via budding at the inner nuclear membrane (368). In addition, colocalisation 
between capsid, tegument and glycoproteins was observed on cytoplasmic, not nuclear, 
membranes of cells infected with independent triple-labelled fluorescent viruses (99, 519). 
The Herpesvirus Assembly Group at Imperial College London studies the late stages of 
alphaherpesvirus morphogenesis. This thesis explores the roles of the tegument protein 
VP22 and the glycoproteins gE and gM in recruiting ICP0 into the HSV-1 particle. 
1.4 ICP0 FUNCTION AND IMPORTANCE 
The 775-residue immediate-early protein ICP0 is a promiscuous transactivator of viral and 
heterologously expressed genes, and a subset of p53-responsive cellular genes (60, 74, 
140, 146, 192, 209, 225, 388). ICP0-null mutants initiate productive replication inefficiently at 
low multiplicities of infection; however, once established, or at high multiplicities, these 
viruses replicate as well as wild-type HSV-1 (60, 142, 145, 149, 470, 514, 583). This defect is 
most pronounced in limited-passage human fibroblasts and cells of neuronal origin (142, 
145, 149, 232, 470, 514). ICP0 also enhances pathogenicity in animal models (196). 
The propensity of ICP0-null HSV-1 to establish latency is caused by an impairment 
downstream from immediate-early gene expression (60, 149, 440, 441). Although exogenous 
ICP0 induces reactivation from latency in tissue culture, Thompson and Sawtell reported that 
ICP0 enhances reactivation but is dispensable for initiation of reactivation in vivo (369, 530). 
1.4.1 THE ICP0 GENE AND ITS EXPRESSION 
ICP0 is encoded by the diploid RL2 gene located within the UL-flanking inverted repeat 
region, and is not conserved outside of the alphaherpesvirus subfamily (145, 209, 269). 
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Figure 1.2: Deenvelopment-reenvelopment model of herpesvirus assembly. Nuclear capsids 
acquire a primary envelope and tegument by budding through the inner nuclear membrane 
(INM). Perinuclear particles enter the cytoplasm via deenvelopment at the outer nuclear 
membrane (ONM). Final tegument and envelope are acquired by budding into sites within 
the late secretory pathway, shown here as Golgi or TGN, or at endocytic tubules (not 
shown). Mature virions are released via the secretory pathway. (Adapted from 248). 
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While the ICP0 homologues of varicella-zoster virus (VZV), the causative agent of chicken 
pox and shingles, bovine herpesvirus type 1 (BHV-1), equine herpesvirus type 1 (EHV-1) and 
the porcine pathogen pseudorabies virus (PRV) diverge at the sequence level, a degree of 
function is preserved (148, 421, 422). RL2 is one of the few intron-containing HSV-1 genes, 
and a repressor of ICP0 activity called ICP0R is expressed from alternatively spliced mRNA 
in some cell types (figure 1.3A) (151, 209, 506, 558). 
1.4.2 PROTEIN FUNCTIONAL DOMAINS AND POSTTRANSLATIONAL MODIFICATION 
A N-terminal zinc-binding cysteine-rich really interesting novel gene (RING) finger (figure 
1.3B) is the only motif conserved among all ICP0 homologues and is essential for ICP0’s 
ability to transactivate gene expression and enhance virus replication (139, 142, 147, 148, 
155, 181, 182, 421, 422). The RING finger and a novel C-terminal herpes virus ubiquitin 
ligase 1 (HUL-1) motif are reported to function as E3 ubiquitin ligases in vitro and in vivo (48, 
144, 208). ICP0 also encodes a nuclear localisation signal (NLS) and sequences required for 
self-interaction and localisation to cellular nuclear domain 10 (ND10) structures (79, 141, 
351, 362). A C-terminal motif that binds the cellular ubiquitin-specific protease 7 (USP7) 
protects ICP0 from autoubiquitination and enhances ICP0 stability, although a balance is 
struck between ICP0-USP7 binding and ICP0-dependent ubiquitination and proteasomal 
degradation of USP7 (45, 65, 157, 362, 363). 
ICP0 is phosphorylated by cell division control protein 2 (cdc2) and the viral kinase UL13 at 
eleven serine and threonine residues contained within three clusters (figure 1.3B) (1, 46, 95, 
411). Along with casein kinase II (CKII)-dependent nucleotidylylation, these modifications 
result in several temporally regulated ICP0 isoforms (34, 35, 373, 374, 430). 
1.4.3 FUNCTIONS OF ICP0 
ICP0 enhances gene expression at or before the level of transcription initiation, and since 
ICP0 does not bind DNA directly the consensus is that a combination of its biological 
activities leads to gene transactivation (145, 147, 159, 209, 256). 
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In a model championed by Bernard Roizman, viral gene expression is silenced by a cellular 
repressor complex composed of histone deacetylases 1 and 2 (HDAC1/2), repressor 
element 1-silencing transcription factor (REST) and corepressor of REST (CoREST) (467, 
468, 590). An interaction between ICP0 and CoREST is proposed to dissociate HDAC1/2 
from the complex; subsequent CoREST phosphorylation by viral kinases precedes late gene-
dependent translocation of CoREST and HDAC1/2 to the cytoplasm (202, 440, 467, 468, 
590). In line with this theory, Gu and Roizman observed a 10- to 100-fold cell type-dependent 
increase in replication of HSV-1 expressing a CoREST construct unable to bind HDAC1/2 
compared with the parental ICP0-null mutant (204). Furthermore, HDAC inhibitors induce 
HSV-1 reactivation in some tissue culture and animal models, while expression of dominant-
negative CoREST enhances in vivo virulence (15, 92, 122, 394, 528). However, Roger 
Everett and coworkers observed no effect of CoREST depletion on the replication of wild-
type or ICP0-null HSV-1, and demonstrated that the CoREST-binding domain of ICP0 is 
dispensable for derepression of HSV-1 genomes (143, 162). In addition, recent data from the 
Roizman laboratory describes a counterintuitive decrease in wild-type HSV-1 replication in 
the presence of small interfering RNAs (siRNAs) directed against CoREST or REST (590). 
Roger Everett and coworkers propose that ICP0 instead counteracts an intrinsic antiviral 
defence posed by ND10 (section 1.8) by targeting a subset of ND10 components labelled 
with the small ubiquitin-related modifier 1 (SUMO-1) for proteasomal degradation (71, 150, 
153, 421). Degradation and dispersal of ND10 components, including the promyelocytic 
leukaemia (PML) protein, speckled protein of 100 kDa (Sp100) and human death-associated 
protein 6 (hDaxx), is linked to the RING finger-dependent inhibition of SUMO-1 conjugation 
and subsequent ubiquitination of these substrates (47, 71, 153, 385, 421). Importantly, 
siRNAs against PML and Sp100 enhance viral gene expression and plaque formation in 
ICP0-null, but not wild-type, HSV-1 (161, 163). Furthermore, ICP0’s E3 ubiquitin ligase 
activity is essential for ND10 dispersal, gene transactivation and low multiplicity HSV-1 
replication in fibroblasts (48, 139, 142, 145, 155, 166, 209). Recently ICP0 was also shown 
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Figure 1.3: ICP0 ORF and protein functional domains. (A) Intron-exon map of the ICP0 ORF 
illustrating how alternative splicing results in expression of ICP0R, which maps to exons 1 
and 2 plus a short glycine-rich domain (grey) encoded by the unspliced intron 2 (506). Exons 
are labelled with the codons they encode. (B) Schematic of ICP0 protein domains with 
phosphorylation sites represented by triangles as follows; cluster I (S224, T226, T231, T232), 
cluster II (S365, S367, S371) and cluster III (S508, S514, S517, T518) (95). RING finger 
(residues 116 to 156) and HUL-1 (618 to 680) E3 ubiquitin ligase domains are highlighted in 
orange (141, 208). The NLS (474 to 509) is shown in beige (141). Green domains below the 
schematic facilitate ICP0 multimerisation and localisation to ND10 (79, 351). Brown domains 
mediate interactions with USP7 and CoREST (156, 204). Flanking residues are specified. 
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to target the cellular DNA damage ubiquitin ligases RING finger proteins 8 and 168 
(RNF8/168), which constitute another intrinsic antiviral defence, for degradation (321, 322). 
Several reports suggest that ICP0 suppresses cytokine secretion by independently blocking 
signalling via interferon regulatory factor 3 (IRF-3) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) (94, 127, 324, 360, 361, 379, 419, 544). This activity is 
distinct from ICP0-dependent ND10 dispersal, since intact ND10 are not required for the 
interferon sensitivity of ICP0-null HSV-1 (165). Furthermore, CKII inhibitors were recently 
shown to increase the interferon-sensitivity of HSV-1 in an ICP0-dependent manner without 
affecting ND10 disruption (499). Nevertheless, IRF-3 depletion does not rescue the plaque 
forming phenotype of ICP0-null mutants (165). 
ICP0 interacts with class II HDACs in glutathione S-transferase (GST) binding assays and 
has been suggested to enhance histone acetylation and reduce histone occupancy at viral 
promoters, though this remains controversial (81, 83, 174, 175, 333, 528). HDAC inhibitors 
do not compensate for ICP0 in all cell types, and reactivation induced by ICP0 and HDAC 
inhibitors follows different kinetics (161, 528). Furthermore, Hancock et al. report that VP16, 
and not ICP0, reduces histone occupancy and enhances histone acetylation (213). 
G2/M growth arrest, prevention of ribosomal RNA degradation, an innate antiviral response, 
and disruption of HSV-1 genome circularisation, which may facilitate genome persistence 
during latency, have also been attributed to ICP0 (66, 225, 241, 313, 502). ICP0 also 
reportedly interacts with translation elongation factor 1δ, cyclin D3 and the transcription 
factor BMAL1, and induces the degradation of centromere proteins CENP-A, -B and -C, the 
transcription factor E2FBP1, the catalytic subunit of DNA-dependent protein kinase and the 
cell surface marker CD83 (152, 186, 266-268, 293, 308, 331, 332). 
1.4.4 ICP0 LOCALISATION DURING HSV-1 INFECTION 
ICP0 is detectable within ND10 from 2 hours postinfection (hpi) at high multiplicities of 
infection (155, 277, 352). At later times ICP0 exhibits a punctate cytoplasmic distribution 
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(129, 155, 266). In Vero, human epidermoid carcinoma 2 (HEp-2), baby hamster kidney 
(BHK) and Madin-Darby bovine kidney (MDBK) cells this shift occurs 4 to 6 hpi (129, 155, 
266). In human foetal foreskin fibroblast (HFFF) cells ICP0 is predominantly cytoplasmic by 3 
hpi, hinting at cell type-specific differences in the factors modulating ICP0 localisation (266). 
Although ICP0 is often said to translocate from the nucleus to the cytoplasm (258, 335, 346, 
545), this has not been unequivocally proven. Since the half-life of ICP0 is approximately 60 
minutes, newly synthesised ICP0 may be retained in the cytoplasm rather than shuttling 
between the two compartments (203, 467). 
1.4.5 EVIDENCE FOR INCORPORATION OF ICP0 INTO THE HSV-1 PARTICLE 
Yao and Courtney first identified ICP0 in extracellular virions collected from Vero and HEp-2 
cells (582). The authors proposed that ICP0 is a tegument component, since virion ICP0 was 
resistant to a detergent treatment that removed the viral envelope and was not detected in 
intranuclear capsids (582). More recently ICP0 was detected in extracellular virions purified 
from HeLa, A549 and Vero cells (336, 416, 486). Along with the identification of ICP0 in 
virions of HSV-1 strains KOS, F and 17+, these data indicate that ICP0 assembly is not cell 
type- or virus strain-specific (129, 336, 486, 579, 582). Yao and Courtney estimated virions to 
contain 150 ICP0 molecules using densitometric analysis of 14C-labelled virions visualised by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (582). Loret et al. 
estimated ICP0 to represent 1% to 4% of the virion’s total protein content by mass 
spectrometry (336). By both accounts ICP0 is a minor virion component. 
Although now widely accepted, for a time ICP0 virion incorporation remained controversial 
(129, 258, 336, 486, 579, 582). In particular Kalamvoki et al. failed to identify colocalisation of 
ICP0 with intracellular virions by immunoelectron microscopy (258). 
1.4.6 THERAPEUTIC RELEVANCE OF ICP0 
Given the importance of ICP0 to simplex virus replication, an ICP0-null HSV-2 live-
attenuated vaccine is in development, with some success in animal models (210, 211). 
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1.5 VP22 FUNCTION AND IMPORTANCE 
The 301-residue leaky late tegument protein VP22 is encoded by the UL49 gene, and is not 
conserved outside of the alphaherpesvirus subfamily (184, 277, 314). 
1.5.1 PROTEIN FUNCTIONAL DOMAINS AND POSTTRANSLATIONAL MODIFICATION 
To date all known VP22 functions map to the C-terminal half of the protein, although N-
terminal sequences contribute to VP22 multimerisation (figure 1.4) (207, 347, 381). A stretch 
of amino acids conserved in the VP22 homologues of HSV-1, BHV-1, EHV-1, VZV and the 
chicken pathogen Marek’s disease virus (MDV) are essential and sufficient for VP22 virion 
incorporation (207, 381, 408). In HSV-1 VP22 this region interacts with VP16 and gE (207, 
408, 409). Despite speculation that VP16 and/or gE might therefore recruit VP22 into the 
virion (130, 207, 408), O’Regan et al. demonstrated that VP16 and gE are individually and 
jointly dispensable for VP22 assembly (407, 409). 
VP22 contains six serine phosphorylation sites targeted by UL13 and the cellular kinases 
CKII and protein kinase C (87, 135, 136, 377). Although phosphorylated VP22 predominates 
in infected and transfected cells, the nonphosphorylated form is enriched in virions; however 
phosphorylation does not absolutely control VP22 packaging in HSV-1 (136, 278, 377, 443). 
VP22 is also nucleotidylylated and (ADP)-ribosylated (34). 
1.5.2 LOCALISATION OF VP22 IN INFECTED CELLS 
VP22 exhibits a diffuse cytoplasmic distribution from 3 hpi in Vero cells infected at high 
multiplicity (134). Later, large static VP22 accumulations appear alongside smaller VP22 
puncta that traffic rapidly to the cell surface in a manner reminiscent of secretory vesicles 
(134, 519). These domains have been proposed to respectively represent tegument 
assembly sites and mature virions during egress (134, 519). A subpopulation of VP22 
localises to punctate nuclear domains surrounding but segregated from the replication 
compartment (235, 439). López et al. also detected VP22 in the vicinity of the nucleolus 
(334). While Pomeranz and Blaho reported that phosphorylated VP22 is predominantly 
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nuclear, and nonphosphorylated VP22 cytoplasmic, in infected cells, we saw no difference in 
VP22 localisation using independent mutant viruses (439, 443). Furthermore, Geiss et al. 
saw no effect of phosphorylation on VP22 localisation during HSV-2 infection (190). 
1.5.3 ROLE OF VP22 IN HSV-1 REPLICATION 
The functions of VP22 remain incompletely understood. Although a major tegument protein, 
VP22 is dispensable for HSV-1, BHV-1 and PRV virion production (102, 124, 129, 317, 438). 
Actin has been shown to replace VP22 in the tegument of VP22-null PRV (101). 
Nevertheless, VP22 enhances low multiplicity replication of HSV-1 in epithelial cells, and 
BHV-1 virulence in vivo (124, 129, 317). The VP22 homologues of VZV and MDV are 
essential for replication (119, 536). The replication defect of VP22-null HSV-1 is thought to 
stem from a deficiency in cell-to-cell spread (124, 438). VP22 itself spreads between cells 
and this activity maps to VP22’s extreme C-terminus (figure 1.4) (8, 9, 52, 133, 403). Duffy et 
al. speculated that VP22 augments virus release via effects on vesicular traffic or through 
known interactions with viral glycoproteins, while Elliott and O’Hare proposed that 
intercellular spread of VP22 primes adjacent cells for infection (124, 133). 
VP22 expressed by transfection binds, bundles and stabilises microtubules and induces their 
hyperacetylation, and causes loss of the microtubule organising centre (132, 288, 347). The 
minimal microtubule-binding domain maps to residues 108 to 212 of VP22; flanking regions 
have been proposed to facilitate microtubule cross-linking (347). While it was suggested that 
VP22 might contribute to microtubule-dependent capsid trafficking during entry or egress 
(132), Beate Sodeik and coworkers recently reported this not to be the case (452, 569). 
During infection microtubules are not bundled and reorganised in the same manner, perhaps 
because interactions with viral proteins titrate VP22 away from microtubules (132). 
Defining a role for VP22 is complicated by the fact that some VP22-null viruses carry 
secondary mutations in the UL41 gene encoding the virion host shutoff protein (vhs) (483). 
This tegument-associated endoribonuclease degrades host mRNAs to enhance viral gene 
expression at early times of infection and also promotes the switch from early to late gene 
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Figure 1.4: VP22 functional domains. VP22 schematic with a region conserved among the 
HSV-1, BHV-1, EHV-1, VZV and MDV VP22 homologues (grey), and serine phosphorylation 
sites located at residues 35, 71, 72, 73, 292 and 294 (triangles), is shown above (381, 443). 
Green domains are involved in VP22 dimerisation, cell-to-cell spread and localisation to 
nuclear dots (133, 207, 381, 403). Brown domains mediate interactions with gE (as shown by 
us and O’Regan et al.), VP16 and microtubules (flanking regions included in the optimal 
microtubule-binding domain may facilitate microtubule cross-linking) (207, 347, 408). 
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expression (128, 167, 294, 295, 456, 515, 587). VP22 and vhs form a complex via their 
shared binding partner VP16 (275, 497, 522). Since vhs is not active within this complex it 
has been proposed that VP22 and VP16 modulate vhs activity (125, 275, 299, 483, 522). 
VP22 is highly basic and nonspecifically binds nucleic acids, with a preference for single-
stranded DNA (117, 484). VP22 has also been shown to mediate intercellular transport and 
virion incorporation of mRNA; both functions were suggested to enhance early stages of 
HSV-1 replication (406, 484). 
ICP0 is not incorporated into VP22-null HSV-1 particles (124, 129). Furthermore, at late 
times of infection VP22 and ICP0 colocalise in punctate cytoplasmic domains thought to be 
involved in tegument assembly (129). Therefore our group first proposed a role for VP22 in 
facilitating ICP0 assembly (129). 
1.5.4 COMMERCIAL APPLICATIONS 
VP22’s capacity to bind nucleic acids and spread between cells has been exploited in the 
development of peptide and nucleic acid delivery vehicles for DNA vaccines and anti-tumour 
therapies (40, 234, 386, 403, 406, 578). 
1.6 ROLES OF VIRAL GLYCOPROTEINS IN HSV-1 REPLICATION 
Additional to their role in entry, viral glycoproteins are thought to facilitate secondary 
envelopment via interactions with the outer tegument (365, 366, 368). In HSV-1, reported 
glycoprotein-tegument interactions include those between gE and UL13, gE and VP22, gH 
and VP16 and gD and VP22 (75, 172, 200, 399, 408). While some glycoproteins, including 
gB, are conserved among the herpesviruses, others are not; gD for instance is unique to the 
simplex viruses (10, 493). Glycoproteins relevant to this thesis are discussed below. 
1.6.1 GLYCOPROTEINS E AND I 
The US7 and US8 gene products gI and gE form a noncovalently linked heterodimer and are 
conserved across the alphaherpesviruses (178, 249, 277). While the gE-gI complex is 
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essential for MDV and VZV replication, it is nonessential in HSV-1, PRV and EHV-1 (82, 243, 
344, 480, 557). However, simultaneous deletion of the PRV and EHV-1 gE and gM 
homologues reportedly impairs secondary envelopment (49, 50, 487). A redundant role for 
gE and gD in HSV-1 morphogenesis remains contentious (170, 304). The gE-gI complex is a 
virion component but does not contribute to HSV-1 attachment and entry (112, 113, 336). 
In addition to its redundant role in secondary envelopment, the gE-gI complex is required for 
efficient cell-to-cell spread of HSV-1 in tissue culture and in vivo (112-114, 194, 454). The 
complex accumulates in the TGN via recycling from the plasma membrane and/or internal 
vesicles, and in polarised epithelial cells is sorted to cell junctions at late times of infection 
(12, 171, 252, 359, 567, 568). TGN localisation is likely mediated by the clathrin adaptor 
proteins AP-1 and AP-2, which bind conserved TGN sorting motifs within the cytoplasmic tail 
of gE (171, 252, 359, 414, 534, 567). Localisation of the gE-gI complex to both the TGN and 
cell junctions is required for gE-gI-dependent targeting of virus progeny to basolateral cell 
junctions for direct cell-to-cell transmission (171, 252, 359, 567). Cell-to-cell viral spread may 
also involve putative interactions between the extracellular domains of gE and gI and cellular 
receptors enriched at cell junctions (436, 567). 
In addition, the gE-gI complex forms an Fc receptor that binds and blocks immunoglobulin G 
to prevent immune clearance of infected cells by antibody- and complement-dependent 
cytotoxicity (29, 123, 179, 249, 250, 389). 
1.6.2 GLYCOPROTEIN M AND THE UL49.5 GENE PRODUCT 
The UL10 (gM) and UL49.5 genes of HSV-1 are conserved across the Herpesviridae family 
(89, 184, 375). In PRV, the betaherpesvirus human cytomegalovirus (HCMV) and the 
gammaherpesviruses HHV-8 and Epstein-Barr virus (EBV) the UL49.5 gene product is 
glycosylated and is called gN; the nonglycosylated homologues of HSV-1, BHV-1 and EHV-1 
are referred to as UL49A (2, 254, 289, 297, 318, 341, 469). The topology of the type III 
integral membrane protein gM is conserved, with eight transmembrane domains and 
cytosolic N- and C-termini (25, 356). Though not formally proven for HSV-1, the gM and 
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UL49A/gN homologues of other herpesviruses form disulphide bond and/or noncovalently 
linked heterodimers (253, 289, 297, 318, 341, 342, 469, 471, 573, 588). In EHV-1, EBV and 
HHV-8, but not PRV, UL49A/gN is required for gM maturation; HSV-1 UL49A enhances gM 
activity (89, 253, 274, 289, 297, 469). The complex is essential in MDV, HCMV and EBV, but 
nonessential in HSV-1, PRV, BHV-1 and EHV-1 (23, 54, 111, 226, 283, 296, 343, 417, 537). 
While virion incorporation of gM is conserved, assembly of the UL49.5 gene product may be 
virus specific and remains contentious in HSV-1 (2, 23, 121, 247, 254, 336, 547). 
In transfected cells the HSV-1 and PRV gM homologues inhibit syncytium formation induced 
by gB, gD and gH-gL by retrieving gD and gH-gL from the plasma membrane to the TGN 
(89). Since gM and the gE-gI complex function redundantly in PRV and EHV-1 secondary 
envelopment (49, 487), a role for gM in recruiting glycoproteins to intracellular assembly sites 
was inferred (89). Reduced presentation of immunogenic glycoproteins was also proposed to 
facilitate immune evasion (89). Although TGN-resident in transfected cells, gM additionally 
localises to the inner and outer nuclear membranes during HSV-1 infection, where it has 
been suggested to inhibit gB-, gD- and gH-gL-induced fusion (25, 89, 588). Unidentified viral 
factors are thought to target gM to the nuclear envelope early in infection by restricting its 
entry into the secretory pathway, while TGN redistribution and UL31 and UL34 may contribute 
at later times (25, 566, 588). Nuclear egress of HSV-1 capsids is reportedly independent of 
gM, however Zhang et al. highlighted known redundancies in glycoprotein function and 
proposed that, as in other herpesviruses, HSV-1 gM induces or maintains membrane 
invaginations to facilitate primary envelopment (57, 307, 434, 588). 
1.7 THE UBIQUITIN PATHWAY 
Ubiquitination, or ubiquitylation, is the covalent attachment of the 76-residue globular 
signalling protein ubiquitin, conserved in eukaryotes but not prokaryotes, as monomers or 
polymeric chains onto a target substrate (433, 561, 562). Five homologous and two 
nonhomologous ubiquitin-like proteins have been identified, including SUMO isoforms 1 to 4, 
interferon-stimulated gene 15 (ISG15), neuronal-precursor-cell-expressed developmentally 
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downregulated protein 8 (NEDD8) and autophagy proteins Atg8 and Atg12 (561, 562). Only 
ubiquitin and SUMO-2 and -3 form polymeric chains (562). Ubiquitin is the most common and 
functionally diverse member of the family (562). 
1.7.1 THE UBIQUITIN CONJUGATION PATHWAY 
Ubiquitination is catalysed by a series of three enzymes, enzyme 1 (E1), E2 and E3 (figure 
1.5) (561, 562). The human genome is predicted to encode three E1, fifty E2 and 600 E3 
proteins (257). The E1 activates the ubiquitin monomer, which forms a thiolester bond with 
E1 via its C-terminal glycine (561, 562). Ubiquitin is then transferred to an E2 ubiquitin-carrier 
protein (UBC) (561, 562). The E2 acts cooperatively with an E3 ubiquitin ligase, which 
confers substrate specificity, to attach ubiquitin to the target (561, 562). A novel class of E4 
ligases reportedly promotes E3-dependent ubiquitin chain elongation (280). The ubiquitin 
pathway is regulated by deubiquitinating enzymes (DUBs), of which the ubiquitin-specific 
proteases (USPs) are the largest of five subfamilies (282, 401, 561, 562). Sumoylation is 
catalysed in an analogous pathway with distinct E1, E2 and E3 enzymes (244, 561, 562). 
Based on their catalytic domains, E3 ubiquitin ligases are assigned to two major classes 
(244). The 350-residue homologous to (human papillomavirus) E6-associated protein C-
terminus (HECT) catalytic domain forms a thiolester bond with ubiquitin, with a conserved 
cysteine catalysing the transfer of ubiquitin from the E2 to the target (219, 432). The globular 
zinc-binding RING catalytic domain acts as a scaffold that mediates E2-substrate interaction 
(219, 432). RING E3 ligases, the largest E3 family, do not directly bind ubiquitin and require 
additional sequences to catalyse ubiquitination (219, 432). The RING E3 ligase ICP0 acts in 
conjunction with the E2 conjugating enzymes UbcH5a and UbcH6 in vitro (48). 
1.7.2 TYPES OF UBIQUITIN MODIFICATION 
Monoubiquitinated substrates are modified with a single ubiquitin molecule, while 
multiubiquitination describes the conjugation of multiple ubiquitin monomers (562). The 
attachment of one or more polymeric ubiquitin chains is called polyubiquitination (562). In 
CHAPTER 1   General Introduction 
 
 54 
 
 
 
 
 
 
 
Figure 1.5: The ubiquitin pathway. Ubiquitin (Ub) is activated via ATP-dependent 
conjugation to the E1 enzyme before transfer to the E2 UBC protein. Ubiquitin is attached to 
the target protein by an E3 ubiquitin ligase in conjunction with E2. Deubiquitinating 
(deubiquitylating) enzymes regulate the pathway by cleaving the isopeptide bond linking 
ubiquitin to the substrate. Substrate degradation in the 26S proteasome, the classical 
outcome of K48 polyubiquitination, is also shown. (Adapted from 78). 
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each case the C-terminal glycine of ubiquitin is linked via an isopeptide bond to a lysine 
residue on the substrate or preceding molecule within a polyubiquitin chain (562). 
Ubiquitination at noncanonical sites, including the N-terminal amino acid and internal 
cysteine residues, has also been reported (19, 36, 51, 58). Ubiquitin polymers can be 
extended via each of ubiquitin’s conserved lysines at positions 6, 11, 27, 29, 33, 48 and 63 
(244). The E2/E3 complex is thought to determine linkage specificity by presenting a single 
acceptor lysine for chain elongation (316). All types of ubiquitin linkage have been detected 
in vivo, with K63- and K11-linked chains being the most abundant after K48 (426). 
A hydrophobic surface within ubiquitin composed of L8, I44 and V70 is recognised by 
proteins carrying various classes of ubiquitin-binding domains (UBDs) (223, 265, 316, 382). 
Although they bind polyubiquitin chains with a higher affinity than monoubiquitin conjugates, 
most UBDs exhibit no linkage specificity (223, 316). Linkage preference is likely conferred by 
independent protein domains or other factors within a receptor complex (316). 
1.7.3 FUNCTIONS OF UBIQUITINATION 
Table 1.1 summarises the known roles of ubiquitin. The classical function involves the 
formation of K48-linked chains of four or more ubiquitin molecules that target the substrate 
for degradation by the 26S proteasome, a multisubunit complex with chymotrypsin-like, 
trypsin-like and caspase-like proteolytic activity (78, 533, 549, 561). K11-linked polyubiquitin 
also directs the proteasomal degradation of specific targets involved in cell cycle regulation 
and the ER-associated protein degradation (ERAD) pathway (13, 20, 246, 433). 
K63-linked chains function in diverse cellular processes (272, 561). These include: error-free 
DNA repair via modification of the DNA polymerase processivity factor proliferating cell 
nuclear antigen (PCNA); inflammatory responses by facilitating activation of inhibitor of NF-
κB kinase (IKK); protein synthesis via polyubiquitination of the mitochondrial ribosomal 
subunit L28; cell signalling by enhancing ubiquitin-dependent endocytosis of receptor 
tyrosine kinases (4, 188, 222, 227, 383, 433, 509, 510, 561, 562). A role in the autophagic 
elimination of misfolded protein aggregates has also been proposed (272, 316). 
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The functions of nonconventional linkages are less well characterised (316). K27-linked 
chains may facilitate autophagic removal of mitochondria (mitophagy) via modification of the 
mitochondrial voltage-dependent anion channel 1 (VDAC1), and regulate transcription by 
recruiting coregulators around the transcription factor androgen receptor and by targeting the 
transcription factor Jun for lysosomal degradation (189, 236, 574). K6-linked ubiquitin 
polymers also regulate androgen receptor, and protect proteins such as the breast cancer 
susceptibility gene product BRCA1 from proteasomal degradation (316, 402, 488, 574). K29-
linked chains target substrates of the HECT E3 ligase atrophin-1-interacting protein 4 (AIP4) 
to the lysosome, and may regulate phosphorylation of AMP-activated protein kinase (AMPK)-
related kinases (11, 68). K33-linked polyubiquitination may also regulate AMPK-related 
kinase activity, and modifies T cell receptor ζ phosphorylation and T cell activation (11, 233). 
Monoubiquitination acts as an internalisation signal and may modify the clathrin-based 
endocytic machinery to stimulate endocytosis of plasma membrane receptors and ion 
channels, targets internalised cargo for lysosomal degradation via sorting to multivesicular 
bodies, functions during meiosis by modifying histone H2B and targets PCNA to promote 
error-prone DNA repair (215, 220, 221, 312, 383, 444, 453, 465, 466, 490, 516, 542, 562). 
1.8 STRUCTURE AND FUNCTION OF ND10 
ND10 are also called PML nuclear bodies (PML-NB), promyelocytic oncogenic domains 
(POD) or Kremer bodies (30). ND10 have been reported to provide a platform for 
posttranslational modification, act as an antiviral defence and a depot for nucleoplasmic 
factors, facilitate nuclear proteasomal degradation and contribute to telomere lengthening, 
transcriptional regulation and DNA replication (30, 458, 526, 541). ND10 may be functionally 
heterogeneous, with each domain performing a subset of these activities (301, 526). 
1.8.1 ND10 COMPOSITION AND STRUCTURE 
ND10 are dense nuclear matrix-associated interchromosomal granular bodies reported to 
localise near cajal bodies, nucleoli, interchromatin granule clusters and transcriptionally 
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Table 1.1: Functions of different types of ubiquitin modification. Mono, monoubiquitination; 
PMPs, plasma membrane proteins; PCNA, proliferating cell nuclear antigen; VDAC1, 
voltage-dependent anion channel 1; AIP4, atrophin-1-interacting protein 4; AMPK, AMP-
activated protein kinase; TCR-ζ, T cell receptor ζ; RIP1, receptor interacting protein 1. 
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Modification Target Biological function References 
Histone H2B Regulation of meiosis (221, 444, 465, 466) 
PMPs Endocytosis & signalling (220, 221, 312, 490, 516, 542) 
Many Lysosomal degradation (222, 435, 453, 504) 
Mono 
PCNA Error-prone DNA repair (215, 562) 
BRCA1 (& others?) Protein stabilisation (402, 488) 
K6 
Androgen receptor Transcriptional regulation (574) 
K11 Many Proteasomal degradation (20, 246, 433) 
Jun Lysosomal degradation (236) 
VDAC1 Mitophagy (189) K27 
Androgen receptor Transcriptional regulation (574) 
AIP4 substrates Lysosomal degradation (68) 
K29 
AMPK-related kinases Kinase activity regulation (11) 
AMPK-related kinases Kinase activity regulation (11) 
K33 
TCR-ζ Receptor activity regulation (233) 
K48 Many Proteasomal degradation (533, 561) 
PCNA Error-free DNA repair (227, 433, 510, 562) 
RIP1 Inflammatory response (4, 383, 562) 
L28 Translation (509, 561) 
PMPs Endocytosis & signalling (188, 222, 383) 
K63 
Many Autophagy (272, 316) 
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active chromatin (30, 42, 76, 100, 197, 224, 353, 517, 554). Approximately one to thirty 
ND10 are present per nucleus depending upon cell type, cell cycle phase and differentiation 
stage (105). During interphase ND10 have a diameter of 0.3 µm to 0.5 µm with a fibrillar 50 
nm to 100 nm shell composed of defined patches of PML, Sp100 and SUMO-1 (38, 281, 
301, 560). This shell does not constrain the typical rapid exchange of ND10 components with 
the nucleoplasm (39, 158, 301). Sumoylation of PML and other ND10 components 
contributes to the structural integrity of ND10 (458, 526). During mitosis ND10 are 
desumoylated, at which point amorphous aggregates of homogeneous PML density lacking 
most other ND10 components are observed (17, 106, 154, 301). 
PML, which forms the structural scaffold of ND10, is expressed as one cytoplasmic (PML VII) 
and six nuclear (PML I to VI) major isoforms through alternative splicing (238, 245). Also 
called TRIM19, PML belongs to the tripartite motif (TRIM) family of proteins and contains the 
characteristic RBCC domain consisting of one RING finger, two B-boxes and an α-helical 
coiled-coil domain (245). PML is modified with SUMO-1 at residues 65, 160 and 490, 
encodes a C-terminal SUMO-interacting motif (SIM) and acts as an E3 SUMO ligase in vitro 
and in yeast (126, 183, 263, 298, 450, 489). Additional ND10 components are recruited by 
PML and include heterochromatin protein 1 (HP1), p53, USP7, hDaxx, SUMO-2/3 and 
SUMO E1, E2 and E3 enzymes (30, 126, 150, 301, 353, 392, 458, 526, 541). 
1.8.2 ND10 AS AN INTRINSIC ANTIVIRAL DEFENCE 
The three major ND10 components PML, Sp100 and the transcriptional repressor hDaxx are 
constitutively expressed and comprise an intrinsic antiviral defence that acts before inducible 
innate and adaptive immune responses kick in (33, 72, 150, 526). ND10 associate with the 
parental genomes and/or replication compartments of all nuclear-replicating DNA viruses 
(150, 526). Viral genomes have been shown to nucleate new, rather than attract existing, 
ND10 through the independent recruitment of PML, Sp100 and hDaxx (91, 158, 161, 163, 
525). PML sumoylation and the SIMs of Sp100 and hDaxx were recently shown to be 
essential for this process, linking the SUMO pathway to this antiviral defence (91). 
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Depletion of PML and/or Sp100 enhances ICP0-null HSV-1, HCMV and adenovirus 
replication in various model systems, while overexpressing these proteins has the opposite 
effect (6, 69, 71, 120, 393, 525, 538, 564). The impact of PML on HSV-1 replication was 
recently linked to PML isoforms I and II, and is dependent upon sumoylation and intact SIM 
and RBCC motifs (90). An interaction between hDaxx and the ND10 component alpha 
thalassaemia/mental retardation syndrome X-linked (ATRX) also restricts HSV-1 gene 
expression (337). HCMV gene expression is also repressed by ATRX, and independently by 
PML and hDaxx; the latter acts in conjunction with HDACs to modify the chromatin structure 
of the major immediate-early promoter (338, 473, 526, 570). In contrast, PML and hDaxx 
suppress adenovirus replication via effects on viral DNA synthesis (538, 539). ND10 also 
restrict retrovirus gene expression, for instance through binding of PML III to the human 
foamy virus transcriptional activator Tas, or hDaxx-dependent HDAC recruitment to reverse 
transcribed avian sarcoma virus DNA (150, 198, 437, 457, 526). The inhibitory mechanisms 
of PML on other RNA viruses remain poorly characterised (150, 526). 
Type I and II interferons augment these antiviral responses by enhancing PML and Sp100 
expression, and by increasing the size and number of ND10 (72, 150, 206, 302). Members of 
the protein inhibitor of activated STAT (PIAS) family of E3 SUMO ligases, which regulate 
interferon signalling, are also enriched at ND10 (32, 287, 327, 521, 571). However, while 
ICP0-null HSV-1, certain HCMV mutants and human foamy virus are highly susceptible to 
interferon in some PML+/+ but not PML-/- cell lines, PML is not essential for the antiviral 
response against ICP0-null HSV-1 in vivo (69, 150, 212, 379, 424, 457). 
1.8.3 VIRAL COUNTERMEASURES AGAINST ND10 
Although members of several virus families modify ND10, the viral countermeasures of the 
herpesviruses are most well characterised (150, 526). The effects of HSV-1 ICP0 on ND10 
have already been described (section 1.4.3). In addition, ICP27 has been shown to enhance 
HSV-2 replication by selectively binding PML pre-mRNA and modulating its splicing to favour 
PML V over PML II synthesis (405). The HCMV immediate-early protein IE72 disrupts ND10 
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by inducing PML desumoylation, while the tegument protein pp71 binds and degrades hDaxx 
(6, 7, 229, 240, 264, 285, 473, 576). During EBV lytic replication the sumoylated immediate-
early protein BZLF-1 has been shown to reduce PML sumoylation and disrupt ND10 by 
competing for SUMO-1; BZLF-1 also disperses Sp100 (3). During latency, binding of EBV 
nuclear antigen leader protein (EBNA-LP, also called EBNA-5) to Sp100 is reported to 
displace Sp100 and HP1α from ND10, while EBNA-1 may disperse ND10 by recruiting the 
cellular proteins CKII and USP7 to mediate PML destabilisation (180, 325, 475, 495, 526). 
1.9 HYPOTHESIS AND AIMS 
This thesis aims to improve our understanding of HSV-1 morphogenesis by dissecting the 
protein-protein interactions contributing to virion incorporation of ICP0, a minor but important 
tegument component. The hypothesis is that the major tegument protein VP22 directly binds 
ICP0 to facilitate ICP0 assembly, and that VP22 modifies ICP0’s biological activities. 
1.9.1 AIMS 
(1) Determine whether VP22 and ICP0 interact, and ascertain whether the association is 
dependent upon other viral proteins. VP22 and ICP0 domains mediating the interaction 
will also be identified. (Chapter 4). 
(2) Characterise the assembly pathways for VP22 and ICP0 by identifying viral protein-
protein interactions essential for VP22 and ICP0 packaging. (Chapters 3 and 4). 
(3) Study the impact VP22 has on the behaviour of ICP0, including its intracellular 
localisation, and function as an E3 ubiquitin ligase and transcriptional activator of gene 
expression. (Chapter 5). 
(4) Investigate whether virion ICP0 contributes to HSV-1 replication. (Chapter 6). 
(5) Evaluate the impact of ICP0 at late times of infection, when VP22 and ICP0 colocalise in 
punctate cytoplasmic domains. (Chapter 7). 
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If not specified here, standard buffers and solutions are detailed in appendix 1. Unless stated 
the solvent for all buffers and solutions was reverse-osmosis water. 
2.1 CELLS AND TISSUE CULTURE 
BHK-21, COS-1, HFFF2, MDBK, U2OS and Vero cells were obtained from the European 
Collection of Cell Cultures (ECACC) (Health Protection Agency, Porton Down, UK).
2.1.1 TISSUE CULTURE TECHNIQUES AND REAGENTS 
Tissue culture was performed in a BioMAT2 class II microbiological safety cabinet (Medical 
Air Technology, Oldham, UK) under biosafety level 2 containment. Sterile practice was 
maintained throughout. Cells were cultured in 75 cm2 tissue culture-treated flasks in 
Dulbecco’s modified eagle medium (DMEM) (appendix 1) supplemented with 100 U/ml 
Penicillin and 100 µg/ml Streptomycin at 37˚C in a Heraeus® HERAcell 240 incubator 
(Thermo Fisher Scientific Inc., Waltham, MA USA) with a humidified 5% carbon dioxide 
atmosphere. HFFF2 medium also contained 10% v/v foetal bovine serum; all other media 
were supplemented with 10% v/v newborn calf serum (NCS). All reagents were from 
Invitrogen (Carlsbad, CA USA) and were warmed to 37˚C before use. All tissue culture 
plasticware was from VWR (West Chester, PA USA). 
Cells were subcultured at 1:3 (HFFF2) or 1:10 (all other cells) dilution twice per week. Briefly, 
culture medium was removed and cells washed twice in a small volume of 0.5 g/L trypsin- 
ethylenediaminetetraacetic acid (EDTA) solution (appendix 1) (Invitrogen). After 5 min 
incubation at 37˚C in 0.5 ml trypsin, cells were resuspended in culture medium and diluted 
into fresh tissue culture flasks in a total volume of 20 ml culture medium. For experiments, 
cells were seeded at the appropriate density in 1 ml (12-well plate), 2 ml (6-well plate) or 5 ml 
(60 mm dish) medium per well or dish. 
Periodically, low-passage cell stocks were frozen for storage in liquid nitrogen. Briefly, 
trypsinised cells were pelleted in 10 ml tissue culture medium at 3,000 rpm for 5 min at 4˚C in 
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a TX-750 swinging bucket rotor for the Heraeus® Megafuge 40R centrifuge (both Thermo 
Fisher Scientific Inc.). Cell pellets were resuspended at a density of 3 x 106 cells/ml in 
RecoveryTM cell culture freezing medium (Invitrogen). Cells were frozen at -80˚C as 1 ml 
aliquots using a 5100 Cryo 1˚C freezing container (Thermo Fisher Scientific Inc.) before 
transfer to liquid nitrogen. To revive, cells were thawed at 37˚C and pelleted in 10 ml culture 
medium at 3,000 rpm for 5 min at 4˚C in a TX-750 swinging bucket rotor for the Heraeus® 
Megafuge 40R centrifuge. Cells were resuspended in 10 ml culture medium and initially 
grown in 25 cm2 tissue culture flasks before transfer to 75 cm2 flasks. 
2.2 VIRUS TECHNIQUES 
All virus work was performed in a BioMAT2 class II microbiological safety cabinet under 
biosafety level 2 containment. Cells for virus work were cultured in a Heraeus® HERAcell 150 
incubator (Thermo Fisher Scientific Inc.). 
2.2.1 VIRUSES 
The wild-type HSV-1 strain 17+ was originally isolated in Glasgow. Strains HFEM and sc16 
were kindly donated by Peter O’Hare (Imperial College London, UK) and Helena Browne 
(University of Cambridge, UK) respectively. 
Viruses that express mutant VP22 were derived from strain 17+ within our lab (figure 2.1). 
Mutants that express green fluorescent protein (GFP)-tagged full-length VP22 (GFP-22) or 
GFP in place of VP22 (∆22) were generated by Gill Elliott (129, 134). Viruses encoding GFP-
tagged residues 108 to 301 (108-301), 160 to 301 (160-301), 1 to 165 (1-165) or 1 to 212 (1-
212) of VP22 were constructed by Wali Hafezi (207). Mutants with small lesions between 
residues 213 to 226 (∆gEbind) or 170 to 192 (∆gEbind2) within the conserved gE-binding 
domain of VP22 were respectively generated by Emmanuelle Bernard and Rachelle Cook 
(518). Viruses in which the serine phosphorylation sites of VP22 are replaced by alanine or 
glutamate residues to mimic the nonphosphorylated (P-) or phosphorylated (P+) forms of 
VP22 respectively were derived by Corinne Potel (443). A virus expressing GFP-tagged full-
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Figure 2.1: VP22 mutants used in this study. (A) VP22 ORF; region conserved among all 
alphaherpesvirus VP22 homologues is shown in grey; triangles represent serine 
phosphorylation sites at positions 35, 71, 72, 73, 292 and 294. (B) VP22 constructs 
expressed in HSV-1 strain 17+; names used in reference to these mutants throughout this 
thesis are shown on the right (bold); where these differ from the literature alternate names 
are shown in brackets. All VP22 constructs are tagged at their N-terminus with GFP and 
were generated within our lab. The virus encoding GFP-tagged full-length VP22 is referred to 
here interchangeably as GFP-22 and 1-301 (134). The VP22 deletion virus (∆22) encodes 
GFP in place of VP22 (129). N-terminal truncation mutants lack the first 107 (108-301) or 159 
(160-301) amino acids respectively (207). C-terminal truncation mutants lack the final 136 (1-
165) or 89 (1-212) residues respectively (207). Constructs with deletions in the gE-binding 
domain have small lesions between residues 213 to 226 (∆gEbind) and 170 to 192 
(∆gEbind2) (518). In mutants mimicking the phosphorylated (P+) and nonphosphorylated (P-) 
forms of VP22, the serine phosphorylation sites were replaced with glutamic acid or alanine 
residues respectively (443). Our NLS-22 mutant has the SV40 NLS inserted between the full-
length VP22 sequence and the N-terminal GFP tag (unpublished data). 
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Figure 2.1 
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length VP22 with the simian virus 40 (SV40) NLS inserted at the N-terminus of VP22 was 
constructed by Ian Hutchinson (unpublished data). 
Viruses encoding mutant ICP0, derived from strain 17+, were kindly donated by Roger 
Everett (Medical Research Council Virology Unit, University of Glasgow, UK) (figure 2.2). 
The YFP-0 virus expresses yellow fluorescent protein (YFP)-tagged full-length ICP0 (not 
shown) (164). The ICP0-null (∆ICP0) mutant lacks the majority of the ICP0 ORF (514). The 
remaining mutants lack the C-terminal 182 amino acids (1-593), or contain deletions between 
residues 594 to 633 (∆USP7) or point mutations at positions 623 and 624 (pm-USP7) within 
the USP7-binding domain, or deletions between residues 106 to 150 within the RING finger 
domain (∆RING) (142, 156, 362). Strain sc16-derived mutants lacking gE (∆gE), gM (∆gM), 
gE and gM (∆gEgM) or gI (∆gI) were kindly donated by Helena Brown and Colin Crump 
(University of Cambridge, UK) (54 and unpublished data). 
2.2.2 VIRUS WORKING STOCK PRODUCTION 
Virus working stocks were prepared from master stocks on BHK-21 cells grown to confluency 
in five 225 cm2 tissue culture flasks (approximately 3 x 108 cells). The culture medium was 
removed from four-day-old monolayers and cells infected at a multiplicity of 0.02 in 50 ml 
infection medium consisting of DMEM supplemented with 100 U/ml Penicillin, 100 µg/ml 
Streptomycin and 2% v/v serum. Cells were incubated at 37˚C until cytopathology was 
detectable (the inoculum was not removed), harvested into the medium and pelleted at 3,000 
rpm for 30 min at 4˚C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend 
RT centrifuge (both Thermo Fisher Scientific Inc.). The cell pellet was resuspended in 2 ml 
sterile phosphate buffered saline (PBS) (VWR) (appendix 1) and subjected to three 
freeze/thaw cycles using dry ice (The Linde Group, Munich, Germany)/ethanol (VWR) and a 
37˚C SUBAqua 12 Plus water bath (Grant Scientific, Shepreth, UK). Cell debris was pelleted 
at 4,600 rpm for 5 min at 4˚C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® 
Legend RT centrifuge and aliquots of the supernatant stored at -80˚C as virus working 
stocks. These stocks were subjected to no more than two freeze/thaw cycles. 
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2.2.3 TITRATIONS 
All titrations were performed in duplicate on Vero cells unless stated; mean titres in plaque-
forming units (pfu)/ml are shown throughout this thesis. Culture medium was removed from 
one-day-old confluent cell monolayers grown in 6-well tissue culture plates and replaced with 
0.5 ml ten-fold serial dilutions of virus in infection medium. Plates were returned to 37˚C. The 
inoculum was removed after one hour and replaced with infection medium supplemented 
with 1% human serum (Sera Laboratories Ltd., Haywards Heath, UK). Cells were incubated 
at 37˚C until plaques were clearly visible by eye, fixed with 2 ml 2X formal saline solution per 
well and stained with 0.5 ml 0.1 % crystal violet (both appendix 1). 
2.2.4 PLAQUE SIZE QUANTIFICATION 
Fixed and stained plaque assay titration plates were scanned using an Epson Perfection 
V700 Photo scanner (Seiko Epson Corporation, Suwa, Japan) and images saved as TIFF 
files (figure 2.3A). Images were converted to binary images using ImageJ software (National 
Institutes of Health, Bethesda, MD USA) to allow plaque size analysis (figure 2.3B). All 
images were adjusted concurrently to prevent the appearance of size difference artefacts 
due to variations in image manipulation. The scale for plaque size measurement was set 
against the known diameter of one well in a 6-well plate (36 mm). Plaque size data were 
collected using the ImageJ ‘analyse particles’ function with the following settings; particle 
size ‘0 – infinity’, circularity ‘0.0 – 1.0’; ‘include holes’ and ‘exclude on edges’ selected. The 
resulting data (figure 2.3C) were exported into Microsoft® Excel 2008 for Mac (Microsoft 
Corporation, Redmond, WA USA) for further analysis. All data were manually verified before 
further analysis and fused plaques and random disturbances in the cell monolayer 
discounted. At least 30 plaque measurements were analysed for each condition. 
2.2.5 EXPERIMENTAL VIRUS INFECTION AND ONE-STEP GROWTH CURVES 
To prepare the inoculum, virus working stock was diluted as required in infection medium. 
The culture medium was removed from one-day-old confluent cell monolayers and cells 
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Figure 2.2: ICP0 mutants used in this study. (A) ICP0 schematic. Orange, RING finger 
(residues 116 to 156) and HUL-1 (616 to 680) E3 ubiquitin ligase domains; beige, NLS (474 
to 509); brown, USP7-binding domain. Phosphorylation sites are represented by triangles as 
follows; cluster I (S224, T226, T231, T232), cluster II (S365, S367, S371) and cluster III 
(S508, S514, S517, T518). (B) ICP0 constructs expressed in HSV-1 strain 17+; names used 
in reference to these mutants throughout this thesis are shown on the right (bold); alternative 
names used in the literature are shown in brackets. The ICP0 deletion mutant (∆ICP0) lacks 
the majority of the ICP0 open reading frame but still expresses a small nonfunctional 
fragment corresponding to the N-terminal 106 ICP0 residues (351, 514). The C-terminal 
truncation mutant (1-593) lacks the C-terminal 182 residues (362). The RING finger (∆RING) 
and USP7-binding (∆USP7) domain deletion mutants lack resides 107 to 149 and 595 to 632 
respectively (142, 362). The pm-USP7 mutant has two point mutations, indicated by red 
lines, at residues 623 and 624 within the USP7-binding domain (156). All mutants were 
originally generated by Roger Everett and coworkers. 
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Figure 2.2 
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Figure 2.3: Plaque size measurement using ImageJ. (A) Scanned image of one well in a 6-
well plaque assay titration plate. (B) Binary image of scanned titration plate created in 
ImageJ. (C) Example of plaque size data generated by ImageJ ‘analyse particle’ function. 
Plaque outlines are highlighted; red numbers represent automatically generated labels for 
each distinct measurement; corresponding calculated areas are also shown. * Example of 
disturbance in cell monolayer excluded from plaque size analysis. 
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incubated for one hour at 37˚C with a small volume of inoculum as follows; 0.4 ml (12-well 
plate), 0.5 ml (6-well plate), 2 ml (60 mm dish). Cells were washed once in sterile PBS and 
returned to 37˚C in fresh infection medium (without virus). 
For one-step growth curves, cells were cultured in 12-well plates; multiplicities of infection 
are stated in figure legends. Cells were harvested into the medium at the indicated times, 
stored at -80˚C at least overnight and subjected to three freeze/thaw cycles using dry 
ice/ethanol and a 37˚C SUBAqua 12 Plus water bath. Cell debris was pelleted at 5,000 rpm 
for 5 min at 4˚C in an airtight fixed angle FA-45-24-11 rotor for the Eppendorf centrifuge 5424 
(both Eppendorf, Hamburg, Germany) and each sample supernatant titrated as described in 
section 2.2.3. For concurrent analysis of protein expression, cells were washed once in ice-
cold PBS and lysed in 200 µl 2X SDS-PAGE loading dye (appendix 1). Samples were 
denatured and analysed by SDS-PAGE and western blot (sections 2.6.1 and 2.6.2). 
2.2.6 INFECTIOUS PARTICLE PURIFICATION 
The culture supernatant from eight 225 cm2 flasks of confluent BHK-21 cells (approximately 
5.6 x 108 cells) infected as described in section 2.2.2 was collected once cytopathology was 
detectable and centrifuged at 3,000 rpm for 30 min at 4˚C in an airtight swinging bucket rotor 
(7500 6445) for the Sorvall® Legend RT centrifuge to remove cell debris. Infectious virus 
particles were pelleted from the cleared supernatant at 9,000 rpm for 90 min at 4˚C in a SLA-
3000 Super-Lite rotor for the Sorvall® RC5C centrifuge (both Thermo Fisher Scientific Inc.). 
The virion pellet was resuspended in 0.5 ml PBS and carefully layered on to a 10 ml 5% to 
15% w/v Ficoll (Sigma-Aldrich, St. Louis, MO USA) gradient in a 13.2 ml thinwall polyallomer 
ultracentrifuge tube (Beckman Coulter, Brea, CA USA). Gradients were centrifuged at 12,000 
rpm for two hours at 4˚C in a SW41 Ti swinging bucket rotor (Beckman Coulter) for the 
Sorvall® DiscoveryTM SE centrifuge (Thermo Fisher Scientific Inc.). For figure 4.2, successive 
1 ml gradient fractions were collected. To purify infectious virus particles the virion band was 
harvested through the side of the tube with a 19 gauge BD MicrolanceTM hypodermic needle 
(Becton Dickinson, Drogheda, Ireland), resuspended in 10 ml PBS and pelleted at 25,000 
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rpm for one hour at 4˚C in a SW41 Ti swinging bucket rotor for the Sorvall® DiscoveryTM SE 
centrifuge. The virion pellet was resuspended in 200 µl PBS and stored at -80˚C. 
Purified virions were equalised against the major capsid protein VP5 by Coomassie blue-
stained SDS-PAGE gel (sections 2.6.1 and 2.6.3) before use. 
2.2.7 SALT EXTRACTION OF VIRIONS 
Purified virions were pelleted at 2,300 g for 5 min at 4˚C in an airtight fixed angle FA-45-24-
11 rotor for the Eppendorf centrifuge 5424 centrifuge and resuspended in 50 µl stripping 
buffer consisting of 10 mM tris(hydroxymethyl)aminomethane (tris)-HCl (pH 7.5) (Sigma-
Aldrich), 1 mM EDTA (Sigma-Aldrich), 1% w/v Nonidet P-40 Substitute (Amresco®, Solon, 
OH USA) and between 0.1 M and 1.0 M NaCl (Sigma-Aldrich) as specified. Following 15 min 
incubation at room temperature, virions were centrifuged as before and pellets resuspended 
in 100 µl 2X SDS-PAGE loading dye. Supernatants were added to 50 µl 2X SDS-PAGE 
loading dye and denatured as detailed in section 2.6.1. When increasing salt concentrations 
were used, separate reactions were set up; virions were not stripped sequentially. 
2.3 BACTERIA STRAINS AND TECHNIQUES 
All plasmids were prepared from Escherichia coli strain HB101 (ECACC). Bacteria work was 
performed with sterile reagents and tools under a blue flame on the bench. Waste was 
disposed of in compliance with Imperial College health and safety policy. 
2.3.1 BACTERIAL CULTURE 
A starter culture was set up by inoculating glycerol stocks (section 2.3.2) or a single colony 
from a Luria-Bertani (LB) agar plate into 2 ml LB media with or without appropriate antibiotics 
(reagents from Sigma-Aldrich; appendix 1). Following incubation at 37˚C with agitation (250 
rpm) for 6 hours in a Max-Q 4000 incubator shaker (Thermo Fisher Scientific Inc.), 250 ml LB 
media with or without antibiotics were inoculated with 500 µl starter culture and incubated at 
37˚C with agitation (170 rpm) overnight in an innovaTM 4300 incubator shaker (Eppendorf). 
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2.3.2 GLYCEROL STOCK PRODUCTION 
Glycerol stocks were prepared by adding 600 µ l starter culture to 400 µ l sterile glycerol 
(Sigma-Aldrich). Stocks were stored at -80˚C and kept frozen on ice throughout use. 
2.3.3 PRODUCTION OF COMPETENT CELLS 
Bacterial cultures were established in 250 ml LB media without antibiotics from HB101 stocks 
as described in section 2.3.1. Cultures were pelleted during the exponential growth phase 
(optical density 0.4 to 0.6) at 5,000 rpm for 5 min at 4˚C in a SLA-3000 Super-Lite rotor for 
the Sorvall® RC5C centrifuge. Bacterial pellets were resuspended in 100 ml ice-cold sterile 
buffer (pH 5.8) consisting of 12.2 g/L rubidium chloride, 30 mM KOAc, 10 mM CaCl2, 50 mM 
MnCl2 and 15% w/v glycerol (all reagents Sigma-Aldrich). Following 5 min incubation on ice, 
bacteria were pelleted as before and resuspended in 10 ml ice-cold sterile buffer (pH 6.5) 
consisting of 10 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 75 mM CaCl2, 10 mM 
rubidium chloride and 15% w/v glycerol (all reagents Sigma-Aldrich). Following 15 to 60 min 
incubation on ice, competent cells were stored as 100 µl aliquots at -80˚C. 
2.3.4 HEAT-SHOCK TRANSFORMATION 
Competent cells were thawed on ice and incubated with 5 ng DNA for 20 min before heat-
shock at 42˚C for 90 s in a water bath (Grant Scientific). Bacteria were returned to ice for 10 
min, added to 1 ml LB media and incubated at 37˚C with agitation (250 rpm) for one hour in a 
Max-Q 4000 incubator shaker. Starter cultures were plated on LB agar plates and incubated 
at 37˚C overnight in a Heraeus® T 5042 E gravity convection oven D 6450 Hanau (Thermo 
Fisher Scientific Inc.). Transformation efficiencies were routinely in the region of 1 x 107 
colonies/µg DNA (data not shown). 
2.4 PLASMIDS AND TRANSFECTIONS 
Plasmids used in this thesis are summarised in table 2.1. Plasmid maps are not included 
because plasmids were not constructed as part of the work presented here. 
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2.4.1 PLASMID PREPARATION 
Plasmids were prepared from 250 ml overnight HB101 cultures (section 2.3.1) in LB media 
supplemented with 50 µg/ml ampicillin or 30 µg/ml kanamycin (both Sigma-Aldrich) as 
appropriate (table 2.1) using the QIAGEN Plasmid Maxi kit (Qiagen, Hilden, Germany) as per 
manufacturer’s instructions. Briefly, bacterial cells were pelleted at 6,000 rpm for 15 min at 
4˚C in a SLA-3000 Super-Lite rotor for the Sorvall® RC5C centrifuge and resuspended in 10 
ml Buffer P1 (all Qiagen buffers detailed in appendix 1). After addition of 10 ml Buffer P2, 
cells were incubated at room temperature for 5 min. Following addition of 10 ml ice-cold 
Buffer P3 and incubation on ice for 20 min, the mixture was centrifuged at 12,000 rpm for 30 
min at 4˚C in a SLA-3000 Super-Lite rotor for the Sorvall® RC5C centrifuge to pellet genomic 
DNA, protein and cell debris. The supernatant was centrifuged again at 4,600 rpm for 15 min 
at 4˚C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend RT+ 
centrifuge (Thermo Fisher Scientific Inc.) and applied to a QIAGEN-tip 500 that had been 
equilibrated with 10 ml Buffer QBT. The QIAGEN-tip was washed twice with 30 ml Buffer QC 
and plasmid DNA eluted in 15 ml Buffer QF. All liquids were allowed to pass through the 
QIAGEN-tip by gravity flow. Solutions were used at room temperature unless stated. 
DNA was precipitated by adding 10.5 ml room temperature 100% isopropanol (Thermo 
Fisher Scientific Inc.) and pelleted at 4,600 rpm for 30 min at 4˚C in an airtight swinging 
bucket rotor (7500 6445) for the Sorvall® Legend RT+ centrifuge. The pellet was washed in 5 
ml 70% ethanol, repelleted at 4,600 rpm for 10 min at 4˚C in an airtight swinging bucket rotor 
(7500 6445) for the Sorvall® Legend RT+ centrifuge, allowed to air-dry, dissolved in a small 
volume of TE buffer (pH 8.0) and diluted to 1 mg/ml before storage at -20˚C. 
2.4.2 TRANSIENT TRANSFECTION 
One-day-old cell monolayers grown to 90% confluency (unless stated) were transfected with 
lipofectamineTM 2000 transfection reagent (Invitrogen) as per manufacturer’s instructions. 
Briefly, tissue culture medium was removed and replaced at 80% volume with antibiotic-free 
culture medium. The remaining volume was made up with Opti-MEM® I reduced serum 
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Table 2.1: Summary of plasmids used in this thesis. Plasmids are named as they appear in 
the literature. pCMV-β-gal, pCP1, pCP5 and pGE155 were generated within our lab. pPO85 
expresses wild-type VP22 linked to the SV5 epitope tag. All GFP fusion proteins are linked to 
the C-terminus of GFP. GFP-tagged mimics of phosphorylated and nonphosphorylated VP22 
are identical to VP22 constructs expressed by the corresponding mutant viruses (figure 2.1). 
In the K0 ubiquitin mutant all seven lysine residues are replaced with arginine, abrogating 
polyubiquitination. The K33, K48 and K63 ubiquitin mutants retain only the given lysine 
residue. The K48R ubiquitin mutant lacks only the lysine at position 48. pGL2-Basic lacks 
eukaryotic promoter and enhancer sequences. The β-galactosidase gene is from E. coli. 
pEGFP-c1, pGE155, pCP1 and pCP5 encode the kanamycin resistance gene; all other 
plasmids encode ampicillin resistance. IE, immediate-early; wt, wild-type; SV5, simian virus 
5; HA, haemagglutinin tag; TK, thymidine kinase. 
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Table 2.1 
 
 
 
 
 
 
Plasmid name Promoter Protein expressed Source 
pcDNA3-gE HCMV IE wt gE Helena Browne 
pcDNA3-gM HCMV IE wt gM Colin Crump (89) 
pcI110 HCMV IE wt ICP0 Roger Everett (156) 
pcI-FXE HCMV IE RING finger deletion mutant of 
ICP0 
Roger Everett (156) 
pCMV-β-gal HCMV IE β-galactosidase Gill Elliott 
pCMV-SV5α HCMV IE SV5 epitope tag Colin Goding1 (214) 
pCP1 HCMV IE GFP-tagged mimic of 
nonphosphorylated VP22 
Corinne Potel (443) 
pCP5 HCMV IE GFP-tagged mimic of 
phosphorylated VP22 
Corinne Potel (443) 
pEGFP-c1 HCMV IE GFP Clontech2 
pGE155 HCMV IE GFP-tagged VP22 Gill Elliott (131) 
pGL2-Basic None Firefly luciferase Promega3 
pGL2-Promoter SV40 Firefly luciferase Promega3 
phRL-TK HSV-1 TK Renilla luciferase Promega3 
pPO85 HCMV IE wt VP22 Peter O’Hare 
pRK5-HA-Ubiquitin-K0 HCMV IE HA-tagged K0 ubiquitin Addgene4 (323) 
pRK5-HA-Ubiquitin-K33 HCMV IE HA-tagged K33 ubiquitin Addgene4 (323) 
pRK5-HA-Ubiquitin-K48 HCMV IE HA-tagged K48 ubiquitin Addgene4 (323) 
pRK5-HA-Ubiquitin-K48R HCMV IE HA-tagged K48R ubiquitin Addgene4 (323) 
pRK5-HA-Ubiquitin-K63 HCMV IE HA-tagged K63 ubiquitin Addgene4 (323) 
pRK5-HA-Ubiquitin-wt HCMV IE HA-tagged wt ubiquitin Addgene4 (323) 
1 Ludwig Institute for Cancer Research Ltd., University of Oxford, UK 
2 Basingstoke, UK 
3 Madison, WI USA 
4 Cambridge, MA USA 
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media (Invitrogen) containing plasmid DNA and lipofectamineTM 2000 at a ratio of 1:2. DNA 
quantities are detailed in figure legends. To prepare the DNA-lipofectamineTM 2000 mixture, 
DNA and lipofectamineTM 2000 were diluted separately in Opti-MEM® I reduced serum media 
as required. After 5 min, DNA and lipofectamineTM 2000 solutions were combined and 
incubated at room temperature for 20 min before addition to cell monolayers. 
2.5 ANTIBODIES 
Primary and secondary antibodies are detailed in tables 2.2 and 2.3 respectively. 
2.6 PROTEIN TECHNIQUES 
All protein samples were stored at -20˚C, or -80˚C for long-term storage. 
2.6.1 SDS-PAGE 
Samples were mixed in a 1:1 ratio with 2X SDS-PAGE loading dye (appendix 1) and 
denatured at 100˚C for 3 min. For gM western blots, samples were denatured at 42˚C for 20 
min to prevent aggregation of this transmembrane protein. Samples were loaded on 10% 
polyacrylamide gels cast in prefabricated 10 cm x 10 cm mini-gel cassettes (Invitrogen); 12% 
gels were used for analysis of the 12 kDa capsid protein VP26 (resolving and stacking gel 
composition detailed in appendix 1). Novex® Sharp Pre-Stained Protein Standards 
(Invitrogen) were used. Electrophoresis was performed at 200 V for 60 min (90 min for 12% 
gels) using the XCell SureLockTM Mini-Cell system (Invitrogen) as per manufacturer’s 
instructions (SDS-PAGE running buffer detailed in appendix 1). 
2.6.2 WESTERN BLOTTING 
Samples were transferred from SDS-PAGE gels to a Whatman® PROTRAN® nitrocellulose 
membrane (Whatman GmbH, Dassel, Germany) at 25 V for 2 hours or at 7 V overnight using 
the XCell SureLockTM Mini-Cell system as per manufacturer’s instructions (transfer buffer 
detailed in appendix 1). Membranes were washed briefly in reverse-osmosis water and 
transfer efficiency confirmed by staining with 0.1% w/v Ponceau S solution in 5% v/v acetic 
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acid (Sigma-Aldrich). Dye was removed by briefly washing membranes in wash buffer 
consisting of 0.5% v/v Triton® X-100 (Sigma-Aldrich) in PBS. 
Membranes were blocked for 2 hours in block buffer consisting of 5% w/v skim milk powder 
and 0.1% v/v Tween® 20 (both Sigma-Aldrich) in PBS. Membranes were then incubated with 
primary antibody for one hour, followed by three brief and three 10 min washes in wash 
buffer. Membranes were incubated with secondary antibody for 30 min and washed as after 
primary antibody incubation. Antibody incubations were performed in PBS with 0.1% v/v 
Tween® 20; see tables 2.2 and 2.3 for antibody dilutions. All steps were performed with 
agitation (30 rpm) on a Stuart® Scientific gyro-rocker SSL3 (Sigma-Aldrich). For gI detection, 
membranes were blocked at 37˚C for one hour in a buffer consisting of 10% w/v skim milk 
powder, 5% v/v NCS and 0.1% v/v Tween® 20 in PBS; primary antibody incubation was 
performed in 5% w/v skim milk powder, 5% v/v NCS and 0.1% v/v Tween® 20 in PBS. 
Western blots were developed with 2 ml SuperSignal® WestPico chemiluminescent substrate 
per membrane, exposed on to FujiFilm RX NIF X-ray film (both Thermo Fisher Scientific Inc.) 
and developed using a JP-33 automatic X-Ray film processor (Jungwon Precision Industries 
Co. Ltd, Seoul, Korea). Blots were digitalised using an Epson Perfection V700 Photo 
scanner. Membranes were stored at 4˚C in PBS and routinely reblocked and probed with 
additional antibodies as described above; membranes were not stripped. 
2.6.3 COOMASSIE BLUE GEL STAINING 
SDS-PAGE gels were washed in reverse-osmosis water for 20 min and stained for one hour 
with 30 ml Pierce Imperial Protein Stain (Thermo Fisher Scientific Inc.). Gels were washed 
several times in reverse-osmosis water (at least overnight) until protein bands were clearly 
visible. Gels were scanned in an Epson Perfection V700 Photo scanner. 
2.6.4 IMMUNOPRECIPITATION 
One-day-old confluent Vero or U2OS (figure 4.13A) cells cultured in 60 mm tissue culture 
dishes were infected at a multiplicity of one as described in section 2.2.5. Alternatively, one-
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Table 2.2: Primary antibodies. All mouse antibodies are monoclonal, all rabbit antibodies 
polyclonal. The gE and gE-gI antibodies ab6510 and 3063 were used for 
immunoprecipitation only. The gE-gI antibody 3063 is specific for gI-bound gE (85). The gI 
antibody 3104 recognises free gI but has a preference for gE-bound gI (85). Antibody FK1 is 
specific for conjugated polyubiquitin chains; FK2 recognises conjugated monoubiquitin and 
polyubiquitin (185). Antibody names are as stated in the literature. * Catalogue order number 
is given where antibody name was not available (accurate on 27/07/2011). The vhs antibody 
has no official name. WB, western blot; IF, immunofluorescence microscopy; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase. 
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Table 2.2 
Antigen Name Secondary Working dilution Source 
   WB IF  
α-tubulin T-5168* mouse 1:10,000  Sigma-Aldrich 
β-galactosidase Z3783* mouse 1:5,000  Promega 
GAPDH 6C5 mouse 1:10,000  Applied Biosystems1 
gB R69 mouse 1:10,000  Helena Browne 
gD LP14 mouse 1:5,000  Tony Minson2 (370) 
gE 3114 mouse 1:10,000  David Johnson3 (85) 
gE ab6510* mouse   AbCam4 
gE-gI 3063 mouse   David Johnson3 (85) 
GFP 632375* mouse 1:10,000  Clontech 
GFP 632460* rabbit 1:10,000  Clontech 
gI 3104 mouse 1:200  David Johnson3 (85) 
gM Ab980 rabbit 1:1,000  Helena Browne (89) 
HA tag sc-7392* mouse  1:50 Santa Cruz5 
ICP0 11060 mouse 1:200 1:50 Santa Cruz5 (151) 
ICP4 10F1 mouse 1:1,000 1:400 Virusys6 (491) 
ICP27 H1113 mouse 1:5,000 1:1,000 Stephen Rice7 (1) 
PML DB75 rabbit  1:50 Peter O’Hare (22) 
polyubiquitin FK1 mouse  1:50 Enzo Life Sciences8 (185) 
Renilla luciferase 5B11.2 mouse 1:5,000  Millipore S.A.S.9 
ubiquitin FK2 mouse  1:50 Enzo Life Sciences8 (185) 
UL42 Z1F11 mouse 1:2,000  Nigel Stow10 (478) 
vhs  rabbit 1:2,000  Duncan Wilson11 (303) 
VP5 3B6 mouse 1:3,000  Virusys6 
VP13/14 5283 rabbit 1:5,000  In-house (117) 
VP16 LP1 mouse 1:5,000  Tony Minson2 (358) 
VP22 C-terminus AGV600 rabbit 1:20,000  In-house (133) 
VP22 N-terminus AGV031 rabbit 1:20,000  In-house (133) 
VP26 VP26/C rabbit 1:10,000  Prashant Desai12 (107) 
1 Carlsbad, CA USA 
2 University of Cambridge, UK 
3 Oregon Health and Science University, Portland, OR USA 
4 Cambridge, UK 
5 Santa Cruz, CA USA 
6 Taneytown, MD USA 
7 University of Minnesota, MN USA 
8 Farmingdale, NY USA 
9 Molsheim, France 
10 Medical Research Council Virology Unit, University of Glasgow, UK 
11 Albert Einstein College of Medicine, Bronx, NY USA 
12 John Hopkins University, Baltimore, MD USA 
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Table 2.3: Secondary antibodies. TrueBlot® anti-rabbit HRP-conjugate does not cross-react 
with denatured immunoglobulin and was used in combination with gM antibody Ab980 only. 
Catalogue numbers accurate on 27/07/2011. * Goat anti-mouse HRP-conjugate was used at 
1:3,000 dilution for gI (3104) and ICP0 (11060) antibodies, and 1:5,000 dilution for ICP4 
(10F1), Renilla luciferase (5B11.2) and vhs antibodies. § Goat anti-rabbit HRP-conjugate was 
used at 1:20,000 dilution for VP22 antibodies AGV031 and AGV600. IgG (H+L), 
immunoglobulin G (heavy and light chains); IF, immunofluorescence microscopy; HRP, 
horseradish peroxidase; WB, western blot. 
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Table 2.3 
 
 
 
 
 
 
Reactivity Details Application Working 
dilution 
Source Catalogue 
number 
mouse IgG (H+L) horse Texas Red® IF 1:200 Vector 
Laboratories1 
TI-2000 
mouse IgG (H+L) goat HRP WB 1:10,000* Bio-Rad 
Laboratories2 
170-6516 
rabbit IgG TrueBlot® HRP WB (gM) 1:1,000 eBioscience3 18-8816 
rabbit IgG (H+L) goat HRP WB 1:10,000§ Bio-Rad 
Laboratories2 
170-6515 
rabbit IgG (H+L) goat Texas Red® IF 1:200 Vector 
Laboratories1 
TI-1000 
1 Burlingame, CA USA 
2 Hercules, CA USA 
3 San Diego, CA USA 
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day-old confluent Vero or COS-1 cells cultured in 60 mm tissue culture dishes were 
transfected as detailed in figure legends and section 2.4.2. Cells were incubated at 37˚C for 
a further 24 hours or as specified in figure legends. Wherever possible, GFP-tagged VP22 
expression was confirmed microscopically using an Olympus IX70 microscope with an 
Olympus U-RFL-T UV burner (Olympus, Tokyo, Japan). Cell monolayers were washed twice 
in ice-cold sterile PBS and harvested in 1.1 ml radioimmunoprecipitation assay (RIPA) buffer 
(appendix 1). Following 20 min incubation on ice, cell debris was pelleted at 12,000 rpm for 
30 min at 4˚C in an airtight fixed angle F-45-18-11 rotor for the Eppendorf Centrifuge 5402 
(both Eppendorf). Samples were kept on ice or at 4˚C for the remainder of the protocol. 
For immunoprecipitation, 400 µ l lysate was incubated with top-over-tail rotation at 4˚C 
overnight in a Stuart® Blood Tube rotator SB1 (Sigma-Aldrich) along with 10 µl polyclonal or 
4 µ l monoclonal antibody as detailed in figure legends. Following addition of 40 µ l protein A 
sepharose beads (GE Healthcare, Uppsala, Sweden) and one hour incubation with top-over-
tail rotation at 4˚C in a Blood Tube rotator SB1, immunoprecipitation beads were washed 
three times in a buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 1% v/v 
Nonidet P-40 Substitute. (Protein A sepharose beads were washed twice in ice-cold PBS 
and resuspended in ice-cold PBS at a 1:1 ratio prior to use.) Following immunoprecipitation, 
beads were resuspended in 40 µl 2X SDS-PAGE loading dye and denatured as described in 
section 2.6.1. All gE and GFP immunoprecipitations were performed with antibodies ab6510 
and 632460 respectively (table 2.2). 
2.7 MICROSCOPY 
One-day-old subconfluent cell monolayers cultured on 16 mm cover slips (VWR) in 12-well 
plates were infected or transfected as detailed in figure legends and sections 2.2.5 and 2.4.2. 
Cells were cultured to 70% confluence at time of fixation. At times indicated in figure legends, 
cells were washed twice in 500 µl ice-cold sterile PBS and fixed for 20 min at room 
temperature in 300 µl 4% w/v paraformaldehyde (Sigma-Aldrich) in PBS. Cells were then 
washed twice in 500 µl ice-cold sterile PBS and stored in sterile PBS at 4˚C until required. 
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Cover slips were washed briefly in reverse-osmosis water and mounted in 20 µ l 10% w/v 
Mowiol® 4-88 mounting medium with 0.1 µg/ml 4’,6-diamidino-2-phenylindole (DAPI) 
(appendix 1) on SuperFrost® WHITE microscope slides (VWR). Slides were stored at 4˚C. 
Images were captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope 
(Carl Zeiss Ltd, Oberkochen, Germany) in combination with Image-Pro Plus 7.0 software 
(Media Cybernetics Inc., Bethesda, MD USA). Alternatively, images were captured on a 
confocal Zeiss LSM510 inverted laser scanning microscope in combination with LSM Image 
Browser 4.2 software (both Carl Zeiss Ltd). Confocal images are shown wherever possible. 
Unless specified all images were captured at 63X magnification under a drop of Immersol® 
518N mineral oil (Carl Zeiss Ltd). 
2.7.1 IMMUNOFLUORESCENCE STAINING 
Fixed cells were permeabilised for 10 min in 500 µ l 0.5% v/v Triton® X-100 in PBS. Cover 
slips were washed twice in 1 ml PBS and blocked for 20 min in 1 ml block solution consisting 
of 10% v/v NCS in PBS. Cover slips were incubated for 20 min with 25 µ l primary antibody 
solution, washed twice in 1 ml PBS and incubated for 10 min with 50 µl secondary antibody 
solution. Cells were washed twice in 1 ml PBS and mounted as described in section 2.7. All 
washes and incubations were performed on the bench at room temperature; final wash at 
each stage was performed for 10 min. Following addition of secondary antibody, all 
incubations were performed in the dark. All antibodies were diluted in block solution as stated 
in tables 2.2 and 2.3. 
2.8 ASSAYS 
2.8.1 LUCIFERASE ASSAYS 
Vero cell monolayers grown to 90% confluency in 12-well tissue culture plates were 
transfected as described in figure legends and section 2.4.2. All transfection reactions were 
made up to a total of 1.1 µg DNA per well using the empty vector pCMV-SV5α. At 24 hours 
posttransfection, monolayers were washed twice in 1 ml ice-cold sterile PBS and lysed for 15 
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min with agitation (30 rpm) on a Stuart® gyro-rocker SSL3 in ice-cold 200 µ l passive lysis 
buffer (Promega). Plates were stored at -20˚C. To quantify luciferase activity, 20 µ l sample 
was combined with 100 µl room temperature Renilla or firefly luciferase substrate (appendix 
1). Luciferase activity was measured using an AutoLumat Plus LB953 luminometer (Berthold 
Technologies GmbH, Bad Wildbad, Germany). 
2.8.2 PROTEIN QUANTIFICATION 
The protein concentration of luciferase assay samples was quantified by adapting the RC 
DCTM Protein Assay (Bio-Rad Laboratories) for 96-well plate format as per manufacturer’s 
instructions. Each biological replicate was analysed in duplicate. Bovine serum albumin (Bio-
Rad Laboratories) protein standards in the range of 0.125 mg/ml to 1.25 mg/ml were 
prepared in passive lysis buffer. Briefly, 25 µl of luciferase assay sample or protein standard 
were transferred to a 96-well tissue culture plate. Samples were incubated with 125 µl RC 
Reagent I for 1 min at room temperature before addition of 125 µ l RC Reagent II. Plates 
were immediately centrifuged at 4,600 rpm for 5 min at 4˚C in an airtight swinging bucket 
rotor (7500 6445) for the Sorvall® Legend RT+ centrifuge. Supernatant was discarded. DC 
Reagents S and A were combined in a 1:50 ratio to produce DC Reagent A’, and 25 µl of this 
was then incubated with each sample for 5 min at room temperature. Following 15 min 
incubation at room temperature with 200 µl DC Reagent B, absorbance was read at 620 nm 
in an Anthos Labtec plate reader (Anthos Labtec Instruments, Salzburg, Austria). 
2.9 STATISTICAL ANALYSIS 
All data were analysed by Student’s t test using Microsoft® Excel 2008 for Mac. Two-tailed 
analysis was performed because the direction of change was always unknown. Welch’s 
correction was universally applied to account for unequal variances among the data 
(heteroscedasticity). This is appropriate as preliminary analyses to determine equality of 
variance do not protect the significance level and are no longer recommended (593). The 
sequentially rejective Bonferroni adjustment was used whenever multiple means were 
compared to one-another or a common control (figures 5.4B, 5.5A, B and E and 6.2B). This 
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correction performs as well as the more complicated multivariate analysis of variance  
(MANOVA) when the number of comparisons is small, is less conservative than the standard 
Bonferroni adjustment (leading to fewer false negatives), and is recommended for use in 
bioscience research projects (195, 413, 463). Statistical analyses are detailed in appendix 2. 
Student’s t test assumes that data follow a normal distribution (413), which was not explicitly 
tested here. However the robustness of the t test in the face of non-normal data has been 
verified, even for small sample sizes (520). 
2.10 SOFTWARE AND IMAGE ADJUSTMENT 
All digital images were prepared using Adobe® PhotoShop® CS5 for Mac (Adobe Systems, 
San Jose, CA USA). Image manipulation was limited to adjustment of brightness and 
contrast for microscopy images. Graphs were prepared using Microsoft® Excel 2008 for Mac 
before export to Adobe® PhotoShop® CS5 for Mac. Diagrams were prepared using Adobe® 
Illustrator® CS5 for Mac (Adobe Systems). Manuscript was prepared using Microsoft® Word 
2008 for Mac (Microsoft Corporation). 
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3.1 CHAPTER INTRODUCTION 
Given our data implicating VP22 in ICP0 packaging (129), it was important to understand the 
factors contributing to VP22 assembly before characterising the ICP0 assembly pathway. As 
discussed in section 1.2.1, interactions between tegument proteins and viral glycoproteins 
are thought to contribute to tegument assembly (365). HSV-1 VP22 is reported to interact 
with gD and gE (75, 172, 408), while PRV VP22 is also known to bind gM (184). Lee et al. 
and Fossum et al. also identified binding of HSV-1 VP22 to the type 2 membrane-associated 
proteins US9 and UL56 in separate yeast-two-hybrid screens (178, 305). 
This chapter addresses the respective contributions of gD, gE and gM to VP22 assembly. 
Data presented in sections 3.2 and 3.3 were published in the Journal of Virology (518). 
3.2 VP22 BINDS gE AND gM IN HSV-1-INFECTED CELLS 
To verify reported interactions between VP22 and gD, gE and gM, Vero cells were infected at 
a multiplicity of one with our GFP-22 and ∆22 viruses (figure 2.1) (129, 134). GFP was 
immunoprecipitated from whole cell lysates collected 24 hpi. GFP and GFP-tagged full-length 
VP22 (GFP-VP22) were precipitated with equal efficiency, and specific coprecipitation of gE 
was observed in the GFP-22, but not the ∆22, virus (figure 3.1). VP22-gM binding was also 
demonstrated for the first time in HSV-1. The well-characterised interaction between VP22 
and VP16 (130, 409) served as a positive control. VP22 consistently failed to interact with gD 
in this assay, and this result was corroborated when VP22 was immunoprecipitated using 
polyclonal antibodies directed against the N- and C-termini of VP22 (data not shown). 
Although this contradicts reports in the literature (75, 172), it is consistent with experiments 
from our group where polyhistidine (His)-tagged VP22 purified from baculovirus-infected Sf9 
insect cells was used to fish for gD expressed in HSV-1-infected Vero cell lysates, and our 
reciprocal immunoprecipitations with a monoclonal gD antibody (518). The exceptionally low 
level of gM expression observed with the ∆22 virus in figure 3.1 is particular to this 
experiment and was not consistently observed (e.g. figure 3.2A). 
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3.3 THE CONSERVED REGION OF VP22 IS ESSENTIAL FOR GLYCOPROTEIN BINDING 
AND VP22 ASSEMBLY 
By testing binding of the GST-tagged gE tail to various VP22 truncation mutants expressed 
transiently in COS-1 cells, Julianna Stylianou from our group refined the gE-binding region to 
residues 174 to 267 of VP22 (518). This domain lies within the region conserved among all 
alphaherpesvirus homologues of VP22 (figure 2.1) (381), and correlates with the existing 
literature (408). HSV-1 mutants expressing GFP-tagged VP22 with two small lesions 
between residues 213 to 226 (∆gEbind) or 170 to 192 (∆gEbind2) within this gE-binding 
domain were then generated by others in our group (figure 2.1) (518). 
GFP-tagged VP22 was immunoprecipitated with equivalent efficiency from Vero cells 
infected at a multiplicity of one with the ∆22, GFP-22, ∆gEbind and ∆gEbind2 viruses (figure 
3.2A). Again, gE and gM coimmunoprecipitated with GFP-tagged VP22 in cells infected with 
the GFP-22 mutant; the ∆22 virus served as a negative control. Coprecipitation of gE and gM 
was abrogated in the ∆gEbind and drastically reduced in the ∆gEbind2 viruses, confirming 
that the conserved region is essential for VP22-glycoprotein interaction. While gE and gM 
expression was slightly impaired in both mutants, this alone cannot account for the complete 
absence of VP22-glycoprotein binding in the ∆gEbind virus. In a repeat of this experiment, 
VP22-VP16 binding was found to be equivalent in cells infected with the GFP-22, ∆gEbind 
and ∆gEbind2 viruses (figure 3.2B). This confirms a report by O’Regan et al. suggesting that 
VP22’s VP16-binding domain does not correspond precisely with regions required for 
glycoprotein interaction (409). 
Emmanuelle Bernard within our group demonstrated that VP22 is not incorporated into 
extracellular ∆gEbind virions purified from BHK-21 cells (figures 3.2C and D) (518). Virions 
were equalised against the major capsid protein VP5, which also served as a loading control. 
The general profile of ∆gEbind virions was unaltered compared with the GFP-22 virus (figure 
3.2C), and gE and VP16 were packaged to equivalent levels in both viruses (figure 3.2D). 
These data demonstrate that the glycoprotein-binding domain of VP22 is essential for VP22 
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Figure 3.1: VP22 interacts with gE and gM in infected cells. Confluent Vero cells were 
infected with the GFP-22 or ∆22 viruses at a multiplicity of one. GFP-tagged VP22 (GFP-
VP22) was immunoprecipitated from lysates harvested 24 hpi using the polyclonal GFP-
specific antibody, and samples subjected to western blot analysis using antibodies raised 
against gM, GFP, VP16, gE or gD. Molecular weight markers (kDa) are shown on the left. 
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Figure 3.2: Residues 170 to 226 of VP22 are essential for glycoprotein binding and VP22 
assembly. Confluent Vero cells were infected at a multiplicity of one with the ∆22, GFP-22, 
∆gEbind or ∆gEbind2 viruses. GFP-tagged VP22 (GFP-VP22) was immunoprecipitated from 
lysates harvested 24 hpi using the polyclonal GFP-specific antibody, and samples subjected 
to western blot analysis using antibodies directed against GFP, gE and gM (A) or VP16 and 
the N-terminus of VP22 (B). Extracellular virions were Ficoll-purified by Emmanuelle Bernard 
from confluent BHK-21 cells infected at a multiplicity of 0.02 with the GFP-22 or ∆gEbind 
viruses, and samples analysed by Coomassie blue-stained SDS-PAGE gel (C) or western 
blot using antibodies directed against VP5, GFP, gE and VP16 (D). Identifiable virion 
components in the stained gel are annotated; GFP-tagged VP22 (GFP-VP22) is highlighted 
with an arrow (left). Molecular weight markers (kDa) are shown on the left; ♯ indicates non-
specific band in panel A. (C and D adapted from 518). 
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virion incorporation, and confirm existing data suggesting that VP16 packaging is 
independent of VP22 (279, 409). 
3.4 N-TERMINAL VP22 SEQUENCES CONTRIBUTE TO GLYCOPROTEIN INTERACTION 
VP22 is a phosphoprotein (137, 278), and having characterised the glycoprotein-binding 
domain it was of interest to assess the effect of phosphorylation on the VP22-glycoprotein 
interaction. Our group previously generated viruses expressing GFP-tagged VP22 in which 
the serine phosphorylation sites are replaced with glutamate or alanine to respectively mimic 
the phosphorylated (P+) and nonphosphorylated (P-) forms of VP22 (figure 2.1) (443). 
GFP-tagged VP22 was immunoprecipitated with equivalent efficiency from Vero cells 
infected at a multiplicity of one with the GFP-22, P+ and P- viruses (figure 3.3A). Compared 
with the GFP-22 virus, both gE and gM coimmunoprecipitated with VP22 at reduced levels in 
the P+ and P- mutants. The ∆22 mutant acted as a negative control. Therefore, VP22-
glycoprotein binding is sensitive to mutation at the phosphorylation sites, although it remains 
unclear whether phosphorylation per se modulates the interaction in wild-type virus infection. 
It should be noted that the first phosphorylation site at position 35 is replaced by alanine 
rather than glutamate in the P+ virus (figure 2.1) (443). Consequently, phosphorylation at this 
site may solely/additionally be required for optimal glycoprotein binding. 
Next, VP22 was immunoprecipitated from Vero cells infected with the N-terminally truncated 
mutants 108-301 and 160-301 (figure 2.1) (207), which lack the N-terminal phosphorylation 
sites. While GFP-tagged VP22 was immunoprecipitated as efficiently in these mutants as in 
the GFP-22 virus, gE and gM coimmunoprecipitated at reduced levels (figure 3.3B). 
3.5 gE AND gM ARE REDUNDANT FOR VP22 VIRION INCORPORATION 
To verify the roles of gE and gM in VP22 assembly, Gill Elliott purified virions from BHK-21 
cells infected with glycoprotein deletion mutants obtained from Helena Browne and Colin 
Crump (54). Unlike our VP22 mutants based on the wild-type HSV-1 strain 17+, these 
viruses were derived from strain sc16 (54). Purified virions were equalised against VP5, 
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which also acted as a loading control (figures 3.4A and B). Deletion of the respective 
glycoproteins in the gE-null (∆gE), gM-null (∆gM) and double knock-out (∆gEgM) mutants 
was verified by western blot (figure 3.4B). The general virion profiles of these viruses were 
relatively unaltered compared to wild-type virus (figure 3.4A). Similarly to our ∆22 and P+ 
mutants (129, 443), gE deletion resulted in reduced gB and/or gC assembly. The ∆gEgM 
mutant failed to package VP22, while deletion of gE or gM alone did not affect VP22 
assembly (figures 3.4A and B). This demonstrates that gE and gM are redundant for VP22 
virion incorporation, and that no other factor compensates for the absence of these 
glycoproteins. VP16 assembly remained unaffected by gE and gM deletion, which agrees 
with existing data suggesting that VP16 packaging is independent of gE, gM and VP22 (279). 
VP22 was then immunoprecipitated from Vero cells infected with these viruses to assess 
VP22-glycoprotein binding. The ∆22 virus served as a negative control. Similar levels of 
VP22 were immunoprecipitated in all viruses. Neither gB nor gD coimmunoprecipitated with 
VP22 (figure 3.4C), confirming that VP22 selectively binds gE and gM. Although VP22-gE 
binding was unaffected by gM deletion (figure 3.4C), gM coimmunoprecipitated with VP22 
extremely weakly in the ∆gE virus (figure 3.4D). Given that VP22 is not packaged in the 
∆gEgM virus it is unlikely that other virion components compensate for VP22 assembly in the 
∆gE mutant (figures 3.4A and B), since VP22 virion incorporation is entirely dependent on 
interactions with gE and gM. The residual level of gM binding seen in figure 3.4D must 
therefore represent the minimal interaction required for VP22 assembly. 
Interestingly, gE deletion consistently induced a mobility shift in VP22; the appearance of a 
more slowly migrating band is particularly noticeable in figure 3.4C. It remains unclear 
whether this shift represents an alteration in the phosphorylation state of VP22, or whether 
VP22’s other known posttranslational modifications are affected by gE deletion. 
3.6 VP22 BRIDGES gE AND gM TO FORM A MULTICOMPONENT COMPLEX 
Given the implications for VP22 assembly, it was important to verify the effect of gE deletion 
on VP22-gM binding. Therefore gM was immunoprecipitated from Vero cells infected with the 
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Figure 3.3: N-terminal VP22 residues enhance VP22-glycoprotein binding. (A) Confluent 
Vero cells were infected at a multiplicity of one with the ∆22, GFP-22, P+ or P- viruses. GFP-
tagged VP22 (GFP-VP22) was immunoprecipitated using the polyclonal GFP-specific 
antibody from lysates harvested 24 hpi, and samples subjected to western blot analysis 
using antibodies directed against GFP, gE or gM. Molecular weight markers (kDa) are shown 
on the left. (B) As for (A) except cells were infected with ∆22, GFP-22 or the N-terminally 
truncated VP22 mutants 160-301 and 108-301. 
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Figure 3.4: gE and gM are redundant for VP22 assembly. (A) Virions were Ficoll-purified by 
Gill Elliott from confluent BHK-21 cells infected at a multiplicity of 0.02 with the wild-type 
HSV-1 strain sc16 (wt), or ∆gE, ∆gM or ∆gEgM viruses. Samples were analysed by 
Coomassie blue-stained SDS-PAGE gel; molecular weight markers (kDa) are shown on the 
left; identifiable virion components are annotated on the right. (B) Purified virions were 
subjected to western blot analysis using antibodies directed against VP5, gE, gM, VP16 and 
VP22 (performed by Gill Elliott). (C) Confluent Vero cells were infected at a multiplicity of one 
with the ∆22, sc16, ∆gE, ∆gM or ∆gEgM viruses and VP22 immunoprecipitated from lysates 
harvested 24 hpi using the N-terminus-specific antibody. Samples were analysed by western 
blot using antibodies specific for gE, gD, gB or the C-terminus of VP22. (D) As for (B) except 
antibodies raised against gM or the N-terminus of VP22 were used for western blot analysis. 
* Indicates the immunoglobulin heavy chain. 
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wild-type strain sc16 or the ∆gE or ∆gM viruses. Equivalent levels of gM were 
immunoprecipitated in both the wild-type and ∆gE viruses (figure 3.5A). Unexpectedly, VP22 
was precipitated in control cells infected with the ∆gM virus, indicating that the polyclonal gM 
antibody nonspecifically targets a VP22-containing complex. This observation can be 
explained by the fact that gE was also precipitated in the absence of gM, suggesting the 
polyclonal gM antibody cross-reacts with the gE-gI Fc receptor. Presumably VP22 was 
coprecipitated via its interaction with gE. This experiment therefore cannot give further 
insights into the effects of gE deletion on VP22-gM binding. 
To characterise the VP22-glycoprotein complex further, gE was immunoprecipitated from 
Vero cells infected with wild-type HSV-1 or the ∆gE or ∆gM viruses. Equivalent levels of gE 
were precipitated from cells infected with wild-type HSV-1 and the ∆gM mutant (figures 3.5B 
and C). The ∆gE virus acted as a negative control. VP22 coimmunoprecipitated with gE at 
similar efficiencies in the GFP-22 and ∆gM viruses (figure 3.5B), corroborating data from 
VP22 immunoprecipitations (figure 3.4C). Notably, an association between gE and gM was 
demonstrated for the first time in any alphaherpesvirus (figures 3.5B and C). The lack of gD 
coprecipitation with the gE or gM antibodies (figures 3.5A and C) confirms the specificity of 
the gE-gM association, and that gD is not present in this VP22-glycoprotein complex. 
Next, gE immunoprecipitations were repeated with various VP22 mutants. Again, interaction 
of gE with VP22 and gM was observed in cells infected with the GFP-22 (1-301) virus (figure 
3.6). In contrast, gM was not coprecipitated with gE in the ∆22 or ∆ gEbind viruses, 
demonstrating that VP22-glycoprotein binding is required for gE-gM complex formation. This 
observation is in agreement with several studies that failed to identify direct gE-gM binding in 
yeast-two-hybrid screens and by tandem affinity purification (172, 178, 184). Instead, VP22 
appears to form a bridge between gE and gM. Compared with the GFP-22 (1-301) virus, gE 
expression and immunoprecipitation levels were reduced in cells infected with the ∆gEbind 
and ∆22 mutants. VP22 levels were also slightly lower in cells infected with the ∆gEbind virus 
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compared to GFP-22 (1-301). Nevertheless, these observations cannot account for the 
complete absence of VP22-gE and gE-gM associations in these viruses. 
3.7 THE VP22-gE-gM COMPLEX CAN INCORPORATE gI 
Given circumstantial evidence that VP22 coimmunoprecipitates with the HSV-1 Fc receptor 
(figure 3.5A), the role of gI in VP22-gE-gM complex formation warranted further investigation. 
Initially gE was immunoprecipitated using an antibody that specifically recognises gE in the 
context of the gE-gI complex (85). The gI antibody available to us worked poorly in western 
blots and gI proved undetectable in whole cell lysates and immunoprecipitation samples 
(figures 3.7A and C). Although gI was detectable in purified virions, confirming that the 
western blotting procedure had worked, these had to be overloaded to enable gI detection. It 
was therefore not possible to verify that the gE-gI antibody coprecipitated gI with gE. 
Bearing this in mind, the gE-gI antibody coprecipitated VP22 and gM from cells infected with 
wild-type HSV-1, but not the ∆gE virus that acted as a negative control (figures 3.7A and B). 
This finding suggests that the VP22-gE-gM complex can incorporate gI. 
Coimmunoprecipitation of gI with VP22 was also undetectable (figure 3.7C). It might have 
been possible to immunoprecipitate gI to test for coprecipitation of VP22, gE and gM, but 
since the immunoprecipitation efficiency could not be verified this was not attempted. As 
before, gB was not coimmunoprecipitated with the VP22-gE-gM complex (figure 3.7B). 
Since gI appeared to be recruited into the VP22-gE-gM complex, gE was immunoprecipitated 
from Vero cells infected with a gI-null (∆gI) virus, kindly donated by Helena Browne and Colin 
Crump (unpublished data), to determine whether gI is essential for VP22-glycoprotein 
complex formation. Equivalent levels of gE were immunoprecipitated from cells infected with 
the wild-type and ∆gI viruses (figure 3.8A). Coimmunoprecipitation of gM was unaffected by 
gI deletion (figure 3.8A). The ∆gE mutant served as a negative control. Furthermore, 
equivalent levels of gM also coimmunoprecipitated with VP22 in cells infected with the wild-
type and ∆gI viruses (figure 3.8B). In this case the ∆22 mutant acted as a negative control. 
CHAPTER 3   Assembly Determinants Of The ICP0-Packaging Protein VP22 
 
 106
 
 
 
 
 
 
 
 
Figure 3.5: VP22 forms a multicomponent complex with gE and gM. Confluent Vero cells 
were infected at a multiplicity of one with the wild-type HSV-1 strain sc16 (wt) or the ∆gE or 
∆gM viruses. Whole cell lysates were harvested 24 hpi and immunoprecipitation performed 
using antibodies directed against gM (A) or gE (B and C). Samples were analysed by 
western blot using gM, gE, gD or VP22 antibodies. * Immunoglobulin heavy chain. 
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Figure 3.6: VP22 is required for gE-gM complex formation. Confluent Vero cells were 
infected at a multiplicity of one with the ∆22, GFP-22 (1-301), ∆gE or ∆gEbind viruses. Whole 
cell lysates were harvested 24 hpi and immunoprecipitation performed with a gE-specific 
antibody. Samples were analysed by western blot using antibodies directed against gE, gM 
or the C-terminus of VP22. Molecular weight marker sizes (kDa) are indicated on the left. 
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Figure 3.7: gI is present within the VP22-gE-gM complex. Whole cell lysates were harvested 
24 hpi from confluent Vero cells infected at a multiplicity of one with the wild-type HSV-1 
strain sc16 (wt) or ∆22 or ∆gE viruses. Immunoprecipitation was performed using antibodies 
specific for the gE-gI complex (A and B) or the N-terminus of VP22 (C). Ficoll-purified sc16 
virions (virions) (A and C) and immunoprecipitation samples were analysed by western blot 
using antibodies specific for gI, gE, gM, gB or the C-terminus (B) or N-terminus (C) of VP22. 
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Figure 3.8: gI deletion does not impair VP22-gE-gM complex formation or VP22 assembly. 
Confluent Vero cells were infected at a multiplicity of one with the wild-type HSV-1 strain 
sc16 (wt), ∆gI or ∆gE  (A) or ∆22 (B) viruses. Whole cell lysates were harvested 24 hpi and 
immunoprecipitation performed using gE- (A) or VP22-specific (B) antibodies. Samples were 
analysed by western blot using antibodies directed against gE, VP22 and gM. * Indicates 
immunoglobulin heavy chain. (C) Virions were Ficoll-purified from confluent BHK-21 cells 
infected at a multiplicity of 0.02 with sc16 (wt) or ∆gI viruses and analysed by Coomassie 
blue-stained SDS-PAGE gel (top panel) or western blot using antibodies specific for VP5, gI, 
gM, gE, VP22 or VP16 (bottom panels). Molecular weight marker sizes (kDa) are shown on 
the left; identifiable virion proteins are annotated on the right; ♯ indicates non-specific band. 
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These data suggest that gI is not essential for VP22-gE-gM complex formation. Western 
blots were not probed for gI due to the consistent lack of gI detection. 
Next, the profiles of purified wild-type and ∆gI virions were compared. Particles were 
equalised against VP5, which also served as a loading control. Deletion of gI in the ∆gI virus 
was confirmed, since gI was only detected in wild-type virions (figure 3.8C). VP22, gM and 
VP16 were incorporated to wild-type levels in the ∆gI virus (figure 3.8C), demonstrating that 
gI is not required for assembly of these proteins. The general virion profile remained 
relatively unaffected, although VP23 may be packaged to increased levels. Incorporation of 
gE also appeared enhanced in the absence of gI, although these data are preliminary. Since 
gE and gM are redundant for VP22 assembly, it would be pertinent to delete gI in various 
combinations with these glycoproteins to exclude a redundant role for gI in VP22 packaging. 
These data collectively imply that gI may be incorporated into the VP22-gE-gM complex, but 
that this glycoprotein is not required for complex formation or VP22 assembly. However, 
further investigations are required to prove this unequivocally. 
3.8 CHAPTER DISCUSSION 
This chapter characterised VP22-glycoprotein interactions and their contributions to VP22 
assembly. The known VP22-gE interaction was explored further and VP22-gM binding was 
demonstrated for the first time in HSV-1. A previously unreported VP22-dependent 
association between gE and gM was also identified. In agreement with data from PRV (184), 
gE and gM were shown to be redundant for VP22 assembly, explaining previous data 
indicating that gE is not essential for VP22 virion incorporation in HSV-1 (407). 
VP22-gM binding was reduced in the absence of gE, while VP22-gE binding was unaffected 
by gM deletion. This suggests that gE is the major glycoprotein binding partner of VP22, with 
optimal recruitment of gM into a complex with VP22 relying on gE. This agrees with our 
observation that gE, but not gM, recruits VP22 to the secretory pathway in transfected cells 
(518). Furthermore, gE deletion induced a mobility shift in VP22 (figures 3.4C and D), 
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implying that gE is additionally required for posttranslational processing of VP22. It is unclear 
whether this shift is due to increased VP22 phosphorylation. The mechanism also remains 
unknown. Perhaps gE alters VP22 localisation or prevents VP22 being targeted by CKII, 
protein kinase C or UL13, which are known to catalyse VP22 phosphorylation (135, 136). 
Since nonphosphorylated VP22 is preferentially recruited into HSV-1 particles (136), it is 
tempting to speculate that gE helps establish or maintain a nonphosphorylated VP22 
subpopulation that is incorporated into virions. It would be interesting to determine whether 
gM assembles both phosphorylated and nonphosphorylated VP22 in the absence of gE. 
Furthermore, VP22 and gE consistently coimmunoprecipitated only the lowest-mobility form 
of gM (e.g. figures 3.3 and 3.5B and C), which presumably represents nonglycosylated gM. 
Therefore posttranslational modification may also modulate recruitment of gM. 
3.8.1 REPRODUCIBILITY OF THE REPORTED VP22-gD INTERACTION 
Despite extensive attempts in various model systems, the reported interaction between VP22 
and gD could not be verified. Evidence for this interaction stems mainly from GST binding 
assays (75). In more relevant immunoprecipitation experiments using infected cell lysates, 
other groups also consistently report only weak binding with high levels of nonspecific 
association (75, 172). Furthermore, Farnsworth et al. documented an inherent nonspecific 
‘stickiness’ of VP22 and proposed that this might contribute to the low-level binding observed 
in their assays (172). Variation in the virus strains and cell types employed may also play a 
part (75, 172, 518). Of specific note is the fact that Chi et al. used a mutant lacking the 
tegument protein vhs (75), which forms a complex with VP16 and VP22 (522). The absence 
of vhs may well affect the composition of protein complexes in infected cells.  We have 
proposed that VP22-gD binding, if present, is weak compared to the highly reproducible 
VP22-gE and VP22-VP16 interactions during HSV-1 infection (518). 
3.8.2 MINIMAL GLYCOPROTEIN BINDING LEVELS REQUIRED FOR VP22 ASSEMBLY 
VP22 cannot be assembled in the absence of both gE and gM (figure 3.4B), implying that 
other proteins do not mediate VP22 packaging. However, it is unclear how the dramatically 
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reduced VP22-gM binding in the ∆gE virus facilitates VP22 assembly (figures 3.4B and D). 
Since VP22-glycoprotein interaction was assessed in Vero cells while VP22 assembly was 
determined in virions purified from BHK-21 cells, cell type-specific differences may explain 
these observations. Time constraints prevented verification of VP22-glycoprotein binding in 
BHK-21 cells, and we have been consistently unable to purify high-quality extracellular virus 
particles from Vero cells within our group. 
On the other hand the residual VP22-gM association observed in the gE-null virus may 
represent minimal binding levels required for VP22 packaging. The proportion of expressed 
VP22 that is recruited into virus particles remains unknown, and it is possible that an excess 
of VP22-gE-gM complexes forms compared with the amount incorporated into virions. 
Alternatively, VP22-gM association may be more dynamic than VP22-gE binding, perhaps 
only becoming stable in the presence of gE. Others within our group have characterised a 
replication deficiency in the ∆gE virus compared to wild-type HSV-1 in HFFF2 cells and the 
African green monkey kidney cell line BSC-1 (unpublished data). However, this mutant is not 
reported to display a defect in Vero cells under conditions in which VP22-glycoprotein 
binding was assessed here (54). Therefore it is unlikely that the ∆gE virus produces a 
reduced number of morphologically normal virions. 
Our 108-301, 160-301, P+ and P- viruses, which exhibit reduced VP22-gE-gM binding (figure 
3.3), also assemble wild-type levels of VP22 (346, 443). Therefore the discrepancy between 
VP22-glycoprotein binding and VP22 assembly is not specific to the ∆gE virus. 
3.8.3 VP22 DOMAINS INVOLVED IN GLYCOPROTEIN BINDING AND VP22 ASSEMBLY 
Figure 3.9 summarises VP22 domains contributing to VP22 assembly. 
Prior to data presented here, our group and others had identified a domain within the 
conserved region of VP22 essential and sufficient for VP22-gE binding and VP22 virion 
incorporation (184, 207, 408, 409). Work outlined in this chapter reaffirms the importance of 
these residues for glycoprotein binding and VP22 assembly (figures 3.2A and D). O’Regan et 
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al. also recently identified a ‘WW’ motif between residues 189 to 221 within the conserved 
region of VP22 that is important for gE binding (407). ‘WW’ motifs are well-characterised 
protein-protein interaction domains consisting of a 35 to 40 residue aromatic amino acid-rich 
sequence sandwiched between two tryptophan residues (237). Our data confirm the 
importance of the region containing the ‘WW’ motif for VP22-glycoprotein binding and VP22 
packaging, as it is disrupted in the ∆gEbind and ∆gEbind2 viruses.  
N-terminal sequences were also shown to contribute to optimal VP22-gE-gM complex 
formation in infected cells (figure 3.3). However this region is neither essential nor sufficient 
for glycoprotein binding and VP22 assembly, suggesting it performs an accessory role in 
complex formation (184, 207, 346, 408, 518). O’Regan et al. recently identified two N-
terminal acidic clusters located between residues 61 to 64 and 71 to 77 that were important 
for VP22 virion incorporation, but not VP22-gE binding (407). These domains facilitated TGN 
localisation of VP22 expressed transiently in Vero cells (407). Substitution with the acidic 
cluster of the cellular protein furin restored TGN localisation and virion incorporation in acidic 
cluster deletion mutants (407). The authors note that acidic clusters can act as secretory 
pathway trafficking signals by interacting with the clathrin sorting machinery (41, 552) and 
suggest that, in addition to gE binding, correct VP22 localisation may be important for VP22 
assembly (407). These findings are intriguing because the primary acidic cluster at positions 
71 to 77 encompasses the N-terminal phosphorylation sites mutated in our study (figure 2.1). 
While O’Regan et al. did not detect an effect of acidic cluster deletion on gE interaction in 
GST pull-down assays (407), immunoprecipitation experiments should be performed with 
infected cell lysates to verify this.  In fact we also observed no effect of VP22 N-terminal 
mutation on VP22-gE binding in GST pull-down assays, highlighting a failure of this system 
to correctly mimic conditions encountered during virus infection (518). Importantly, along with 
O’Regan et al., we detected unaltered assembly of N-terminally truncated VP22 (207, 346, 
408), which contrasts with the lack of VP22 packaging in acidic cluster mutants (407). It is 
therefore possible that these mutants induce substantial misfolding of VP22 above and 
CHAPTER 3   Assembly Determinants Of The ICP0-Packaging Protein VP22 
 
 118
 
 
 
 
 
Figure 3.9: VP22 domains important for glycoprotein binding and VP22 assembly. VP22 
schematic is shown above. The conserved region is highlighted in grey. Triangles represent 
serine phosphorylation sites at positions 35, 71, 72, 73, 292 and 294. Green sequences 
denote dimerisation domains identified by Mouzakitis et al. (381). Brown shading highlights 
regions involved in gE binding and/or VP22 packaging that were previously identified by 
O’Regan et al. (407, 408), Schlegel et al. (479), and Hafezi et al. (207). Details are described 
in main text. Sequences required for minimal (212 to 301) and optimal (160 to 301) VP22 
assembly identified by our group (Hafezi et al.) are shown (207). Principal (red) and N- and 
C-terminal accessory (yellow) glycoprotein-binding domains characterised here and by 
Julianna Stylianou within our group (518) are shown below. ? Symbolises the unconfirmed 
contribution of C-terminal sequences to VP22 assembly. AC, acidic clusters between 
residues 71 to 77 (primary cluster) and 61 to 64 (secondary cluster) reportedly required for 
TGN localisation of VP22; ‘WW’, ‘WW’ protein interaction motif (407). 
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Figure 3.9 
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beyond deletion of the entire N-terminal region. Moreover, our group and others consistently 
do not observe TGN localisation of wild-type VP22 expressed by transient transfection in 
Vero and other cells (9, 131-133, 190, 334, 347, 518). It would therefore be prudent to 
generate independent acidic cluster mutants to verify the importance of these sequences to 
VP22 assembly. 
Although the VP22 phosphorylation site mutants validate the role of N-terminal sequences in 
glycoprotein binding, the impact of natural phosphorylation remains unclear. However VP22 
modification and VP22-gM binding was altered in the ∆gE virus, possibly implying that VP22 
phosphorylation impairs gM association. This could be investigated further by 32P-labelling 
HSV-1-infected cells, or by treating cell lysates with phosphatases to determine whether the 
glycoproteins preferentially bind phosphorylated or nonphosphorylated VP22. Since a role for 
the C-terminal phosphorylation cluster in VP22-glycoprotein binding could not be ruled out, 
VP22 constructs harbouring only N- or C-terminal phosphorylation site mutations should also 
be generated. In line with previous data from our lab (207), Schlegel and Blaho identified a 
packaging signal within the C-terminal fifteen residues of VP22 that was sufficient for VP22 
assembly (479). While it is tempting to infer a role for the C-terminal phosphorylation sites in 
VP22 assembly, these data are difficult to reconcile with our observation that this region 
alone does not bind gE or gM (518). It is therefore possible that, in isolation, the extreme C-
terminus of VP22 is incorporated into virus particles nonspecifically. 
The mechanism by which N-terminal, and possibly C-terminal, sequences enhance VP22-
gE-gM binding is unclear. Residues within these domains may form part of a glycoprotein-
binding pocket along with the essential ‘WW’ motif, although crystallography data confirming 
this hypothesis is lacking. Alternatively these regions may bind other virion components to 
stabilise the VP22-glycoprotein interaction. Another intriguing possibility relates to the 
contribution of VP22 dimerisation to VP22-glycoprotein binding. Mouzakitis et al. identified 
two dimerisation domains corresponding with the N-terminal phosphorylation cluster and 
‘WW’ glycoprotein-binding motif (381). Therefore VP22 dimerisation may stabilise the VP22-
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gE-gM interaction within multimeric VP22-glycoprotein complexes. This possibility is 
appealing because VP22 bridges gE and gM, and it is difficult to envisage how the small 
glycoprotein-binding domain can accommodate both gE and gM in a single VP22 molecule. 
The relevance of VP22’s N-terminus to herpesvirus assembly also remains unclear, as this 
region is not essential for VP22 packaging (207, 346, 408) and, along with the 
phosphorylation sites, is poorly conserved among VP22 homologues (381). Perhaps this 
region is important for HSV-1 maturation in neurones. Alternatively, although morphologically 
normal, the integrity of virus particles may be compromised in N-terminal deletion mutants. 
Stripping purified virions with a detergent/salt buffer would reveal whether tegument 
components dissociate under less stringent conditions in viruses encoding N-terminally 
truncated VP22. Finally, redundancy in VP22-glycoprotein binding may simply allow wild-type 
levels of VP22 assembly in the face of an overall reduction in VP22-gE-gM association. 
3.8.4 CONTRIBUTION OF gI AND UL49A TO VP22 ASSEMBLY 
The data presented here suggest gI can be incorporated into the VP22-gE-gM complex, but 
that gI is not required for complex formation or VP22 assembly (figures 3.7 and 3.8). 
Although Farnsworth et al. also coimmunoprecipitated VP22 with gE-gI, the group used a 
mixture of gE- and gI-specific antibodies that would additionally have targeted non-gI-bound 
gE (172). Therefore our immunoprecipitations using a Fc receptor-specific antibody provide 
more substantial evidence for incorporation of gI into the VP22-gE-gM complex. The 
significance of this observation remains unknown, since our group and others detected 
VP22-gE association in the absence of gI in GST pull-downs, tandem affinity purification 
experiments and yeast-two-hybrid screens (172, 178, 184, 518). While gI might still enhance 
VP22-glycoprotein association, our preliminary data suggest gI is not essential for VP22-gE-
gM binding or VP22 assembly. Since the majority of gE is complexed with gI in infected cells 
(249, 250), recruitment of gI into the VP22-gE-gM complex may be coincidental. 
It would have been interesting to assess the contribution of UL49A to VP22-gE-gM complex 
formation, since interactions between the UL49.5 gene products and gM homologues of PRV, 
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HHV8, EBV and HCMV have been described (253, 289, 297, 341). This was not possible 
because no antibody against HSV-1 UL49A currently exists (personal communication, Colin 
Crump). Nevertheless our group and others have confirmed UL49A-independent VP22-gM 
association in GST binding assays and yeast-two-hybrid screens (184, 518). Although 
Adams et al. detected UL49A in purified extracellular HSV-1 virions (2), Loret et al. did not 
(336). On the other hand the UL49.5 gene products of EBV and PRV are known to be 
incorporated into mature virions (247, 254, 336). It would therefore be interesting to generate 
a HSV-1 UL49A-specific antibody or an UL49A knock-out virus to reassess HSV-1 UL49A 
virion incorporation and the role of UL49A in VP22-glycoprotein binding and VP22 assembly. 
3.8.5 CONCLUDING REMARKS 
In this chapter VP22 was shown to bridge gE and gM to form a complex involved in VP22 
assembly. Efficient VP22-gM association requires the additional presence of gE and may be 
modified by posttranslational modification of VP22 and/or gM. Glycoprotein binding within the 
conserved region of VP22 is enhanced by N-terminal VP22 sequences. Similarly to the 
situation in PRV, gE and gM are redundant for VP22 assembly in HSV-1. 
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4.1 CHAPTER INTRODUCTION 
Our group provided the first evidence that ICP0 is not incorporated into virions in the 
absence of VP22 (129). Duffy et al. also reported greatly reduced ICP0 assembly in their 
independent VP22-null mutant (124). We later showed that ICP0 packaging is specifically 
abrogated in our P+ virus, suggesting that VP22 phosphorylation might modulate ICP0 
assembly (443). In addition, Sedlackova and Rice reported that the immediate-early protein 
ICP27, which is conserved among all herpesvirus families, is required for ICP0 virion 
incorporation (486). ICP27 is a nucleocytoplasmic shuttling protein that inhibits mRNA 
splicing, facilitates cytoplasmic export of HSV-1 mRNA, helps mediate the switch between 
early and late gene expression, and is essential for HSV-1 replication (355, 501). ICP27 has 
also been implicated in the cytoplasmic accumulation of ICP0 in infected and transfected 
cells (486, 592). In line with previous reports (336, 416, 582), Sedlackova and Rice did not 
detect ICP27 within mature virus particles, and proposed that ICP27 contributes to ICP0 
assembly by facilitating recruitment of ICP0 to cytoplasmic tegument assembly sites (486). 
This chapter explores the roles VP22, gE, gM and ICP27 play in ICP0 assembly, and 
characterises VP22 and ICP0 motifs required for ICP0 virion incorporation. Data presented in 
sections 4.2 to 4.4, 4.6, 4.9 and 4.10 were published in the Journal of Virology (346). 
4.2 ICP0 IS TIGHTLY ASSOCIATED WITH THE VIRAL CAPSID 
Since the presence of ICP0 within virus particles remained somewhat controversial at the 
outset of this project, extracellular virions of the wild-type HSV-1 strain 17+ were collected 
from BHK-21 cells and purified across a Ficoll gradient. Others within our group verified that 
these purified particles represent bona fide infectious virions (346). Virions were treated with 
detergent/salt buffers containing varying amounts of salt (0.2 to 1.0 M NaCl). Solubilised 
virion components were segregated from capsid-associated proteins by centrifugation. The 
detergent in this buffer removes the viral envelope and glycoproteins, while the salt disrupts 
tegument protein-protein interactions. Equivalent amounts of untreated virions, soluble 
supernatants and capsid-containing pellets were analysed by Coomassie blue-stained SDS-
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PAGE gel and western blot (figure 4.1). Equal gel loading was confirmed by equivalent levels 
of the glycoproteins gB and gD in input virions and supernatant fractions, and by equivalent 
levels of the capsid proteins VP5 and VP26 in virions and pellet fractions. 
While the major tegument protein VP13/14 was stripped completely with just 0.4 M NaCl, 
ICP0 remained capsid-associated even in the presence of 1.0 M salt. A small proportion of 
the capsid proteins VP5 and VP26 became solubilised under these conditions, suggesting 
that no further tegument components would be specifically removed with higher salt 
concentrations. Two recent reports confirm that ICP0 is tightly capsid-associated (104, 452). 
Importantly, we also demonstrated that ICP0 is not present in purified intranuclear capsids 
(346). Collectively these data confirm previous reports suggesting that ICP0 is assembled 
into the tegument of infectious HSV-1 particles (486, 582), and show that ICP0 is recruited 
into the virion downstream of capsid maturation in the nucleus (346). 
In addition, this experiment identified two types of tegument proteins. A proportion of the 
tegument, including VP13/14, was loosely associated with the capsid. Other tegument 
components, like ICP0, bound the capsid tightly. Some tegument proteins, including VP16, 
VP22 and vhs, appeared to be assembled into two distinct subpopulations, one that was 
easily removed with 0.4 M salt, and one that remained tightly capsid-associated at higher salt 
concentrations. Although these findings do not shed light on the physical localisation of 
tegument components within the virion, they do hint at an underlying tegument structure. Of 
additional note is the fact that, of the glycoproteins, gE and gM were more tightly tegument-
associated than gB and gD, possibly due to more stable interactions with their respective 
tegument binding partners. 
4.3 ICP27 IS INCORPORATED INTO THE HSV-1 TEGUMENT 
Given the proposed role of ICP27 in ICP0 assembly (486), it was of interest to reassess 
whether ICP27 itself is incorporated into virions. Surprisingly, ICP27 was readily detectable in 
purified virions from the wild-type HSV-1 strain HFEM (figure 4.2A). ICP27 cofractionated 
with the capsid protein VP5 and the tegument protein VP16 when virions were stripped in a 
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Figure 4.1: ICP0 associates tightly with the capsid. Virions from the wild-type HSV-1 strain 
17+ were incubated with a stripping buffer containing detergent and increasing salt 
concentrations. Soluble supernatant (S/N) and insoluble pellet fractions were segregated by 
centrifugation and compared with an equal quantity of untreated virions (Input) by Coomassie 
blue-stained SDS-PAGE gel (top panel) or western blot using antibodies as annotated (lower 
panels). Molecular weight marker sizes (kDa) are shown on the left. Virion components 
visible in the stained gel are annotated. Tegument proteins are grouped according to whether 
they dissociate completely at low salt concentrations (T1), remain tightly capsid-associated 
even at high salt concentrations (T2) or segregate into two subpopulations (T1/2). 
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Figure 4.2: ICP27 is packaged into the HSV-1 tegument. (A) Ficoll-purified extracellular 
virions from the wild-type HSV-1 strain HFEM were stripped using a buffer containing 
detergent and 0.2 M NaCl. The insoluble tegument/capsid fraction (T/C) and soluble 
supernatant containing envelope-associated proteins (Env) were separated by centrifugation 
and compared with untreated virions (Input) by western blot with antibodies as annotated. (B) 
Successive fractions were collected across the 5 to 15% Ficoll gradient used to purify the 
virions shown in (A). Infectivity was assayed by titration on Vero cells (top) and fractions 
subjected to western blot analysis using antibodies raised against ICP27, VP5 and VP16 
(bottom). Virions shown in (A) correspond with fraction 7. 
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detergent/salt buffer. The absence of ICP27 in the envelope fraction confirms that ICP27 was 
not present as a contaminant on the outside of virus particles. Importantly, when virions 
where purified across a 5 to 15% Ficoll gradient, ICP27 cofractionated with virus infectivity 
(figure 4.2B). These data show that ICP27 is incorporated into the tegument of bona fide 
infectious particles, contradicting previous reports (336, 416, 486, 582). 
4.4 VP22 AND ICP0 FORM A COMPLEX IN INFECTED CELLS 
Since VP22 is required for ICP0 virion incorporation (129), VP22-ICP0 binding was assessed 
in infected cells. Initially, confluent Vero cells were infected at a multiplicity of one with our 
GFP-22 or ∆22 mutants (figure 2.1). VP22 was immunoprecipitated from whole cell lysates 
harvested at various times postinfection and samples analysed by western blot. In line with 
our previous data (129, 134), maximum GFP and GFP-tagged VP22 expression was 
achieved by 18 hpi, and ICP0 expression was delayed and reduced in the absence of VP22 
(figure 4.3A). Levels of VP22 immunoprecipitation correlated with VP22 expression. Specific 
coimmunoprecipitation of ICP0 with VP22 was apparent from 18 hpi in the GFP-22, but not 
the ∆22, virus, demonstrating that VP22 and ICP0 form a complex during HSV-1 infection. 
Importantly, the levels and timings of coimmunoprecipitation of ICP0 with VP22 were 
comparable in the GFP-22 virus and its parental wild-type strain 17+ (figure 4.3B). Although 
expression of both proteins was slightly accelerated in the GFP-22 virus compared to wild-
type HSV-1 in this experiment, this was not reproducible (data not shown). Therefore VP22 
and ICP0 also form a complex during wild-type HSV-1 infection. Yu et al. recently confirmed 
VP22-ICP0 coimmunoprecipitation in HSV-1-infected Vero cells (586). 
All three viruses replicated equally well under these experimental conditions, with peak 
infectious particle production observed from 18 hpi (figure 4.3C). Although VP22-ICP0 
complex formation appeared to correlate with peak virus assembly, assay limitations might 
prohibit detection of low-level VP22-ICP0 association at early time points. Furthermore, 
VP22-ICP0 association correlated with levels of VP22 expression and immunoprecipitation 
(figures 4.3A and B), implying that VP22-ICP0 complex formation may not be time-
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dependent. In subsequent experiments cells were harvested between 20 and 24 hpi, when 
VP22-ICP0 association was readily detectable (figures 4.3A and B). 
To confirm VP22-ICP0 complex formation, the reciprocal pull-down was attempted. ICP0 was 
immunoprecipitated from Vero cells infected with the wild-type HSV-1 strain 17+ or the ICP0-
null (∆ICP0) mutant kindly provided by Roger Everett (514), which acted as a negative 
control. Although ICP0 and VP22 expression was robust, and ICP0 immunoprecipitation was 
readily observed, coprecipitation of VP22 was undetectable (figure 4.4A). Next, YFP-tagged 
ICP0 was immunoprecipitated from Vero cells infected with the YFP-0 virus, also kindly 
donated by Roger Everett (164), using the polyclonal GFP-specific antibody. Again, no 
coimmunoprecipitation of VP22 with ICP0 was observed (figure 4.4B). VP22-ICP0 complex 
formation may be more readily observed when VP22 is immunoprecipitated because a 
higher proportion of VP22 might associate with ICP0 than vice versa. Alternatively, ICP0 
might be immunoprecipitated less efficiently than VP22 in this system. 
4.5 VP22-ICP0 BINDING COULD NOT BE DEMONSTRATED IN TRANSFECTED CELLS 
To assess VP22-ICP0 binding in the absence of other viral proteins, confluent Vero cells 
were transiently transfected with our existing plasmid expressing GFP-tagged VP22 (131), 
and/or a vector expressing wild-type ICP0 kindly provided by Roger Everett (156). Only 
phosphorylated VP22 is detectable in transfected cells (136, 443). Therefore existing vectors 
expressing GFP-tagged VP22 mimicking the phosphorylated and nonphosphorylated forms 
of VP22 (443) were also tested to account for the possible impact of VP22 phosphorylation 
on VP22-ICP0 complex formation. Cells transfected with a GFP expression vector or infected 
with our GFP-22 virus served as negative and positive controls respectively. Table 2.1 
summarises plasmid details. VP22 was immunoprecipitated from whole cell lysates 
harvested 24 hours after transfection/infection, and samples analysed by western blot. 
VP22 levels were lower in transfected than infected cells (figure 4.5A), though whether this 
resulted from a reduced number of VP22-expressing cells or lower VP22 levels per cell was 
not tested. ICP0 levels were greatly reduced in cells cotransfected with VP22 or GFP (see 
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Figure 4.3: VP22 and ICP0 form a complex in infected cells. (A) Vero cells infected at a 
multiplicity of one with the GFP-22 or Δ22 viruses were harvested at various times 
postinfection, and VP22 immunoprecipitated using our C-terminus-specific VP22 antibody. 
Samples were analysed by western blot using monoclonal antibodies directed against GFP 
or ICP0. Molecular weight marker sizes (kDa) are shown on the left. (B) As for (A) except 
cells were infected with the GFP-22 virus or the parental wild-type HSV-1 strain 17+ (wt). 
Western blots were probed with antibodies directed against ICP0, GFP (GFP-22) or the N-
terminus of VP22 (VP22). * Indicates the immunoglobulin heavy chain. (C) One step growth 
curves for strain 17+, GFP-22 and Δ22 viruses. Total infectious virus was collected 
concurrently with the experiment described in (A) and titrated on Vero cells. 
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Figure 4.4: Immunoprecipitation of ICP0 does not coprecipitate VP22. (A) ICP0 was 
immunoprecipitated from whole cell lysates collected 20 hpi from Vero cells infected at a 
multiplicity of one with the wild-type HSV-1 strain 17+ (wt) or the ΔICP0 virus using an ICP0-
specific antibody. Samples were analysed by western blot with antibodies raised against 
ICP0 (left panel) or the C-terminus of VP22 (right panel). Molecular weight marker sizes 
(kDa) are shown on the left; ♯ denotes a nonspecific band. (B) As for (A) except that cells 
were infected with the ΔICP0 or YFP-0 viruses. ICP0 was immunoprecipitated using the 
polyclonal GFP-specific antibody. 
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Figure 4.4 
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Figure 4.5: VP22-ICP0 interaction was not detected in the absence of other viral proteins. 
Confluent Vero cells were transfected with 2.5 µg per 60-mm dish of plasmids expressing 
ICP0, GFP, GFP-tagged VP22 (GFP-VP22) or GFP-tagged constructs mimicking 
phosphorylated (P+) or nonphosphorylated (P-) VP22. Plasmids were transfected 
individually, or GFP or VP22 coexpressed with ICP0. As a positive control cells were infected 
with the GFP-22 virus at a multiplicity of one. Samples were harvested 24 hours after 
transfection/infection and immunoprecipitation performed on samples expressing both ICP0 
and GFP or VP22 with our C-terminus-specific VP22 antibody. Samples were analysed by 
western blot using GFP and ICP0 antibodies. (A) Inputs; (B) immunoprecipitation samples. 
Molecular weight marker sizes (kDa) are shown on the left; ♯ indicates nonspecific bands. 
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Figure 4.5 
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chapter 5). Coimmunoprecipitation of ICP0 with VP22 was readily detected in infected, but 
not transfected, cells (figure 4.5B). A comprehensive series of follow-up experiments also 
failed to demonstrate VP22-ICP0 association (data not shown). For instance, the alternative 
VP22 vector pPO85 (table 2.1), kindly provided by Peter O’Hare, and expression in COS-1 
cells by lipofectamineTM 2000 and calcium phosphate transfection were tested. Several 
plasmid preparation techniques and lysis buffers were trialled to account for reagent-specific 
inhibitory factors. To overcome low ICP0 levels, independently prepared VP22 and ICP0 
lysates were mixed posttransfection. Finally, an alternative immunoprecipitation method 
developed by Chi et al., performed at 37˚C, that reportedly better mimics in vivo conditions 
was tested (75). Attempts to demonstrate VP22-ICP0 binding using His-tagged VP22 purified 
from baculovirus-infected Sf9 insect cells were aborted due to technical difficulties. While it is 
plausible that VP22-ICP0 binding was not detected due to poor ICP0 expression, these data 
could indicate a role for other viral factors in VP22-ICP0 complex formation. 
4.6 ICP27 IS NOT INCORPORATED INTO THE VP22-ICP0 COMPLEX 
Since ICP27 contributes to ICP0 assembly (486), its role in VP22-ICP0 complex formation 
was investigated. GFP-tagged VP22 was immunoprecipitated with the polyclonal GFP 
antibody from Vero cells infected with the GFP-22 and ∆22 viruses; the latter served as a 
negative control. In line with existing yeast-two-hybrid screen data (178), ICP27 did not 
coimmunoprecipitate with VP22 (figure 4.6A). The same antibody was used to 
immunoprecipitate YFP-tagged ICP0 from Vero cells infected with the YFP-0 virus. In this 
case the ∆ICP0 mutant acted as a negative control. ICP27 also failed to coprecipitate with 
ICP0 (figure 4.6B), confirming that ICP27 is not incorporated into the VP22-ICP0 complex. 
Virion incorporation of the immediate-early proteins ICP0 and ICP4 is VP22-dependent 
(129). Therefore ICP27 assembly was assessed in purified virions from the wild-type HSV-1 
strains 17+ and sc16, and our ∆22 mutant. Purified virus particles were equalised against the 
major capsid protein VP5, which also served as a loading control. Both VP22 and ICP0 were 
readily detected in the wild-type, but not ∆22, virions (figure 4.6C). Unlike ICP0 assembly, 
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ICP27 packaging was unaffected by VP22 deletion. Importantly, ICP27 was readily detected 
in virions from both wild-type strains, confirming that ICP27 virion incorporation is not strain-
specific. Collectively these findings show that ICP27 packaging is independent of VP22 and 
ICP0 assembly, and that ICP27 does not physically mediate VP22-ICP0 binding. The data do 
not rule out an indirect role for ICP27 in VP22-ICP0 complex formation. 
4.7 VP22-ICP0 COMPLEX FORMATION IS ENHANCED BY gE AND gM 
Since gE and gM facilitate VP22 assembly (chapter 3), their contribution to VP22-ICP0 
complex formation was assessed. Initially, VP22 was immunoprecipitated from Vero cells 
infected with the wild-type HSV-1 strain sc16 or the ∆22, ∆gE, ∆gM or ∆gEgM viruses. The 
∆22 mutant acted as a negative control. All viruses expressed similar levels of VP22, ICP0 
and VP16 (figure 4.7A). Despite equivalent levels of VP22 immunoprecipitation, ICP0 
coprecipitation was greatly reduced in the absence of either gE or gM. In contrast, VP22-
VP16 binding was unaffected, indicating that gE and gM specifically enhance VP22-ICP0 
association. The experiment was repeated with our GFP-22 and ∆gEbind viruses (figure 2.1), 
with the ∆22 mutant serving as a negative control. VP22-ICP0 association was markedly 
reduced in the ∆gEbind mutant compared with the GFP-22 virus (figure 4.7B). While the 
∆gEbind virus expressed lower levels of VP22 and ICP0, this does not explain the dramatic 
reduction in VP22-ICP0 association. Therefore VP22-glycoprotein binding, rather than gE or 
gM expression, enhances VP22-ICP0 interaction. Since optimal VP22-gM binding requires 
gE (figure 3.4D), VP22-ICP0 association might only depend upon gM. 
Gill Elliott showed that ICP0 levels were drastically reduced in virions from the ∆gE and ∆gM 
viruses (figure 4.7C), correlating with reduced VP22-ICP0 association (figure 4.7A). ICP0 
assembly was abrogated in the ∆gEgM virus (figure 4.7C), since VP22 itself is not packaged 
in this mutant (figure 3.4B). For the same reason ICP0 is not incorporated into ∆gEbind 
virions (346). Virions were equalised against VP5, which also acted as a loading control. 
To further examine formation of the VP22-gE-gM-ICP0 complex, Vero cells were infected 
with the GFP-22, ∆gEbind, ∆22 and ∆gE viruses, and gE immunoprecipitated from lysates 
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Figure 4.6: ICP27 is not present in a complex with VP22 and ICP0. (A) Confluent Vero cells 
infected at a multiplicity of one with the GFP-22 or ∆22 viruses were harvested 24 hpi, and 
immunoprecipitation performed using a polyclonal GFP-specific antibody. Samples were 
subjected to western blot analysis using antibodies directed against GFP and ICP27. 
Molecular weight markers (kDa) are shown on the left. (B) As for (A) except cells were 
infected with the ∆ICP0 or YFP-0 viruses. Western blots were probed with antibodies 
directed against ICP0 and ICP27. * Indicates immunoglobulin heavy chain. (C) Ficoll-purified 
virions from the ∆22 virus and the wild-type HSV-1 strains sc16 and 17+ were analysed by 
western blot using antibodies directed against VP5, VP22, ICP0 and ICP27. 
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Figure 4.7: gE and gM are required for optimal VP22-ICP0 complex formation and ICP0 
assembly. (A) Confluent Vero cells were infected at a multiplicity of one with the wild-type 
HSV-1 strain sc16 (wt) or ∆22, ∆gE, ∆gM or ∆gEgM viruses. Whole cell lysates were 
harvested 24 hpi, and VP22 immunoprecipitated using the N-terminus-specific antibody. 
Western blots were probed for ICP0, VP16 or the N-terminus of VP22. (B) As for (A) except 
cells were infected with the ∆22, GFP-22 or ∆gEbind viruses. Molecular weight marker sizes 
(kDa) are shown on the left. * Immunoglobulin heavy chain; ♯ nonspecific band. (C) 
Extracellular virions were Ficoll-purified by Gill Elliott from BHK-21 cells infected at a 
multiplicity of 0.02 with the wild-type strain sc16 (wt) or ∆gE, ∆gM or ∆gEgM viruses. Western 
blots were probed for VP5, VP22 and ICP0. 
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Figure 4.7 
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collected 24 hpi. VP22 and ICP0 coimmunoprecipitated with gE (figure 4.8), confirming that 
ICP0 is incorporated into the VP22-gE-gM complex. The ∆gE mutant acted as a negative 
control. However, ICP0 did not coprecipitate with gE in the ∆22 or ∆gEbind mutants, 
indicating that ICP0 does not bind gE directly. ICP0 expression was similar in all viruses, and 
the slightly reduced gE immunoprecipitation efficiency in the mutants compared to the GFP-
22 virus does not explain the complete absence of ICP0 coimmunoprecipitation with gE. 
Taken together these data demonstrate that ICP0 is assembled via recruitment into the 
VP22-gE-gM complex. While gE and gM enhance VP22-ICP0 binding, VP22 is probably 
ICP0’s primary binding partner within the complex because residual VP22-ICP0 association 
was observed in the absence of VP22-glycoprotein interaction (figures 4.7A and B). 
Furthermore, ICP0 does not directly bind gE (figure 4.8), while two recent reports failed to 
identify ICP0-gM binding in independent yeast-two-hybrid screens (178, 184). 
4.8 THE VP22-gE-gM-ICP0 COMPLEX WAS NOT RECONSTITUTED IN TRANSFECTED 
CELLS 
In an attempt to reconstitute the VP22-gE-gM-ICP0 complex in the absence of other viral 
proteins, Vero or COS-1 cells were transfected with plasmids expressing ICP0, gE and gM 
(89), in the presence or absence of the VP22 expression vector pPO85 (table 2.1). VP22, gE 
and gM levels were markedly lower in lysates harvested 24 hours posttransfection from both 
cell types compared with cells infected with the wild-type HSV-1 strain sc16 (figure 4.9A). 
Unlike the situation in the absence of the glycoproteins, ICP0 levels were unaffected by 
VP22 coexpression in the presence of gE and gM (compare figures 4.5A and 4.9A). VP22 
coexpression did however impair gE and gM expression (figure 4.9A). Equivalent gel loading 
was confirmed by probing western blots for α-tubulin. Since overall protein expression was 
higher in COS-1 cells, this cell type was used in subsequent experiments. 
The VP22-induced reduction in gE and gM levels was overcome by introducing the VP22 
plasmid 24 hours after transfection with the ICP0, gE and gM expression vectors (figure 
4.9B). Cells were harvested 24 hours after VP22 transfection. Using this improved 
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transfection protocol, COS-1 cells were transfected with ICP0, gE and gM expression vectors 
and plasmids encoding GFP-tagged VP22 or the GFP-tagged VP22 phosphorylation 
mutants. All proteins were expressed at equivalent levels across all samples, and GFP and 
the GFP-tagged VP22 mutants were immunoprecipitated at similar efficiencies using the 
polyclonal GFP antibody (figure 4.9C). However, ICP0, gE and gM all failed to coprecipitate 
with VP22. In an independent but simultaneous experiment VP22-gE coimmunoprecipitation 
was readily detectable in infected cell lysates (data not shown). Furthermore, gE, gM and 
ICP0 did not coimmunoprecipitate with non-GFP-tagged VP22 (data not shown). 
4.9 THE N-TERMINUS OF VP22 IS REQUIRED, BUT NOT SUFFICIENT, FOR VP22-ICP0 
ASSOCIATION 
Previous data from our lab suggested that VP22 phosphorylation inhibits ICP0 packaging 
without affecting VP22 assembly (443). Therefore VP22-ICP0 complex formation was 
assessed in our VP22 phosphorylation mutant viruses (figure 2.1). VP22 and ICP0 
expression levels were comparable in Vero cells infected with the GFP-22, P+ and P- viruses 
(figure 4.10). However, ICP0 coimmunoprecipitated with VP22 to a lesser degree in both 
phosphorylation mutants compared with the GFP-22 virus. The ∆22 mutant served as a 
negative control. The small reduction in VP22 immunoprecipitation efficiency in the P+ 
mutant does not entirely account for the lack of VP22-ICP0 association in this mutant. 
Given the role of VP22’s N-terminus in VP22-gE-gM complex formation (figure 3.3), VP22-
ICP0 association was tested in our N-terminally truncated VP22 mutant viruses 108-301 and 
160-301 (figure 2.1). Despite comparable levels of VP22 and ICP0 expression and VP22 
immunoprecipitation, VP22-ICP0 complex formation was greatly and equally reduced in both 
mutants compared with the GFP-22 (1-301) virus (figure 4.11A). Emmanuelle Bernard within 
our group assessed ICP0 and VP22 virion incorporation in the GFP-22 (1-301), 108-301, 
160-301 and ∆22 viruses. Purified virions were equalised against the major capsid protein 
VP5, which also served as a loading control. In line with our previous data (207), N-terminally 
truncated VP22 was packaged at levels equivalent to full-length VP22 (figure 4.11B). ICP0 
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Figure 4.8: VP22 recruits ICP0 into the VP22-gE-gM complex. Confluent Vero cells were 
infected at a multiplicity of one with the ∆22, GFP-22, ∆gEbind or ∆gE viruses. Whole cell 
lysates were harvested 24 hpi and gE immunoprecipitated. Samples were subjected to 
western blot analysis using antibodies directed against gE, VP22 and ICP0. Molecular weight 
marker sizes (kDa) are shown on the left. 
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Figure 4.9: The VP22-gE-gM-ICP0 complex was not reconstituted in transfected cells. (A) 
Confluent Vero or COS-1 cells were mock treated or transfected with 2.5 µg per 60-mm dish 
of gE, gM and ICP0 expression vectors in the presence (+ VP22) or absence (- VP22) of the 
wild-type VP22 plasmid. Confluent Vero cells infected at a multiplicity of one with wild-type 
HSV-1 (strain sc16) acted as a positive control. Samples were harvested 24 hours after 
infection/transfection, and analysed by western blot using antibodies directed against VP22, 
gE, gM, ICP0 or α-tubulin. (B) Confluent COS-1 cells were treated as in (A) except that the 
VP22 expression vector was added 24 hours after the other plasmids. Cells were harvested 
after a further 24 hours. (C) Confluent COS-1 cells were transfected as for (B) using vectors 
expressing GFP, GFP-tagged VP22 (GFP-VP22) or GFP-tagged mutants mimicking 
phosphorylated (P+) or nonphosphorylated (P-) VP22. Following GFP immunoprecipitation, 
samples were analysed by western blot using antibodies directed against GFP, gE, gM and 
ICP0. Molecular weight marker sizes (kDa) are shown on the left. 
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Figure 4.10: The VP22 phosphorylation clusters are required for optimal VP22-ICP0 binding. 
Confluent Vero cells were infected at a multiplicity of one with the ∆22, GFP-22, P+ and P- 
viruses. Whole cell lysates were collected 24 hpi, and immunoprecipitation performed with 
the C-terminus-specific VP22 antibody. Samples were analysed by western blot using VP22- 
and ICP0-specific antibodies. Molecular weight marker sizes (kDa) are shown on the left. 
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Figure 4.11: The N-terminus of VP22 is required for VP22-ICP0 binding and ICP0 assembly. 
(A) The C-terminus-specific VP22 antibody was used to immunoprecipitate VP22 from whole 
cell lysates harvested 20 hpi from Vero cells infected at a multiplicity of one with the Δ22, 
GFP-22 (1-301), 108-301 or 160-301 viruses. Samples were analysed by western blot with 
antibodies directed against GFP and ICP0. (B) Extracellular virions purified by Emmanuelle 
Bernard from BHK-21 cells infected at a multiplicity of 0.02 with viruses described in (A) were 
analysed by western blot using antibodies raised against ICP0, VP5 or the C-terminus of 
VP22 (adapted from 346). Molecular weight marker sizes (kDa) are shown on the left. 
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assembly on the other hand was drastically reduced in the 108-301 and 160-301 mutants 
compared with the GFP-22 (1-301) virus. Residual ICP0 virion incorporation was observed in 
the 108-301, but not the 160-301, mutant. This discrepancy is probably of little consequence 
because the overriding trend in both mutants is for drastically reduced VP22-ICP0 
association and ICP0 assembly. Nevertheless VP22 residues 108 to 160 may modulate ICP0 
assembly independently of effects on VP22-ICP0 association. 
To determine whether VP22’s N-terminus is sufficient for ICP0 assembly, the experiment 
was repeated with the C-terminally truncated VP22 mutant 1-165 (figure 2.1) (207). 
Coimmunoprecipitation of ICP0 with VP22 was detectable in the GFP-22 (1-301), but not the 
1-165, virus (figure 4.12). Therefore VP22’s N-terminus is not sufficient for ICP0 interaction. 
Yu et al. recently confirmed that deletion of the N-terminal 150 residues of VP22 impairs 
VP22-ICP0 binding, while this region alone is not sufficient for VP22-ICP0 interaction (586). 
4.10 ICP0’S RING FINGER IS REQUIRED FOR VP22-ICP0 COMPLEX FORMATION 
Having characterised the VP22 domains required for VP22-ICP0 complex formation, the 
contributions of ICP0 regions were assessed using mutant viruses kindly provided by Roger 
Everett (figure 2.2) (156, 362). Infections were performed in U2OS cells because the effect of 
ICP0 mutation on HSV-1 replication is limited in this cell type (583). Levels of VP22 
expression and immunoprecipitation were comparable among all ICP0 mutants tested (figure 
4.13A). The ∆22 virus acted as a negative control. Coimmunoprecipitation of ICP0 with VP22 
was detectable in all viruses apart from the RING finger deletion mutant ∆RING, indicating 
that the RING finger is required for VP22-ICP0 complex formation. Although ICP0 expression 
was markedly reduced in this mutant, a longer exposure of the western blot failed to detect 
VP22-ICP0 association (data not shown). Yu et al. also recently confirmed that the RING 
finger is required for VP22-ICP0 binding (586). The extreme C-terminus of ICP0, which is 
deleted in the 1-593 virus, including the USP7-binding domain mutated in the ∆USP7 and 
pm-USP7 viruses, was not required for VP22-ICP0 association (figure 4.13A). However the 
data do not exclude a role for other untested ICP0 regions. 
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Emmanuelle Bernard within our group analysed the profiles of virions purified from BHK-21 
cells infected with the same panel of ICP0 mutants. Virus particles were equalised against 
the major capsid protein VP5, which also served as a loading control. The ∆ICP0 virus was 
included as a negative control. VP22 and VP16 were assembled at equivalent efficiencies in 
all mutant viruses (figure 4.13B). ICP0 assembly on the other hand was abrogated in the 
∆RING and 1-593 viruses, and enhanced in the ∆USP7 and pm-USP7 mutants. Delboy et al. 
also recently reported that the RING finger is required for ICP0 assembly (104). Therefore, 
while the RING finger is essential for VP22-ICP0 complex formation and ICP0 assembly, 
ICP0’s C-terminus may play a role in determining the level of ICP0 assembly without 
affecting VP22 packaging or VP22-ICP0 complex formation. 
4.11 CHAPTER DISCUSSION 
In this chapter ICP27 was shown for the first time to be recruited into the HSV-1 tegument. 
Furthermore, ICP27 assembly is independent of VP22 and ICP0. ICP0 was found to be 
tightly capsid-associated, while VP22, VP16 and vhs are present as two distinct 
subpopulations within the tegument. An ICP0 assembly complex incorporating VP22, gE and 
gM was characterised in infected cells. While ICP27 facilitates ICP0 assembly (486), ICP27 
was not recruited into this complex. As proposed by Sedlackova and Rice, ICP27 may 
facilitate ICP0 assembly indirectly by assisting its cytoplasmic translocation by modifying 
ICP0 phosphorylation in tandem with the cellular kinase CKII and/or via formation of a 
putative translocation complex incorporating ICP0 and ICP4 (486). While both ICP27 and 
ICP0 bind ICP4 (420, 584), ICP0-ICP27 association was not detected here (figure 4.6B). 
VP22-ICP0 association appeared to correlate with peak infectious progeny production (figure 
4.3). Interestingly, Newcomb and Brown reported time-dependent alterations in tegument 
structure (395). Although the ratio of the major tegument proteins VP13/14, VP16 and VP22 
remained unchanged (395), it might be worth investigating whether virion incorporation of 
minor tegument components, like ICP0, occurs at specific points in the infectious cycle. 
However it is not clear how time-dependent ICP0 assembly would benefit the virus, and it 
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Figure 4.12: VP22’s N-terminus is not sufficient for ICP0 interaction. The N-terminus-specific 
VP22 antibody was used to immunoprecipitate VP22 from whole cell lysates harvested 20 
hpi from Vero cells infected at a multiplicity of one with the Δ22, GFP-22 (1-301) or 1-165 
viruses. Samples were analysed by western blot using ICP0- and GFP-specific antibodies. 
Molecular weight marker sizes (kDa) are shown on the left; ♯ denotes nonspecific band. 
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Figure 4.13: The RING finger and C-terminus of ICP0 are required for ICP0 assembly. (A) 
Our N-terminus-specific VP22 antibody was used to immunoprecipitate VP22 from whole cell 
lysates harvested 20 hpi from U2OS cells infected at a multiplicity of one with the wild-type 
HSV-1 strain 17+ (wt), our Δ22 mutant or the ICP0 mutant viruses ΔRING, ΔUSP7, 1-593 or 
pm-USP7. Samples were analysed by western blot using antibodies directed against ICP0 or 
the N-terminus of VP22. (B) Extracellular virions were Ficoll-purified by Emmanuelle Bernard 
from confluent BHK-21 cells infected at a multiplicity of 0.02 with strain 17+ (wt) or the 
∆ICP0, ∆USP7, 1-593, ∆RING or pm-USP7 viruses. Western blots were probed for ICP0, 
VP16, VP5 or the N-terminus of VP22. (Adapted from 346). 
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seems more probable that experimental limitations prohibited detection of low-level VP22-
ICP0 association at early times of infection. 
4.11.1 THE ICP0 ASSEMBLY COMPLEX 
Recruitment of ICP0 into the VP22-gE-gM complex is VP22-specific (figure 4.8), suggesting 
VP22 is ICP0’s primary binding partner within the complex. In support of this, Fossum et al. 
detected VP22-ICP0 binding in a yeast-two-hybrid screen (178), while Yu et al. recently 
reported VP22-ICP0 coimmunoprecipitation in cells transfected with VP22 and ICP0 (586). 
Despite extensive attempts, VP22-ICP0 binding was not demonstrated in transfected cells 
here. Attempts were made to account for the possible effects of VP22 phosphorylation, 
although it should be noted that our phosphorylation mutants themselves exhibited impaired 
VP22-ICP0 complex formation in infected cells (figure 4.10). ICP0 is also a phosphoprotein, 
and phosphorylation-dependent modulation of ICP0 activity is affected by the context of ICP0 
expression (transfection versus infection) (1, 5, 46, 95). Therefore aberrant posttranslational 
modification of transiently expressed VP22 and/or ICP0 may have influenced VP22-ICP0 
binding. Furthermore, the intracellular localisation of both proteins is altered in transfected 
cells compared with infected cells (132, 133, 592), which might have affected complex 
formation. It would be interesting to check whether simultaneous expression of ICP27 with 
VP22, gE, gM and ICP0 results in detectable VP22-ICP0 binding by modifying ICP0 
localisation. Nonetheless these factors should also apply to assays performed by Yu et al. 
(586), implying that experimental limitations probably prohibited detection of VP22-ICP0 
binding in our hands. Perhaps insufficient cells simultaneously expressed all complex 
components. Poor protein expression might also have played a part. 
VP22-glycoprotein binding enhances VP22-ICP0 association, with a knock-on effect on ICP0 
assembly (summarised in table 4.1). While gE and gM are redundant for VP22 assembly, 
both are required for optimal VP22-ICP0 binding. ICP0 does not bind gE directly (figure 4.8), 
and did not interact with gM in yeast-two-hybrid screens (178, 184). It would be pertinent to 
immunoprecipitate ICP0 from infected cells to reassess ICP0-gM binding. In fact gM may be 
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solely required for optimal VP22-ICP0 association since VP22-gM interaction is reduced in 
the ∆gE virus (table 4.1). Importantly, gE and gM do not recruit ICP0 into the virion in the 
absence of VP22 (table 4.1) (129, 518), reaffirming the dominant role of VP22 in ICP0 
assembly. Addition of gE and gM did not result in VP22-ICP0 coimmunoprecipitation in 
transfected cells, although the VP22-gE-gM complex itself was also not reconstituted. 
The mechanism by which gE and gM enhance VP22-ICP0 association remains unclear. 
Perhaps these glycoproteins stabilise the VP22-ICP0 interaction within a higher-order 
glycoprotein-tegument complex, or modulate the intracellular localisation of VP22 and/or 
ICP0.  In fact gE, but not gM, relocalises VP22 to the TGN during transient transfection and 
colocalises with VP22 during infection (518). Therefore gE may facilitate VP22-ICP0 complex 
formation by recruiting VP22 to cytoplasmic sites of tegument assembly. This could be tested 
by assessing VP22 localisation in cells infected with the glycoprotein-null mutants. 
4.11.2 VP22 SEQUENCES THAT MEDIATE VP22-ICP0 INTERACTION 
The N-terminal 160 residues of VP22 are essential, but not sufficient, for VP22-ICP0 
complex formation and ICP0 virion incorporation (table 4.1). It is unclear whether ICP0 
physically interacts with this VP22 region or whether these sequences are solely required for 
optimal gE/gM, and hence ICP0, binding. This region is also known to mediate VP22 
dimerisation (figure 4.14) (381). It is therefore conceivable that VP22 dimerisation, rather 
than VP22-glycoprotein binding, is required for VP22-ICP0 complex formation. While it will be 
challenging to rule out a role for VP22 dimerisation due to overlap with the glycoprotein-
binding domains, reduced VP22-ICP0 complex formation in the ∆gE, ∆ gM and ∆ gEgM 
viruses (table 4.1) unequivocally proves that the glycoproteins are required for optimal VP22-
ICP0 association. Furthermore, it could be argued that VP22-ICP0 interaction might be 
required for optimal VP22-gE-gM complex formation rather than vice versa. This seems 
unlikely because, although VP22-gE-gM association was not directly tested in the ∆ICP0 
virus, VP22 assembly was unaffected by ICP0 deletion (figure 4.13B), while VP22-ICP0 
binding and ICP0 packaging was impaired in the glycoprotein-null mutants (table 4.1). 
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Table 4.1: Summary of data presented in chapters 3 and 4 relevant to ICP0 virion 
incorporation. Data for wild-type HSV-1 (wt) refer to strains 17+, sc16 and HFEM as detailed 
in the main text. +/- Denotes reduced ICP0 binding or assembly; N.D., not done. Citations 
refer to data collected by other members of our group. 
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Table 4.1 
 
 
 
 
 Interaction   Assembly 
Virus 
VP22-gE VP22-gM VP22-ICP0 VP22 ICP0 
wt + + + + 5 + 
GFP-22 (1-301) + + + + 3 + 4 
∆22 - - - - 4 - 4 
∆gE - +/- +/- +	 5 +/- 5 
∆gM + - +/- + 5 +/- 5 
∆gEgM - - +/- - 5 - 5 
∆gEbind - - +/- - 3 - 3 
108-301 +/- +/- +/- + 6 +/- 2 
160-301 +/- +/- +/- + 6 - 2 
1-165 N.D. N.D. - - 6 - 2 
P+ +/- +/- +/- + 1 - 1 
P- +/- +/- +/- + 1 + 1 
1 Corinne Potel (443) 
2 Emmanuelle Bernard (346) 
3 Emmanuelle Bernard (518) 
4 Gill Elliott (129) 
5 Gill Elliott (manuscript in preparation) 
6 Wali Hafezi (207) 
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Figure 4.14: VP22’s ICP0-binding domain defined in this study. VP22 schematic is shown 
above. The conserved region (grey) and serine phosphorylation sites located at residues 35, 
71, 72, 73, 292 and 294 (triangles) are highlighted. Dimerisation domain defined by 
Mouzakitis et al. is shown in green (381). Principal glycoprotein-binding domain identified by 
Julianna Stylianou within our group is shown in red (518). Accessory region additionally 
required for optimal VP22-gE-gM complex formation characterised in chapter 3 is shown in 
yellow (? signifies unknown contribution of C-terminal phosphorylation sites). Region 
essential, but not sufficient, for ICP0-binding (identified here) is shown in red. 
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Both phosphorylation mutants exhibited reduced VP22-ICP0 association, likely due to 
impaired VP22-gE-gM binding (table 4.1). The impact of VP22 phosphorylation per se during 
wild-type HSV-1 infection was not assessed. Yu et al. observed binding of ICP0 to 
phosphorylated VP22 in transfected cells, although binding to nonphosphorylated VP22 was 
not ruled out (586). Since nonphosphorylated VP22 is preferentially recruited into wild-type 
HSV-1 virions (136), ICP0 must also bind this form of VP22. Hence VP22-ICP0 complex 
formation may not be regulated by VP22 phosphorylation, although this remains to be 
proven. Our group previously reported that ICP0 packaging is abrogated in our 
phosphomimetic VP22 mutant and unaltered in the construct mimicking nonphosphorylated 
VP22 (443), despite equally reduced VP22-ICP0 binding in both viruses (table 4.1). These 
inconsistencies might reflect cell type-specific differences, since virions were purified from 
BHK-21 cells whereas immunoprecipitations were performed in Vero cell lysates. However, 
although consistently observed before, reduced ICP0 packaging in the phosphomimetic 
VP22 virus was not replicated in recent experiments (data not shown). Therefore additional 
data are needed before firm conclusions can be drawn regarding the effects of VP22 
phosphorylation on ICP0 assembly. Nevertheless, the region encompassing the N-terminal 
phosphorylation sites is clearly important for VP22-ICP0 association and ICP0 assembly. 
4.11.3 ICP0 SEQUENCES REQUIRED FOR VP22-ICP0 BINDING AND ICP0 ASSEMBLY 
In line with two recent reports (104, 586), ICP0’s RING finger was essential for VP22-ICP0 
association and ICP0 assembly (figure 4.13). Whether this represents a physical or 
functional requirement is unclear. In agreement with our preliminary observations (data not 
shown), Liu et al. observed cytoplasmic accumulation of ICP0 in a RING finger deletion virus 
(329). Hence aberrant ICP0 localisation cannot account for impaired VP22-ICP0 association 
in the ∆RING virus. Delboy et al. reported that point mutation at residue 144, but not 151, 
within the RING finger abrogates ICP0 assembly (104). Roger Everett and coworkers note 
that both mutations impair ND10 disruption, gene activation and virus replication, although in 
vitro ubiquitin conjugation is unaffected (48, 139, 144, 421). Therefore ICP0 assembly can be 
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separated from ICP0 function. It would be interesting to evaluate VP22-ICP0 binding in these 
particular mutants. RING finger domains mediate protein-protein interactions (43, 199, 350), 
and VP22 was recently shown to bind the cellular RING finger protein RNF10 (315). It is 
therefore plausible that ICP0’s RING finger physically interacts with VP22. 
C-terminal ICP0 truncation abrogated ICP0 assembly but not VP22-ICP0 complex formation 
(figure 4.13). The packaging defect is not unexpected because, in line with more recent data 
implicating ICP27 in ICP0 assembly (486), ICP0’s extreme C-terminus has long been known 
to be required for ICP0 packaging and ICP27-mediated cytoplasmic accumulation of ICP0 
(figure 4.15) (95, 580, 592). ICP0’s C-terminus also reportedly mediates interactions with 
CoREST, USP7, EF-1δ, ICP4 and ICP0 itself, is required for ND10 localisation and 
HDAC1/2-CoREST-REST complex dissociation, and encodes the HUL-1 ubiquitin ligase 
domain (figure 4.15) (79, 155, 156, 202, 204, 208, 266, 351, 362, 584). ICP27 
responsiveness seems a likely candidate for the role of C-terminal sequences in ICP0 
packaging. However any or all of these activities, except USP7-binding, which was not 
required for ICP0 packaging (figure 4.13B), might facilitate ICP0 assembly. Notably, Bernard 
Roizman and coworkers propose that completion of ICP0’s nuclear functions are required for 
cytoplasmic accumulation of ICP0 (205, 259), which, according to Sedlackova and Rice, is 
required for ICP0 assembly (486). 
More surprising, given that VP22 and ICP0 colocalise in the cytoplasm, and not the nucleus, 
of infected cells (129, 235, 443), is the fact that VP22-ICP0 association is unaffected in the 
C-terminal truncation mutant (figure 4.13A), which remains nuclear throughout infection 
(362). In this case the VP22-ICP0 complex may form after cell lysis. Attempts to 
immunoprecipitate VP22 following nuclear/cytoplasmic cell fractionation were unsuccessful 
because satisfactory fractionation was not achieved (data not shown), perhaps because 
HSV-1 infection may compromise nuclear envelope architecture (485, 494, 565). Regardless 
of whether C-terminally truncated ICP0 binds VP22-ICP0 in situ, ICP0’s C-terminus is 
dispensable for VP22-binding. 
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Figure 4.15: Functions reportedly encoded by ICP0’s C-terminus. (A) Schematic 
summarising ICP0 domains relevant to work discussed here, with the RING finger (residues 
116 to 156), NLS (474 to 509) and HUL-1 ubiquitin ligase (616 to 680) domains highlighted 
(141, 208). Phosphorylation sites are represented by triangles as follows; cluster I (S224, 
T226, T231, T232), cluster II (S365, S367, S371) and cluster III (S508, S514, S517, T518) 
(95). C-terminal sequences reportedly required for interaction with USP7 (156), ICP4 (584), 
CoREST (204), EF-1δ (266) and ICP0 itself (79), as well as ND10 localisation (351) and 
ICP27-mediated cytoplasmic accumulation (592) and virion incorporation of ICP0 (580) are 
detailed below. (B) Viruses used here that harbour mutations at the C-terminus of ICP0 (see 
also figure 2.2). 
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Figure 4.15 
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Finally, disrupting USP7 binding augmented ICP0 assembly without affecting VP22-ICP0 
complex formation (figure 4.13). USP7 interaction enhances ICP0 stability by preventing 
autoubiquitination-induced ICP0 degradation, and although the mutants used here are 
therefore less stable than wild-type ICP0, their cytoplasmic accumulation in infected cells is 
more pronounced (45, 65, 144). This might account for enhanced ICP0 virion incorporation. 
4.11.4 INCORPORATION OF ICP27 INTO THE VIRION 
Data presented here demonstrated specific VP22-independent recruitment of ICP27 into 
bona fide extracellular infectious particles from the wild-type HSV-1 strains 17+, sc16 and 
HFEM (figures 4.2 and 4.6C). In contrast, several groups failed to detect ICP27 in 
extracellular virions from strains F and KOS (336, 416, 486, 582), perhaps due to differences 
in the virion purification protocols used. Loret et al. note minor variations in the profiles of 
virus particles purified from HeLa and BHK-21 cells (336). Consequently, ICP27 packaging 
might be cell type-specific since our group routinely isolates virions from BHK-21 cells, while 
other groups used Vero, HEp-2, HeLa or A549 cells (336, 416, 486, 582). Importantly, our 
data indicate that ICP27 assembly is not virus strain-specific, although strains F and KOS 
were not tested. 
4.11.5 HERPESVIRUS TEGUMENT COMPOSITION 
HSV-1 tegument proteins can be categorised into two classes based on their behaviour in 
virion stripping experiments (452). Other groups confirmed that ICP0, as well as UL37, US3, 
VP1/2, ICP34.5 and ICP4, are tightly capsid-associated, while US11 is another tegument 
component weakly associated with the capsid (104, 452, 569). In contrast to results 
presented here, Beate Sodeik and coworkers observe segregation of VP13/14 into two 
subpopulations (452, 569), similarly to VP22, which might stem from variations in the virus 
strains or experimental protocols used. VP22, VP16 and vhs consistently form two 
subpopulations within the virion (104, 452, 569), as also reported here. These proteins are 
known to form a complex in infected cells (522), and since they behave similarly in virion 
stripping experiments, VP22, VP16 and vhs may also be present within a higher-order 
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complex in the virion. This remains to be proven, and it is important to note that VP16 can be 
assembled independently of VP22 (chapter 3). 
These experiments do not shed light on the localisation of tegument components within the 
virus particle since a proportion of VP22, considered to constitute the outer tegument (368), 
is as tightly capsid-associated as inner tegument proteins such as VP1/2 and UL37 (452, 569 
and figure 4.1). The biological basis governing segregation of tegument proteins into distinct 
subpopulations is unknown, but could originate from differences in their binding partners, 
posttranslational modification or intracellular site of virion incorporation. 
Of relevance to ICP0 assembly, a proportion of VP22 dissociates from the virion along with 
gE and gM, while the remainder behaves like ICP0 (figure 4.1). HSV-1 virions contain 
approximately 10-fold less ICP0 than VP22 (217, 336, 582), hence only a fraction of VP22 
within the VP22-gE-gM complex can be associated with ICP0. Alternatively, only some VP22 
may associate with both glycoproteins, a prerequisite for interaction with ICP0. Presumably 
ICP0-bound VP22 represents the tightly capsid-associated population, which might be 
stabilised by interactions between inner tegument components and VP22 and/or ICP0. 
Weakly capsid-associated VP22 on the other hand probably interacts with gE and gM, and 
might be incorporated into higher-order VP22-gE-gM-ICP0 complexes along with ICP0-
bound VP22 via VP22 self-interaction. It would be interesting to assess segregation of virion 
VP22 in our 160-301 virus, in which VP22-ICP0 binding, but not VP22 assembly, is impaired. 
As discussed in section 1.2.1, it is becoming clear that the tegument, often described as 
amorphous, exhibits an underlying structure (104, 452, 464, 569). Observations made here 
and by others suggest this structure might be at least partially determined by tegument-
tegument and tegument-glycoprotein interactions (366, 368). 
4.11.6 CONCLUDING REMARKS 
This chapter describes an ICP0 assembly pathway involving VP22, gE and gM. VP22 acts as 
the major determinant for ICP0 packaging by recruiting the glycoproteins and ICP0 into the 
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assembly complex. VP22’s N-terminus, previously without ascribed functions, was shown 
here and in chapter 3 to enhance interactions with ICP0, gE and gM. This represents the first 
direct characterisation in infected cells of a multicomponent herpesvirus tegument assembly 
complex incorporating several glycoproteins and tegument components. ICP0 is tightly 
capsid-associated, and the highly specific nature of ICP0 assembly implies that virion ICP0 
performs important functions during the infectious cycle; these will be explored in chapter 6. 
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5.1 CHAPTER INTRODUCTION 
At the outset of this project, the impact of VP22 on ICP0 function had not been directly 
addressed. However our group reported that, compared with wild-type HSV-1, ICP0 
expression is delayed and ICP0 levels reduced in Vero cells infected with our ∆22 virus 
(129). This effect was later shown to be influenced by VP22 phosphorylation (443). 
Furthermore, late in infection VP22 and ICP0 colocalise in cytoplasmic puncta proposed to 
play a role in tegument assembly (129, 207). While early localisation of ICP0 to ND10 
domains and cytoplasmic accumulation of ICP0 remain unaffected, ICP0 is not recruited to 
cytoplasmic puncta in our VP22-null virus, which does not package ICP0 (129). It was 
therefore suggested that these sites facilitate ICP0 virion incorporation (129). 
This chapter explores the impact VP22 has on ICP0 localisation and its ability to 
transactivate gene expression, disrupt ND10 and catalyse ubiquitin conjugation. Findings 
shown in figures 5.1, 5.3, 5.8 and 5.11 were published in the Journal of Virology (346). 
5.2 VP22 MUTATION ALTERS ICP0 LOCALISATION IN INFECTED CELLS 
Subconfluent Vero cells were infected at a multiplicity of ten with our GFP-22 (1-301), ∆22, 
160-301 and 1-165 viruses, and the C-terminally truncated VP22 mutant 1-212 (figure 2.1) 
(207). Cells were fixed 6 hpi and immunofluorescence staining performed for ICP0. Large 
cytoplasmic VP22 puncta, previously shown to be static and proposed to represent tegument 
assembly sites (section 1.5.2) (134, 519), were clearly visible in cells infected with the GFP-
22 (1-301) virus (figure 5.1). Some smaller VP22-positive domains, which likely represent 
tegument within secretory vesicles or mature virions during egress (section 1.5.2) (134, 519), 
were observed in a Golgi-like distribution. These smaller puncta are more clearly visible in 
figure 5.2. In agreement with our published data (129, 443), ICP0 colocalised with a subset 
of the large VP22-positive domains in cells infected with the GFP-22 (1-301), but not the ∆22, 
virus (figure 5.1). This phenomenon is not cell type-specific, as VP22 and ICP0 localised to 
similar domains in MDBK, BHK-21 and HFFF2 cells (129, figure 5.2 and data not shown). 
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As previously published (207), VP22 was detected within small cytoplasmic puncta in cells 
infected with the 160-301 mutant (figure 5.1). This construct does not localise to the large 
static puncta observed in the GFP-22 (1-301) virus (207). VP22 did not localise to 
cytoplasmic puncta in cells infected with the 1-165 or 1-212 mutants, confirming previous 
observations (207). Therefore localisation of VP22 to small, presumably mobile, cytoplasmic 
puncta correlates with VP22-gE-gM complex formation (518 and table 4.1). 
In cells infected with the 1-212 mutant, ICP0 displayed a punctate cytoplasmic distribution 
(figure 5.1). VP22 on the other hand was largely diffuse throughout the cell in cells infected 
with this virus. The ∆gEbind virus encodes the same region as the 1-212 mutant, with the 
addition of the C-terminal 75 residues of VP22 (figure 2.1). Therefore, similarly to the 
∆gEbind mutant, neither VP22 nor ICP0 are assembled in the 1-212 virus (207, 346 and 
table 4.1). In addition, VP22-ICP0 complex formation can be expected to be greatly reduced 
in the 1-212 virus, since, like the ∆gEbind mutant, this construct lacks VP22’s glycoprotein-
binding domain. In the 160-301 virus, ICP0 localised to cytoplasmic puncta that were distinct 
from the small mobile VP22-containing domains (figure 5.1). The 160-301 mutant assembles 
VP22, but not ICP0 (table 4.1). Collectively these data show that localisation of ICP0 to 
cytoplasmic puncta is not sufficient for ICP0 assembly. 
Interestingly, the steady-state distribution of ICP0 was distinctively nuclear in our 1-165 
mutant (figure 5.1), implying that VP22 can modify ICP0 localisation even in the absence of 
detectable VP22-ICP0 complex formation (table 4.1). Importantly, VP22 mutation had a 
similar impact on ICP0 localisation in Vero and HFFF2 cells (compare figures 5.1 and 5.2), 
indicating that these observations are not cell type-specific. 
5.3 ICP0 REMAINS NUCLEAR THROUGHOUT INFECTION IN CERTAIN VP22 MUTANTS 
It was important to confirm that the infectious process is not merely delayed in cells infected 
with our 1-165 mutant, in which ICP0 was distinctively nuclear 6 hpi (figures 5.1 and 5.2). 
Although VP22 localisation is unaltered, ICP0 is also nuclear in our phosphomimetic VP22 
mutant P+ (figure 2.1) (443). Subconfluent Vero cells were infected at a multiplicity of ten 
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Figure 5.1: VP22 mutation modifies ICP0 localisation in infected Vero cells. Subconfluent 
Vero cells were infected at a multiplicity of ten with the Δ22, GFP-22 (1-301), 160-301, 1-165 
or 1-212 viruses. Cells were fixed in 4% paraformaldehyde 6 hpi and immunofluorescence 
staining performed for ICP0. Green, GFP; red, ICP0. Images were captured on a Zeiss 
Axiovert S100 TV inverted fluorescence microscope. For corresponding confocal images 
(taken by Gill Elliott) refer to our publication (346). The ability of VP22 constructs to complex 
with ICP0 and mediate ICP0 assembly is summarised on the right. Emmanuelle Bernard 
within our group assessed ICP0 virion incorporation in the 1-212 mutant (346). Reduced 
VP22-ICP0 complex formation in this mutant is inferred from the ∆gEbind construct, which 
encodes the same VP22 region with additional C-terminal sequences (figure 2.1). 
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Figure 5.1 
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Figure 5.2: VP22 mutation modifies ICP0 localisation in infected HFFF2 cells. Subconfluent 
HFFF2 cells were infected at a multiplicity of ten with the ∆22, GFP-22 (1-301), 160-301, 1-
165 or 1-212 viruses. Cells were fixed in 4% paraformaldehyde 6 hpi and 
immunofluorescence staining performed for ICP0. Green, GFP; red, ICP0. Images were 
captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope. 
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Figure 5.2 
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with the GFP-22 (1-301), 1-165 and P+ viruses. Cells were fixed 6, 12 and 16 hpi and 
immunofluorescence staining performed for ICP0. While ICP0 colocalised with VP22 in 
cytoplasmic puncta from 6 hpi in cells infected with the GFP-22 (1-301) virus, ICP0 remained 
distinctively nuclear as late as 16 hpi in the 1-165 and P+ mutants (figure 5.3). Therefore 
ICP0 does not appear nuclear due to a delay in the infectious process in these viruses. 
Collectively the data presented in sections 5.2 and 5.3 show that VP22 mutation alters ICP0 
localisation in a manner that does not depend upon detectable VP22-ICP0 association. 
5.4 OPTIMISATION OF A GENE TRANSACTIVATION ASSAY 
A reporter assay was developed to measure the impact VP22 has on ICP0’s ability to 
transactivate gene expression. All plasmids are summarised in table 2.1. Initially, confluent 
Vero cells were transiently transfected with the plasmid phRL-TK, which expresses Renilla 
luciferase under the control of the HSV-1 TK promoter. Luciferase expression was measured 
24 hours later in the presence of increasing amounts of the empty vector pCMV-SV5α, which 
encodes the HCMV immediate-early promoter (214). The luciferase activity in cells 
transfected with just the reporter plasmid was taken as 100%. Cotransfection with pCMV-
SV5α reduced luciferase activity in a dose-dependent and statistically significant manner by 
up to 60% (figure 5.4A), presumably due to competition for transcription factors. Therefore all 
subsequent luciferase assay transfections were equalised using this plasmid. This was 
appropriate because all protein expression plasmids used here, but not the reporter 
constructs, are also driven by the HCMV immediate-early promoter (table 2.1). The statistical 
significance of the differences between means was assessed by student’s t test analysis 
throughout, as detailed in section 2.9 and appendix 2. 
Next, the phRL-TK reporter plasmid was cotransfected with increasing amounts of the ICP0 
expression vector pcI110. Compared to cells transfected with the reporter plasmid alone, as 
little as 0.025 µg pcI110 induced an eight-fold increase in luciferase activity (figure 5.4B), 
which is comparable with previous reports (139, 585, 586). Luciferase expression was 
induced to a lesser degree when ICP0 was overexpressed, possibly due to off-target effects 
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on cell function. The RING finger deletion mutant pcI-FXE (∆RING) (156) only induced 
promoter activity by up to two-fold, replicating findings by Everett et al. (139), and confirming 
assay specificity. In subsequent experiments cells were transfected with 0.1 µg pcI110, since 
this amount induced robust promoter activation. Although reporter assays typically include an 
additional plasmid expressing a distinct luciferase (e.g. firefly luciferase) driven by an 
alternative promoter to account for transfection variability, this was not possible here 
because ICP0 transactivates all exogenously introduced promoters (145, 209). 
5.5 VP22 NEGATIVELY REGULATES TK PROMOTER ACTIVITY 
To evaluate the impact VP22 has on ICP0’s transactivator activity, Vero cells were 
transfected with the reporter plasmid phRL-TK and increasing amounts of the VP22 
expression vector pPO85 in the presence or absence of the ICP0 expression vector pcI110. 
VP22 reduced ICP0-dependent promoter activation by up to 60% (figure 5.5A, + ICP0). This 
effect was most pronounced when greater quantities of VP22 expression vector were added, 
although even 0.1 µg pPO85 had a statistically significant impact. However, VP22 also 
reduced luciferase expression in the absence of ICP0 (figure 5.5A, - ICP0). While this effect 
was only significant in the presence of larger quantities of VP22, this result indicates that 
VP22 has an ICP0-independent impact on gene expression. Therefore the specific effects of 
VP22 on ICP0’s transactivator activity could not be assessed using this assay. 
To verify the specificity of VP22’s effects on gene expression, Vero cells were transfected 
with the reporter plasmid phRL-TK and increasing amounts of pPO85 and pCMV-β-gal, 
which respectively encode VP22 and the control protein β-galactosidase. While VP22 
consistently reduced luciferase activity by up to 50% in the absence of ICP0 (figures 5.5A 
and B), β-galactosidase did not affect luciferase expression (figure 5.5B). To confirm β-
galactosidase expression the experiment was repeated, this time in the presence of ICP0, 
and samples harvested 24 hours posttransfection in SDS-PAGE loading dye. As little as 0.2 
µg pCMV-β-gal resulted in detectable β-galactosidase expression (figure 5.5C). As expected, 
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Figure 5.3: The nuclear localisation of ICP0 in certain HSV-1 mutants is not due to a delay in 
the infectious process. Subconfluent Vero cells were infected at a multiplicity of ten with our 
GFP-22 (1-301), 1-165 or P+ viruses. Cells were fixed in 4% paraformaldehyde at the times 
indicated and immunofluorescence performed for ICP0. Images were captured using a Zeiss 
Axiovert S100 TV inverted fluorescence microscope. (A) Composite images showing GFP 
fluorescence in green and ICP0 in red. (B) ICP0 only. 
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Figure 5.3 
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Figure 5.4: Luciferase reporter assay optimisation. (A) Confluent Vero cells were transfected 
with 0.2 µg phRL-TK and increasing amounts of the empty vector pCMV-SV5α. Luciferase 
expression was measured 24 hours posttransfection and is presented as a percentage of 
luciferase activity observed in the absence of pCMV-SV5α. (B) Increasing amounts of the 
wild-type ICP0 (wt) or RING finger deletion mutant (ΔRING) expression vectors pcI110 and 
pcI-FXE were cotransfected with 0.2 µg phRL-TK. Luciferase activity was measured 24 
hours posttransfection and is presented as fold induction over background luciferase activity 
in the absence of ICP0. All plasmid quantities are per well of a 12-well plate. Data represent 
the mean of three replicates. Error bars depict the standard deviation. ** p < 0.01. 
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Figure 5.4 
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Figure 5.5: VP22 suppresses HSV-1 TK promoter activity. (A) Confluent Vero cells were 
transfected with 0.2 µg phRL-TK in the presence (+ ICP0) or absence (- ICP0) of 0.1 µg of 
the ICP0 expression vector pcI110. Cells were cotransfected with increasing amounts of the 
VP22 expression vector pPO85. Luciferase activity was measured 24 hours posttransfection 
and is presented as a percentage of activity in the absence of VP22, with or without ICP0 as 
appropriate. (B) As for (A) except cells were transfected with increasing amounts of pPO85 
(VP22) or the β-galactosidase expression vector pCMV-β-gal (β-gal) in the absence of ICP0. 
(C and D) Cells transfected with increasing amounts of pCMV-β-gal (C) or pPO85 (D) in the 
presence of 0.2 µg phRL-TK and pcI110 were harvested in SDS-PAGE loading dye 24 hours 
posttransfection and analysed by western blot using antibodies against β-galactosidase (β-
gal), VP22’s C-terminus, Renilla luciferase (luc), α-tubulin or ICP0. (E) Protein quantification 
performed 24 hours posttransfection on Vero cells transfected as in (A) with phRL-TK alone 
(luc) or in the presence (+ ICP0) of pcI110 and increasing amounts of the VP22 expression 
vector pPO85. All plasmid quantities are per well of a 12-well plate. All data are the mean of 
three replicates. Error bars represent the standard deviation. * p < 0.05; ** p < 0.01. 
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Figure 5.5 
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luciferase (and ICP0) levels remained unaltered in the presence of up to 0.6 µg of pCMV-β-
gal. Uniform gel loading was confirmed by probing blots for α-tubulin. 
When the experiment was repeated with the VP22 expression vector pPO85, VP22 
suppressed both luciferase and ICP0 expression (figure 5.5D). This may explain why VP22 
had a more pronounced effect on luciferase activity in the presence of ICP0 (figure 5.5A), 
since VP22 will have suppressed luciferase expression and impaired ICP0-dependent 
promoter activation by reducing ICP0 levels. These data demonstrate that VP22 specifically 
represses TK promoter-driven luciferase expression in the presence and absence of ICP0. 
To confirm that none of these observations are due to effects on cell viability, the experiment 
depicted in figure 5.5A was repeated and samples harvested 24 hours posttransfection. 
Transfection of Vero cells with plasmids phRL-TK, pcI110 and pPO85 did not significantly 
affect protein levels, which are indicative of cell number (figure 5.5E). Therefore VP22 does 
not suppress gene expression by affecting cell viability. 
5.6 THE EFFECTS OF VP22 ON GENE EXPRESSION ARE NOT PROMOTER-SPECIFIC 
Since VP22 decreased HCMV immediate-early promoter-driven ICP0 as well as TK 
promoter-driven Renilla luciferase expression (figure 5.5D), the effect of VP22 on other 
promoters was investigated. The VP22-dependent reduction in ICP0 levels was confirmed by 
western blot in cell lysates from Vero cells transfected with just the VP22 and ICP0 
expression vectors pPO85 and pcI110. As before (figure 5.5D), cotransfection with 
increasing amounts of the VP22 expression vector reduced ICP0 levels in a dose-dependent 
manner (figure 5.6A). A similar VP22-dependent decrease in GFP levels was observed when 
the VP22 expression vector was cotransfected with the HCMV immediate-early promoter-
driven plasmid pEGFP-c1 (figure 5.6B and table 2.1). Uniform gel loading was confirmed by 
probing western blots for α-tubulin (figures 5.6A and B). 
Next, Vero cells were transfected with 0.3 µg of the VP22 expression vector pPO85 and 0.2 
µg of the reporter plasmids pGL2-Promoter (SV40), encoding firefly luciferase linked to the 
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SV40 promoter, or pGL2-Basic (none), which lacks eukaryotic promoter and enhancer 
elements. The TK promoter-driven reporter plasmid phRL-TK (TK) used in previous 
experiments was included as a positive control. Compared with basal luciferase activity in 
cells transfected with the reporter plasmids alone (taken as 100%), VP22 significantly 
reduced expression from each reporter construct by up to 50% (figure 5.6C). Note that the 
basal level of firefly luciferase expression from pGL2-Basic was two orders of magnitude 
lower than from pGL2-Promoter (data not shown). Yu et al. recently reported similar effects 
on the SV40 and HSV-1 ICP4 (immediate-early), TK (early) and gC (late) promoters (585). 
Collectively these data demonstrate that VP22 reduces gene expression in a promoter-
independent manner, and that this effect is not reporter protein-specific. 
5.7 VP22 MUTATION DOES NOT AFFECT ICP0-MEDIATED ND10 DISPERSAL 
ICP0 transactivates gene expression, at least in part, through ND10 disruption (145, 209). 
Since the VP22-mediated reduction in gene expression prohibited direct assessment of any 
effect of VP22 on ICP0-induced gene transactivation, the impact of VP22 mutation on ICP0-
dependent ND10 dispersal was investigated. While ICP0 disperses ND10 in the absence of 
other viral proteins (421), it remained plausible that VP22 augments or dampens this activity. 
Our group reported that VP22 phosphorylation regulates the ability of VP22 to enhance ICP0 
levels in infected cells (443). Therefore subconfluent Vero cells were mock treated or 
infected at a multiplicity of ten with our GFP-22, P+ or P- viruses (figure 2.1). Cells were fixed 
6 hpi and immunofluorescence staining performed for PML. PML-positive punctate ND10 
were visible in the nucleus of mock infected cells, alongside some diffuse nuclear and 
cytoplasmic PML (figure 5.7). In cells infected with our GFP-22 virus, ND10 were completely 
dispersed and PML exhibited a diffuse distribution in the nucleus and cytoplasm, replicating 
reported effects of wild-type HSV-1 infection (153). ND10 were equally disrupted in cells 
infected with our P+ and P- viruses. GFP autofluorescence confirmed comparable levels of 
infection. To test the impact of more disruptive VP22 mutations, the experiment was 
repeated with our GFP-22 (1-301), ∆22, 160-301, 1-165 and 1-212 viruses. Again, all viruses 
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Figure 5.6: VP22-dependent downregulation of gene expression is not promoter specific. (A 
and B) Confluent Vero cells transfected with increasing amounts of the VP22-expressing 
plasmid pPO85 and 0.1 µg of either the ICP0 (A) or GFP (B) expression vectors pcI110 and 
pEGFP-c1 were harvested 24 hours posttransfection in SDS-PAGE loading dye and samples 
analysed by western blot using antibodies against ICP0, VP22’s C-terminus, GFP or α-
tubulin. (C) Confluent Vero cells were transfected with 0.2 µg phRL-TK (TK), pGL2-Promoter 
(SV40) or pGL2-Basic (none) in the presence or absence of 0.3 µg pPO85. Luciferase 
activity was measured 24 hours posttransfection and is presented as a percentage of the 
background activity in the absence of VP22. All plasmid quantities are per well of a 12-well 
plate. Mean of three replicates shown. Error bars represent standard deviation. ** p < 0.01. 
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Figure 5.6 
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Figure 5.7: Mutation of VP22’s phosphorylation sites does not affect the ability of ICP0 to 
disrupt ND10. Subconfluent Vero cells were mock treated or infected at a multiplicity of ten 
with our GFP-22, P+ or P- viruses. Cells were fixed 6 hpi in 4% paraformaldehyde and 
immunofluorescence staining performed for PML. Images were captured on a Zeiss Axiovert 
S100 TV inverted fluorescence microscope. 
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completely dispersed ND10 by 6 hpi, and GFP fluorescence confirmed robust infection of the 
cell monolayer (figure 5.8). Furthermore, all mutants disrupted ND10 to a comparable level 
as the GFP-22 (1-301) virus when ND10 dispersal was assessed 3 hpi (data not shown). 
Therefore VP22 mutation, and VP22 deletion, failed to alter ICP0’s ability to disrupt ND10. 
5.8 VP22-POSITIVE CYTOPLASMIC DOMAINS CONTAIN CONJUGATED UBIQUITIN 
Nuclear and cytoplasmic ICP0 colocalises with conjugated ubiquitin during HSV-1 infection 
and in cells transfected with ICP0 expression vectors (144, 422). Although VP22 did not 
affect ICP0-induced ND10 dispersal early in infection it remained plausible that VP22 
modulates the ability of ICP0 to conjugate ubiquitin late in infection, when VP22 and ICP0 
colocalise in cytoplasmic puncta. Initially it was important to verify ICP0-specific cytoplasmic 
ubiquitin conjugation. Therefore subconfluent Vero cells were infected at a multiplicity of ten 
with the wild-type HSV-1 strain 17+, our GFP-22 virus or the catalytically inactive ICP0 
mutant ∆RING (figure 2.2). Cells were fixed 6 hpi and stained for immunofluorescence using 
the FK2 antibody that recognises conjugated, but not free, ubiquitin (table 2.2) (185). ICP0-
specific accumulation of ubiquitin within discrete cytoplasmic puncta was observed in cells 
infected with wild-type HSV-1, but not in mock treated cells or cells infected with the ∆RING 
virus (figure 5.9). Importantly, ubiquitin colocalised with a subset of the large VP22-positive 
cytoplasmic domains in cells infected with our GFP-22 virus. This is the first time that the 
ICP0- and ubiquitin-positive cytoplasmic puncta observed by others have been confirmed to 
correspond to our VP22-containing cytoplasmic sites. 
5.9 VP22 MUTATION DOES NOT ALTER ICP0-DEPENDENT UBIQUITIN CONJUGATION 
Subconfluent Vero cells were mock treated or infected with the GFP-22, P+ or P- viruses at a 
multiplicity of ten to assess the impact of VP22 mutation on the ability of ICP0 to conjugate 
cytoplasmic ubiquitin. Cells were fixed 6 hpi and immunofluorescence staining performed for 
conjugated ubiquitin. In mock infected cells ubiquitin exhibited a diffuse nuclear and 
cytoplasmic distribution with some nuclear aggregates (figure 5.10A). Infection with the GFP-
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22 virus induced the appearance of cytoplasmic ubiquitin-containing puncta that colocalised 
with the large VP22-positive cytoplasmic domains. As previously reported (443), VP22 
localised in a similar pattern in cells infected with our phosphorylation mutants and the GFP-
22 virus. In cells infected with the P+ virus conjugated ubiquitin exhibited a highly punctate 
nuclear distribution with limited cytoplasmic ubiquitin-positive dots, which did not colocalise 
with VP22. On the other hand, in cells infected with our P- virus ubiquitin localisation 
reflected the situation with our GFP-22 virus. The distribution of conjugated ubiquitin mirrored 
the previously reported localisation of ICP0 in these viruses (figure 5.10B) (443). 
The experiment was repeated with the GFP-22 (1-301), ∆22, 160-301, 1-165 and 1-212 
mutants. Figure 5.11A shows the subcellular distribution of conjugated ubiquitin 6 hpi in 
infected Vero cells. Figure 5.11B depicts ICP0 localisation as a comparison (adapted from 
figure 5.1). The respective localisation of conjugated ubiquitin and ICP0 was comparable for 
each virus tested. Therefore VP22 mutation does not alter the ability of ICP0 to act as an E3 
ubiquitin ligase, since ubiquitin conjugates specifically accumulated in subcellular domains 
known to contain ICP0 in infected cells. 
5.10 CHAPTER DISCUSSION 
This chapter addressed the functional relationship between VP22 and ICP0. No impact of 
VP22 mutation on ICP0’s ability to conjugate ubiquitin and disrupt ND10 was observed. 
Furthermore, preliminary experiments found no effect of VP22 mutation on the localisation of 
ICP0’s binding partner USP7 (data not shown). In light of the reduced ICP0 levels in our ∆22 
virus (129), and given more time, it would have been interesting to assess the impact VP22 
has on ICP0 stability. While the effect of VP22 on ICP0’s other functions, such as HDAC1/2-
CoREST-REST complex disruption, could also have been explored, the available evidence 
suggests VP22 does not modulate ICP0 activity. Interestingly, VP22 itself was shown to 
reduce gene expression in a promoter-independent manner, prohibiting direct assessment of 
the impact VP22 has on ICP0’s transactivator function. This may explain previous difficulties 
in expressing VP22 alongside ICP0, gE and gM in transfected cells (figures 4.5 and 4.9). 
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Figure 5.8: VP22 mutation does not affect the ability of ICP0 to disrupt ND10. Subconfluent 
Vero cells were mock treated or infected at a multiplicity of ten with our GFP-22 (1-301), ∆22, 
160-301, 1-165 or 1-212 viruses. Cells were fixed 6 hpi in 4% paraformaldehyde and 
immunofluorescence staining performed for PML. Images were captured on a Zeiss Axiovert 
S100 TV inverted fluorescence microscope. For corresponding confocal images (taken by 
Gill Elliott) refer to our publication (346). 
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Figure 5.8 
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Figure 5.9: Conjugated ubiquitin is present in a subset of cytoplasmic VP22-containing 
puncta. Subconfluent Vero cells were mock treated or infected at a multiplicity of ten with the 
wild-type HSV-1 strain 17+ (wt) or the GFP-22 or ∆RING viruses. Cells were fixed in 4% 
paraformaldehyde 6 hpi and immunofluorescence staining performed using the FK2 antibody 
that recognises conjugated, but not free, ubiquitin (185). Images were captured using a 
confocal Zeiss LSM510 inverted laser scanning microscope. Red, conjugated poly- and 
monoubiquitin (poly/mono-ub); green, GFP; blue, DAPI. 
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Figure 5.9 
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Figure 5.10: Mutation of VP22’s phosphorylation sites does not affect ICP0’s E3 ubiquitin 
ligase activity. Subconfluent Vero cells were mock treated or infected at a multiplicity of ten 
with our GFP-22, P+ or P- viruses. Cells were fixed 6 hpi in 4% paraformaldehyde and 
immunofluorescence staining performed using the FK2 antibody specific for conjugated 
ubiquitin (A) or an ICP0-specific antibody (B). Green, GFP; red, conjugated poly- and 
monoubiquitin (poly/mono-ub) (A) or ICP0 (B). Images were captured on a Zeiss Axiovert 
S100 TV inverted fluorescence microscope. 
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Figure 5.10 
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Figure 5.11: VP22 mutation does not affect ICP0’s E3 ubiquitin ligase activity. (A) 
Subconfluent Vero cells were mock treated or infected at a multiplicity of ten with our GFP-22 
(1-301), ∆22, 160-301, 1-165 or 1-212 viruses. Cells were fixed 6 hpi in 4% 
paraformaldehyde and immunofluorescence staining performed using the ubiquitin-specific 
antibody FK2. Green, GFP; red, conjugated poly- and monoubiquitin (poly/mono-ub). Images 
were captured on a Zeiss Axiovert S100 TV inverted fluorescence microscope. For 
corresponding confocal images (taken by Gill Elliott) refer to our publication (346). (B) Effect 
of VP22 mutation on ICP0 localisation (adapted from figure 5.1). Green, GFP; red, ICP0. 
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Figure 5.11 
 
 
CHAPTER 5    Impact Of VP22 On ICP0’s Biological Activities 
 
 204
In addition to the known roles ICP27 and ICP4 play in modulating ICP0 localisation (486, 
592), VP22 mutation was shown here to affect the subcellular distribution of ICP0. 
Furthermore, localisation to cytoplasmic puncta was found to be insufficient for virion 
incorporation of ICP0 in the 160-301 and 1-212 mutants (figures 5.1 and 5.2). 
5.10.1 SITE OF ICP0 VIRION INCORPORATION 
VP22 localises to two distinct types of cytoplasmic domain in infected cells (134, 519). The 
small mobile puncta have been suggested to represent tegument accumulations within 
secretory vesicles or mature virions during egress (134, 519). ICP0 was not observed within 
these puncta (129 and figures 5.1 and 5.2), although the techniques used may not be 
sensitive enough to detect this minor virion component in intracellular virus particles. 
Localisation of VP22 to these domains correlated with VP22-gE-gM complex formation and 
VP22 assembly (figures 5.1 and 5.2 and table 4.1), supporting the suggestion that these 
cytoplasmic puncta represent intracellular virus progeny (99, 519). Sugimoto et al. and de 
Oliveira et al. observed colocalisation of capsid, tegument and glycoproteins in similar 
domains in live cells infected with independent triple-labelled fluorescent viruses (99, 519). 
The second type of VP22-containing cytoplasmic domain is larger and static, and is more 
pronounced at high multiplicities of infection (134). These puncta are also known to 
accumulate ICP0 and VP16 (129, 207 and figures 5.1 and 5.2), and have been proposed to 
represent sites of secondary envelopment (207, 519). However, localisation to these sites is 
not sufficient for ICP0 assembly, and VP22 is assembled in our 160-301 virus without 
steady-state localisation to these domains (figures 5.1 and 5.2). We proposed that tegument 
proteins transit through ICP0-positive cytoplasmic sites as a critical step in the herpesvirus 
assembly pathway (346). In this scenario the steady-state localisation, but not trafficking 
through these domains, is altered in the 160-301 VP22 construct. How ICP0 itself is recruited 
to these sites remains unknown. Optimal VP22-binding is dispensable for localisation of ICP0 
to these domains in the 160-301 and 1-212 mutants (figures 5.1 and 5.2). Preliminary 
observations made with the ∆gEgM virus indicate gE and gM are also dispensable (data not 
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shown). Work led by Bernard Roizman suggests proteasome components may be involved 
(335, 545). Although ICP0 must be packaged in the cytoplasm, since ICP27-dependent 
cytoplasmic accumulation is essential for ICP0 assembly (486), the exact site of ICP0 virion 
incorporation remains unknown. 
5.10.2 IMPACT OF VP22 ON ICP0 LOCALISATION 
ICP0 is strikingly nuclear in cells infected with our 1-165 and P+ viruses (figure 5.3). A 
subpopulation of full-length VP22 localises to punctate nuclear domains juxtaposed with 
ICP0 (235), and it is tempting to speculate that nuclear events involving VP22 modulate 
cytoplasmic accumulation and virion incorporation of ICP0. While our 1-165 VP22 construct 
does not appear to bind ICP0 (table 4.1), it is worthwhile pointing out that, as well as 
localising to ND10, ICP0 exhibits a diffuse distribution within the nucleus (155, 352). It is 
therefore conceivable that ICP0 associates dynamically with VP22 within VP22-positive 
nuclear puncta, at a level that is undetectable by immunoprecipitation. 
Alternatively, VP22 mutation might affect as-yet unidentified binding partners of VP22 that 
promote cytoplasmic accumulation of ICP0. Although ICP27 facilitates the cytoplasmic 
localisation of ICP0 in infected and transfected cells (486, 592), ICP27 is unlikely to be 
involved because it does not interact with VP22 or ICP0 (figures 4.6A and B). Furthermore, 
gE and gM can be excluded because ICP0 is cytoplasmic in cells infected with our 1-212 
VP22 mutant (figures 5.1 and 5.2), which, like the 1-165 construct, lacks the glycoprotein-
binding domain (figure 2.1). VP22 may engage cellular factors such as cyclin D3, cdk4, the 
HDAC1/2-CoREST-REST complex, or ND10 or proteasome components, all of which have 
been implicated in localising ICP0 to the cytoplasm (160, 205, 259, 260, 268, 335, 545, 546). 
ICP0 is dynamically phosphorylated in infected cells and Advani et al. correlated the 
appearance of highly modified ICP0 with its cytoplasmic localisation late in infection (1, 5). 
Davido et al. reported that the NLS-adjacent phosphorylation cluster III of ICP0 (figure 1.3B) 
modulates ICP0 localisation in transfected cells (95). It is possible that VP22 indirectly 
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modifies ICP0 localisation by modulating the cellular (cdc2 and CKII) and viral (UL13) kinases 
that regulate ICP0 phosphorylation (5, 95).  
Given that certain VP22 mutations induce nuclear retention of ICP0, it remains unclear how 
ICP0 can accumulate in the cytoplasm of cells infected with our ∆22 virus (129 and figures 
5.1 and 5.2). We have drawn parallels with observations that Lopez et al. made with an 
ICP4-null virus (335, 346). ICP0 accumulates in the cytoplasm of cells infected with this 
mutant even though post-immediate-early gene expression, known to be required for 
cytoplasmic localisation of ICP0, is impaired (335, 467). The authors proposed that an early 
or late gene product actively retains ICP0 in the nucleus (335). This viral protein may be 
targeted by VP22 to allow cytoplasmic accumulation of ICP0. Alternatively, since VP22 
deletion affects several aspects of HSV-1 replication (124, 125, 129), ICP0 behaviour may be 
grossly altered in the ∆22 virus. 
5.10.3 FACTORS KNOWN TO REGULATE ICP0 FUNCTION 
Although VP22 does not regulate ICP0 activity, other factors are known to modulate ICP0 
function. Nagel et al. recently reported that ICP0 interacts with and is polyubiquitinated in 
vitro and in vivo by the cellular E3 ubiquitin ligase seven in absentia homolog 1 (SIAH-1) 
(390). This interaction may modify ICP0 stability in infected cells (390). In addition, ICP0R, 
the truncated form of ICP0 expressed via alternative splicing (figure 1.3A), represses ICP0-
mediated gene transactivation by an undetermined mechanism requiring the RING finger 
domain that ICP0R shares with ICP0 (151, 506, 558). Phosphorylation of ICP0 also modifies 
its intracellular localisation and ability to disrupt ND10 and transactivate gene expression, 
with phosphorylation cluster I (figure 1.3B) being critical for ICP0-dependent enhancement of 
HSV-1 replication (95). The cellular transcription factors insulinoma-associated 1 (INSM1) 
and E2FBP1 regulate transcription from the ICP0 promoter (186, 262). In addition, Liu et al. 
report that ICP4 represses ICP0 mRNA synthesis, and that ICP0 counteracts this activity by 
binding ICP4 (328). While work outlined here could imply a role for VP22 in regulating ICP0 
expression, VP22-dependent gene silencing is not promoter-specific (figure 5.6C). 
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5.10.4 ROLE OF VP22 IN MODULATING GENE EXPRESSION 
The effects of VP22 on gene expression should be verified in infected cells, however all our 
mutant viruses encode GFP-tagged VP22, and GFP is known to quench luciferase activity 
through a complex and unpredictable phenomenon termed bioluminescence resonance 
energy transfer (BRET) (44, 459). Although non-GFP-tagged VP22 mutants or a 
chloramphenicol acetyltransferase reporter assay could have been developed, this was not 
justified given that Yu et al. published similar findings concurrently with this work (585, 586). 
Yu et al. concluded that VP22-ICP0 binding inhibits ICP0-mediated gene transactivation, but 
did not account for the effects of VP22 itself on gene expression, which the authors also 
observed (585, 586). The group also reported reduced TK and gC mRNA levels in wild-type 
HSV-1-infected Vero cells transfected with a VP22 expression vector, suggesting VP22 acts 
prior to translation (586). Since VP22 nonspecifically binds nucleic acids (117, 339, 406, 
484), it might be worthwhile evaluating the effect VP22 has on mRNA stability in vitro. 
Duffy et al. reported that VP22 deletion results in reduced accumulation of a subset of viral 
mRNAs early in infection without affecting viral protein levels (125). Later, global protein 
levels were reduced, by which point viral mRNA levels had recovered (125). VP22 did not 
affect protein stability (125). We do not observe a global reduction in protein synthesis with 
our ∆22 virus, although certain viral proteins, including ICP0, accumulate to lower levels and 
there is a delay in viral protein expression (129). These inconsistencies may stem from 
differences in the parental HSV-1 strains used (124, 129). The viral endoribonuclease vhs, 
which forms a complex with VP22 and VP16 (522), disrupts translation by indiscriminately 
degrading host and viral mRNAs (294). Duffy et al. therefore proposed that VP22 modulates 
protein expression by regulating vhs activity (125). This does not explain observations made 
here and by Yu et al. in the absence of vhs (585, 586 and figures 5.5 and 5.6). It is also 
unclear why VP22 should enhance gene expression during infection yet have the opposite 
effect in transfected cells, although other viral proteins may modulate VP22 activity. 
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An intriguing possibility is that the effects of VP22 on gene expression involve the punctate 
ND10-adjacent nuclear domains VP22 localises to in infected cells (235). Cellular structures 
called interchromatin granule clusters or nuclear speckles are also known to associate with 
ND10 (14, 239). These structures transiently accumulate HSV-1 RNAs in infected cells and, 
like the VP22-positive nuclear puncta, are restricted to the periphery of the viral replication 
compartment (31, 116, 235, 447). Interchromatin granule clusters have been implicated in 
spliceosome assembly, splice factor storage and mRNA processing and export, although the 
presence of cellular RNA at these sites remains contested (31, 37, 88, 371, 474, 529). Cajal 
bodies, which also function in RNA processing, have also been observed in the vicinity of 
ND10 (30, 353). Perhaps VP22 suppresses gene expression by targeting RNA processing 
factors and/or mRNAs present in interchromatin granule clusters or cajal bodies. 
Interestingly, VP22 was shown to bind the splicing factor U2AF1 in a recent yeast-two-hybrid 
screen (315). It would be prudent to confirm whether VP22-positive nuclear dots represent 
interchromatin granule clusters and/or cajal bodies, and that VP22 localises to these sites in 
transfected cells, before exploring this avenue further. 
It is important to note that GFP also reduced ICP0 levels in transfected cells (figure 4.5A). 
This is likely a quirk specific to GFP, since β-galactosidase did not impair gene expression 
(figures 5.5B and C). In fact GFP is known to cause cellular toxicity through the production of 
reactive oxygen species (459). 
5.10.5 CONCLUDING REMARKS 
In this chapter VP22 was found to modify ICP0 localisation, but have no effect on ICP0 
function. In the future it may be worthwhile assessing whether other components of the ICP0 
assembly complex, such as gE or gM, modulate ICP0 activity. The impact ICP0 has on 
VP22’s activities, particularly VP22 stability, should also be addressed. As discussed in 
section 1.5.3, the biological functions of VP22 remain incompletely understood. Therefore the 
discovery that VP22 suppresses gene expression in transfected cells opens a new avenue of 
research to better understand the role VP22 plays during alphaherpesvirus infection. 
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6.1 CHAPTER INTRODUCTION 
Chapters 3 and 4 revealed an ICP0 assembly pathway dependent upon VP22, gE and gM. 
The tightly controlled nature of VP22-gE-gM-ICP0 complex formation and ICP0 assembly, 
involving hierarchical protein-protein interactions, implies a vital role for virion ICP0. 
At the outset of this project, little was known about the contribution of virion ICP0 to HSV-1 
replication. Yao and Schaffer had observed impaired ICP4 expression in Vero cells infected 
with an ICP0-null mutant, and then sequentially treated with cycloheximide and actinomycin 
D to inhibit protein and then RNA synthesis, suggesting virion ICP0 enhances immediate-
early gene expression (583). In addition, we speculated that the cell type-dependent growth 
defect of our ∆22 virus might be caused, at least in part, by the lack of ICP0 within incoming 
virus particles (129, 518). The ∆22 virus exhibits a similar defect at low multiplicities of 
infection in MDBK cells as our ∆gEbind mutant, in which VP22’s glycoprotein-binding domain 
and hence VP22-gE-gM-ICP0 complex formation and ICP0 assembly are disrupted in a 
background of normal VP22, gE, gM and ICP0 expression (518 and figures 2.1, 3.2A and 
4.7B). Furthermore, gE- and gM-null viruses, which also lack virion ICP0 (figure 4.7C), are 
reported to display similar growth defects (54, 304). The contribution impaired ICP0 
assembly makes to the phenotypes of these mutants remains unknown. This chapter 
describes a preliminary investigation into the role virion ICP0 plays in HSV-1 replication. 
6.2 ∆22 AND ∆ICP0 VIRUS WORKING STOCK TITRATION IN DIFFERENT CELL LINES 
The effects of ICP0 deletion are most pronounced in limited passage fibroblasts and cells of 
neuronal origin, in which ICP0-null mutants display a respective three- or four-log replication 
defect (142, 144, 145, 149, 232, 470, 514). In BHK, Vero, HEp-2 and HeLa cells ICP0 
deletion results in a more modest 20- to 100-fold defect (142, 144, 470, 514, 583). Yao and 
Schaffer first noted that ICP0-null mutants replicate similarly to wild-type HSV-1 in the U2OS 
osteosarcoma cell line (583). One aim of this work was to use our VP22-null virus that 
expresses, but fails to package, wild-type ICP0 to assess the role of virion ICP0. Therefore 
plaque formation was compared in the ∆22 and ∆ICP0 viruses (figures 2.1 and 2.2). Working 
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stocks of these mutants, and the parental wild-type strain 17+, were titrated on U2OS, Vero 
or HFFF2 cells. Infections in each cell line were fixed concurrently between three to six days 
postinfection. Time of fixation varied among cell lines to give measurable plaques. 
The titre of wild-type HSV-1 was the same in every cell line (figure 6.1). In line with previous 
publications (60, 142, 144, 149, 232, 470, 514, 583), the ∆ICP0 mutant exhibited a three- to 
four-log plaque forming deficiency in HFFF2 cells compared with U2OS cells, and a less 
pronounced defect in Vero cells. VP22 deletion had negligible impact on plaque formation, 
suggesting virion ICP0, absent in our ∆22 virus, is dispensable for initiation of infection. 
6.3 CELL TYPE-SPECIFIC PLAQUE SIZE DEFECTS IN VP22- AND ICP0-NULL HSV-1 
Plaque size was assessed in titrations shown in figure 6.1. Titrations were performed in the 
presence of human serum, which neutralises cell-free virus. Therefore plaque size 
comparisons measure direct cell-to-cell spread in addition to virus replication. Unlike in 
U2OS and Vero cells, in HFFF2 cells wild-type HSV-1 formed irregular plaques in which the 
cell monolayer did not detach completely from the culture plate (figure 6.2A). This may reflect 
the irregular cell monolayer and incomplete cytopathology in these cells. Furthermore, in line 
with a previous report (149), plaque formation was accelerated in HFFF2 cells. The ∆22 and 
∆ICP0 mutants formed smaller plaques in each cell line than the parental virus, verifying and 
expanding on reports that ICP0-null mutants form small plaques in BHK and Vero cells (470, 
514). This defect was most pronounced in HFFF2 cells, and least obvious in Vero cells. 
To quantify these observations, at least thirty plaques were measured for each condition 
using ImageJ software as described in materials and methods. Plaque size could not be 
quantified in HFFF2 cells due to the irregular cell monolayer and poorly defined plaques. 
Although wild-type HSV-1 appeared to form similar sized plaques in U2OS and Vero cells 
(figure 6.2B), this is not the case because cells were not fixed concurrently. Deletion of VP22 
or ICP0 reduced plaque size in both U2OS and Vero cells by over 60% and in a statistically 
significant manner (statistical analysis is detailed in materials and methods and appendix 2). 
The ICP0-null defect was similar in both cell lines, indicating that the ICP0-complementing 
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Figure 6.1: Deletion of ICP0, but not VP22, impairs HSV-1 plaque formation in a cell type-
specific manner. Working stocks of the wild-type HSV-1 strain 17+ (wt) or ∆22 or ∆ICP0 
mutants were titrated on confluent U2OS, Vero and HFFF2 cells. Cells were fixed in formal 
saline solution and stained with crystal violet once defined plaques were clearly visible. 
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Figure 6.1 
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Figure 6.2: Effect of VP22 or ICP0 deletion on HSV-1 plaque size. The wild-type HSV-1 
strain 17+ (wt) or the ∆22 or ∆ICP0 mutants were titrated on confluent U2OS, Vero or HFFF2 
cells. Infections in each cell line were fixed concurrently; timing of fixation varied between cell 
lines to give measurable plaques. (A) Representative crystal violet-stained 6-well titration 
plates. (B) Mean plaque size determined using ImageJ software (U2OS and Vero cells only). 
At least 30 plaques were measured for each condition. Error bars represent the standard 
deviation; ** p < 0.01. 
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Figure 6.2 
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activity of U2OS cells does not compensate for ICP0 in terms of virus spread. In contrast, our 
∆22 virus exhibited a greater deficit in U2OS cells, highlighting cell type-specific differences 
in the importance of VP22 to HSV-1 replication. Plaque size was reduced significantly by 
over 50% in our ∆22 virus compared with the ∆ICP0 mutant in U2OS cells, demonstrating 
that VP22 contributes to HSV-1 replication and/or cell-to-cell spread beyond its role in ICP0 
assembly. Therefore our ∆22 virus is not an appropriate tool for dissecting the role of virion 
ICP0 in HSV-1 replication. 
6.4 TARGETING VP22 TO THE NUCLEUS AUGMENTS ICP0 VIRION INCORPORATION 
In chapter 5, nuclear events involving VP22 were hypothesised to modulate cytoplasmic 
accumulation of ICP0. Within our group Ian Hutchinson generated a virus expressing GFP-
tagged full-length VP22 with the SV40 NLS inserted at the N-terminus of VP22 (NLS-22) 
(figure 2.1) (unpublished data). This mutation increases the nuclear subpopulation of VP22, 
although VP22 still localises to its characteristic cytoplasmic domains (figure 6.3A). Gill Elliott 
analysed NLS-22 virions purified from BHK-21 cells. Virus particles were equalised against 
the major capsid protein VP5, which also served as a loading control. VP22 was assembled 
at comparable levels in the NLS-22 mutant and the wild-type HSV-1 strain 17+ (figure 6.3B). 
A 40 kDa breakdown product was detected in purified NLS-22 virions; this may represent 
NLS-modified VP22 that has lost the GFP tag. Compared to wild-type HSV-1, virion 
incorporation of ICP0 was enhanced in the NLS-22 virus. Importantly, both VP22 and ICP0 
are assembled at similar levels in the GFP-22 virus and its parental wild-type strain 17+ (134 
and data not shown). Therefore the augmented ICP0 virion incorporation seen here (figure 
6.3B) is entirely due to nuclear targeting of VP22. 
To compare ICP0 assembly and VP22-ICP0 complex formation in the NLS-22 mutant, 
confluent Vero cells were infected at a multiplicity of one with the GFP-22, NLS-22 and ∆22 
viruses. Cells were harvested 20 hpi and VP22 immunoprecipitated. VP22, VP16 and ICP0 
were expressed at similar levels in the GFP-22 and NLS-22 viruses (figure 6.3C). As 
previously reported (129), ICP0 levels were reduced in the ∆22 mutant. VP22 was 
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immunoprecipitated with equivalent efficiency in the GFP-22 and NLS-22 viruses; the ∆22 
mutant served as a negative control. Both VP16 and ICP0 coimmunoprecipitated with VP22 
at comparable levels in the GFP-22 and NLS-22 viruses. Importantly, GFP-tagged VP22 is 
known to bind ICP0 at similar levels as wild-type VP22 (figure 4.3B). Therefore, nuclear 
VP22 modulates ICP0 assembly (figure 6.3B) without affecting VP22-ICP0 complex 
formation (figure 6.3C). VP22-VP16 binding is also unaffected by nuclear targeting of VP22. 
VP22 and ICP0 localisation was also assessed 6 hpi in Vero cells infected at a multiplicity of 
ten with the NLS-22 and GFP-22 viruses. As usual, ICP0 colocalised with VP22 in a subset 
of large cytoplasmic puncta in cells infected with the GFP-22 virus (figure 6.3D). At 6 hpi the 
localisation of ICP0 in the NLS-22 mutant was indistinguishable from the GFP-22 virus. 
6.5 THE NLS-22 MUTANT REPLICATES FASTER THAN ITS PARENTAL VIRUS 
Since it packages enhanced levels of ICP0, the NLS-22 virus represents a convenient tool 
for investigating the importance of virion ICP0, bypassing the growth defect caused by VP22 
deletion (figure 6.2). Subconfluent Vero cells were infected with the NLS-22 or GFP-22 virus 
at a multiplicity of ten. Cells were fixed in 4% paraformaldehyde at various times 
postinfection and immunofluorescence staining performed for ICP0. Microscope settings 
were kept constant to allow direct comparison between slides. In cells infected with our GFP-
22 virus, limited ICP0 expression was detectable in the nucleus of some cells from 2 hpi 
(figure 6.4, left panel). By 4 hpi ICP0 was expressed in every cell, and a proportion localised 
to cytoplasmic puncta. At 6 hpi ICP0 was fully cytoplasmic. Immediate-early gene expression 
appeared accelerated in our NLS-22 virus, with ICP0 visible in the nucleus of a proportion of 
cells as early as 1 hpi, and all cells by 2 hpi (figure 6.4, right panel). By 4 hpi the expression 
and localisation of ICP0 was indistinguishable from the GFP-22 virus. 
When GFP autofluorescence was imaged as a marker for late gene expression, low levels of 
GFP-tagged VP22 were detected from 4 hpi in the cytoplasm of most cells infected with the 
GFP-22 virus (figure 6.5, left panel). At 6 hpi robust VP22 expression was observed, and 
VP22 localised to characteristic cytoplasmic puncta. VP22 expression was accelerated in the 
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Figure 6.3: Increasing the proportion of nuclear VP22 enhances ICP0 virion incorporation. 
(A) Subconfluent Vero cells infected at a multiplicity of ten with the GFP-22 and NLS-22 
viruses were fixed in 4% paraformaldehyde 6 hpi, and GFP autofluorescence imaged. (B) 
Western blot depicting equivalent amounts of extracellular virions purified from confluent 
BHK-21 cells infected at a multiplicity of 0.02 with the wild-type HSV-1 strain 17+ (wt) or the 
NLS-22 virus. Blots were probed with antibodies raised against ICP0, VP5 or the N-terminus 
of VP22. Molecular weight marker sizes (kDa) are shown on the left. Data collected by Gill 
Elliott. (C) The N-terminus-specific VP22 antibody was used to immunoprecipitate VP22 from 
whole cell lysates harvested 20 hpi from confluent Vero cells infected at a multiplicity of one 
with the GFP-22, NLS-22 or ∆22 viruses. Samples were analysed by western blot using 
monoclonal antibodies directed against GFP, ICP0 and VP16. (D) As for (A) except 
immunofluorescence staining was additionally performed for ICP0. Green, GFP; red, ICP0. 
All images were captured on a confocal Zeiss LSM510 inverted laser scanning microscope. 
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Figure 6.4: ICP0 expression is accelerated in our NLS-22 mutant. Subconfluent Vero cells 
were infected at a multiplicity of ten with our GFP-22 or NLS-22 viruses. Cells were fixed in 
4% paraformaldehyde at the indicated times (far left) and immunofluorescence staining 
performed for ICP0. Images were captured on a confocal Zeiss LSM510 inverted laser 
scanning microscope. Arrows indicate early nuclear ICP0 expression. 
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Figure 6.5: Late gene expression is accelerated in our NLS-22 virus. Subconfluent Vero 
cells were infected at a multiplicity of ten with our GFP-22 or NLS-22 viruses. Cells were 
fixed in 4% paraformaldehyde at the indicated times (far left) and images captured on a 
confocal Zeiss LSM510 inverted laser scanning microscope. 
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NLS-22 virus, with nuclear VP22 detected from 3 hpi (figure 6.5, right panel). By 4 hpi, high 
levels of nuclear and cytoplasmic VP22 were observed, although the punctate cytoplasmic 
distribution of VP22 was more pronounced at 6 hpi. Note that the speckled GFP pattern at 2 
hpi (GFP-22 and NLS-22) and 3 hpi (GFP-22) is due to input material, as it was also 
observed immediately after infection (data not shown). 
These data demonstrate that infection proceeds more rapidly in the NLS-22 mutant 
compared with the parental GFP-22 virus. 
6.6 ND10 DISPERSAL IS ACCELERATED IN THE NLS-22 VIRUS 
One of ICP0’s earliest functions during infection is to facilitate productive infection by 
counteracting the intrinsic antiviral defence posed by ND10 (145, 209). Therefore ND10 
dispersal was imaged in the NLS-22 mutant under the same conditions as in section 6.5. 
Distinctive PML-positive ND10 were readily visible in mock treated Vero cells (figure 6.6A). 
ND10 remained intact in cells infected with the GFP-22 virus at 2 hpi (figure 6.6B, left panel). 
At 3 hpi ND10 were dispersed in a proportion of cells, and by 4 hpi the entire cell population 
lacked visible ND10. The NLS-22 mutant on the other hand disrupted ND10 in a proportion of 
cells as early as 2 hpi, with complete ND10 dispersal observed by 3 hpi (figure 6.6B, right 
panel). These data do not prove that accelerated ND10 dispersal results from enhanced 
ICP0 assembly. Instead, ND10 disruption acts as a marker for early infectious processes, 
confirming that infection proceeds more rapidly in the NLS-22 mutant. 
6.7 CHAPTER DISCUSSION 
The major finding of this chapter is that the NLS-22 mutant, which packages enhanced levels 
of ICP0, replicates faster than its parental virus GFP-22 in Vero cells (figures 6.3 to 6.6). 
Furthermore, our ∆22 virus, which does not package ICP0, initiated plaque formation as 
efficiently as wild-type HSV-1 in U2OS, Vero and HFFF2 cells (figure 6.1). Collectively these 
data imply that virion ICP0 is not required for establishing productive infection, but that it 
augments virus replication. Nevertheless, by 6 hpi the progress of GFP-22 and NLS-22 
CHAPTER 6    Importance Of Virion ICP0 
 
 225 
infection was indistinguishable by immunofluorescence microscopy at high multiplicities of 
infection (figures 6.4 and 6.5). These data are preliminary and should be confirmed by 
repeating inconclusive plaque size experiments and growth curves, performed by Clare 
Labiran within our group, comparing the NLS-22 and GFP-22 viruses (data not shown). 
Immunofluorescence microscopy data should also be verified by western blot for other 
markers of infection. 
Of particular note is the observation that the ∆ICP0 mutant displays a distinctive plaque size 
reduction in U2OS cells (figure 6.2). While ICP0 deletion is reported to have no effect on 
HSV-1 replication in U2OS cells (149, 583), the plaque size phenotype has not been 
addressed in this cell line. The new data presented here suggest ICP0 contributes to virus 
replication and/or spread beyond its role in establishing productive infection (see chapter 7). 
6.7.1 IMPACT OF NUCLEAR VP22 ON ICP0 VIRION INCORPORATION 
In chapter 5, nuclear events involving VP22 were hypothesised to affect ICP0 localisation. 
Here, increasing the proportion of nuclear VP22 augmented ICP0 virion incorporation without 
altering VP22-ICP0 complex formation or ICP0 localisation (figure 6.3), although cytoplasmic 
ICP0 appeared earlier in infection (figure 6.4). These data support a model in which nuclear 
VP22 modifies ICP0 behaviour. Nuclear events might enhance ICP0 assembly without 
affecting VP22-ICP0 binding by modifying ICP0 and/or VP22 to preferentially select ICP0-
bound VP22 for recruitment into the virion. In cells infected with the NLS-22 virus VP22 
would still engage the putative factors required for cytoplasmic accumulation of ICP0 
(chapter 5), but at enhanced levels that augment ICP0 assembly. 
Note that viruses with mutations in ICP0’s USP7-binding domain also assemble enhanced 
levels of ICP0, while VP22-ICP0 association remains unaltered (figure 4.13). Therefore the 
factors regulating ICP0 virion incorporation, above and beyond recruitment of ICP0 into the 
VP22-gE-gM-ICP0 complex, are complex and remain incompletely understood. 
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Figure 6.6: ND10 dispersal is accelerated in cells infected with our NLS-22 virus. 
Subconfluent Vero cells were mock treated (A) or infected at a multiplicity of ten with our 
GFP-22 or NLS-22 viruses (B). Cells were fixed in 4% paraformaldehyde at the indicated 
times (B, far left) and immunofluorescence staining performed for PML. Mock was fixed 4 
hpi. Images were captured on a confocal Zeiss LSM510 inverted laser scanning microscope. 
Arrows highlight cells with disrupted ND10. Red, PML; blue, DAPI. 
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6.7.2 ROLES OF VIRION ICP0 
While targeting VP22 to the nucleus in our NLS-22 virus might itself augment HSV-1 
replication, VP22 was not detectable until 3 hpi in cells infected with the NLS-22 virus (figure 
6.5). By this point the NLS-22 virus displayed a clear advantage in terms of ICP0 expression 
and ND10 dispersal (figures 6.4 and 6.6B). Therefore these effects are likely due to virion 
VP22, other virion components (e.g. ICP0) or factors expressed early in infection. 
Furthermore, our ∆gEbind, ∆ 22 and phosphomimetic viruses, which lack virion ICP0, are 
known to grow poorly in tissue culture (129, 443, 518). These anecdotal observations hint at 
a link between virion ICP0 levels and virus replication, although conclusive evidence remains 
lacking. An elegant way of verifying these data would be to culture ICP0-null mutants on 
control or ICP0-expressing cell lines, though others have found this technically challenging 
(103 and personal communication, Chris Boutell). The resulting virus stocks could be used to 
assess the role of virion ICP0 in the absence of de novo ICP0 expression or other mutations. 
Alternatively, the ability of UV-inactivated wild-type and ICP0-null HSV-1 to disperse ND10 
could be tested. Replication of the NLS-22 mutant could also be assessed in U2OS cells, in 
which any growth advantage due to enhanced levels of virion ICP0 should be irrelevant. 
The mechanism by which virion ICP0 might enhance virus infection is unknown. Although 
ICP0 is not conserved outside the alphaherpesvirus subfamily, its ND10-disrupting properties 
are, and the tegument proteins ORF75c and pp71 of murine gammaherpesvirus 68 and 
HCMV have been shown to modify ND10 components, even in cells infected with UV-
inactivated virus (209, 270, 326, 338, 495). It is tempting to infer that virion ICP0 performs a 
similar function. Although ND10 were disrupted more rapidly by the NLS-22 than the GFP-22 
virus (figure 6.6B), ND10 dispersal was used purely as an early marker of infection. If virion 
ICP0 does act via ND10 dispersal, the replication advantage of the NLS-22 virus should be 
negated after silencing PML expression with siRNA. It is worth highlighting several reports 
demonstrating that tegument-associated ICP0 is not sufficient for inhibition of innate immune 
responses (360, 378, 400). Delboy and Nicola recently noted that capsid trafficking to 
CHAPTER 6    Importance Of Virion ICP0 
 
 229 
nuclear pores is impaired in mutants that fail to package ICP0 (103). The authors proposed 
that a proteasome-dependent ICP0 function facilitates post-penetration capsid movement, 
either by aiding tegument dissociation or by degrading the host cytoskeleton (103). In an 
early study, Yao and Courtney suggested that virion ICP0 merely acts as a backup for the 
major viral transactivator VP16, since ICP0 is a minor virion component (582). 
ICP0 remains capsid-associated when virions are stripped in a detergent/salt buffer (104, 
452, 569 and figure 4.1). While these experiments may not entirely mimic virion disassembly 
during virus entry, capsids produced in this way are competent for microtubule transport, 
nuclear pore docking and viral genome uncoating (412, 569). Therefore virion ICP0 might 
conceivably be delivered to the nucleus to boost the infectious process. Furthermore, ICP0 
localisation is regulated by phosphorylation (1, 5, 95), and it can be hypothesised that the 
highly modified cytoplasmic form of ICP0 would be the one assembled into virus particles. It 
is unclear why this phosphorylated form should enter the nucleus after virus entry, but not 
during late stages of infection. However, VP22 and other tegument components are known to 
be targeted by viral and cellular kinases to facilitate tegument disassembly (377). Therefore 
virion ICP0 may also become modified to allow its nuclear localisation. Alternatively, ICP0’s 
tegument binding partner ICP4 might transport ICP0 into the nucleus, or virion ICP0 might 
boost HSV-1 replication via its incompletely understood cytoplasmic functions. 
6.7.3 CELL TYPE-DEPENDENT IMPACT OF ICP0 AND VP22 DELETION 
The ∆22 and ∆ ICP0 viruses displayed equivalent reductions in plaque size relative to wild-
type HSV-1 in Vero cells, while the ∆22 mutant exhibited a larger deficiency in U2OS cells 
(figure 6.2B). Although this observation may be coincidental, it is possible that the VP22-null 
defect is solely due to the absence of virion ICP0 in Vero cells, with an additional 
requirement for VP22 in U2OS cells. Exogenously expressing ICP0 in infected U2OS and 
Vero cells would reveal to what extent the VP22-null phenotype is due to the lack of virion 
ICP0. Since Vero cells are defective for interferon production (110), it would be worthwhile 
testing whether exogenous interferon increases the severity of the VP22-null phenotype in 
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Vero cells. Our recent unpublished observations indicate that the ∆22 virus exhibits a more 
pronounced plaque size phenotype in all tested human cell lines, particularly keratinocytes 
(data not shown), which are highly relevant to initial infection in humans. 
The reason for the cell type dependency of the ∆ ICP0 virus is not known. Work led by 
Priscilla Schaffer initially suggested that a cellular activity upregulated after release from 
G0/G1 growth arrest and by growth factor treatment compensates for ICP0 in Vero and 
neuroblastoma cells (59, 255, 455). It later became clear that isoleucine deprivation, used to 
synchronise cells in these experiments, heat-shock and UV irradiation induce stress 
responses that, rather than G1/S phase transition, complement the ICP0-null phenotype (53, 
445). The cellular factors involved remain unknown, but the ICP0-complementing activity pre-
exists in U2OS cells and is not induced by virus infection (53, 59, 583). Poon et al. suggested 
that differences in HDAC1/2 regulation lead to reduced viral gene silencing in U2OS cells 
(440). In contrast, Mossman et al. proposed that U2OS cells lack an interferon-inducible 
antiviral defence counteracted by ICP0, since ICP0-null HSV-1 and wild-type vesicular 
stomatitis virus are resistant to interferon treatment in this cell type (379, 380). Hsu and 
Everett noted inefficient ICP0-mediated ND10 disruption in a human neuroblastoma cell line 
that exhibits aberrant ND10, and inferred that differences in ND10 might contribute to the cell 
type dependency of the ICP0-null phenotype (232). Cell density, age and growth rate have 
also been proposed to play a part, as ICP0 deletion causes a greater defect in slow growing 
HFFF2 cells than in rapidly dividing BHK and HeLa cells (59, 142). The biological basis for 
the cell type dependency of the VP22-null phenotype is poorly understood, but these and/or 
additional factors might play a part. 
6.7.4 CONCLUDING REMARKS 
Results presented here support a role for virion ICP0 in enhancing the early stages of HSV-1 
replication, but not the initiation of productive infection per se. Further evidence hinting at a 
nuclear relationship between VP22 and ICP0, which impacts on ICP0 virion incorporation, 
was also presented. These preliminary findings provide exciting avenues for future research. 
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7.1 CHAPTER INTRODUCTION 
An intriguing finding from chapter 6 is that ICP0-null HSV-1 displays a plaque size defect in 
U2OS cells (figure 6.2), in which ICP0 is dispensable for initiation of productive replication 
(149, 583). These data suggest ICP0 may enhance late stages of infection, or cell-to-cell 
spread. ICP0’s late functions are incompletely understood. ICP0 colocalises with VP22 in 
cytoplasmic puncta at late times of infection (chapter 5), when at least a subset of ICP0 is 
present within the VP22-gE-gM-ICP0 complex (chapter 4). Furthermore, Paladino et al. 
reported that cytoplasmic ICP0 blocks IRF-3 activation (419). Based on an interaction with 
elongation factor 1 δ, cytoplasmic ICP0 has also been proposed to regulate translation (266). 
VP22 mutation has no discernable impact on ICP0 function (chapter 5), and it remains 
feasible that VP22 binding serves only to facilitate ICP0 packaging. Nevertheless, 
characterising ICP0’s late roles might reveal novel functions for VP22-associated ICP0. 
Here, the importance of ICP0 at late stages of infection was re-evaluated. 
7.2 ICP0-NULL HSV-1 ESTABLISHES INFECTION INEFFICIENTLY IN FIBROBLASTS 
The ∆ICP0 phenotype is most pronounced in limited passage fibroblasts (142, 144, 149, 232, 
470, 514). Therefore, replication of the ∆ICP0 virus (figure 2.2) was reassessed in HFFF2 
cells at high multiplicities of infection. Under these conditions ICP0 is dispensable for 
initiation of productive replication (149). Any additional phenotype would therefore indicate a 
role for ICP0 late in infection. The experimental rationale was based on work by Everett et al. 
(149). The authors quantified the number of virus particles (by electron microscopy), infected 
cell foci (by ICP4 immunofluorescence) and apparent titres (pfu) in wild-type and ICP0-null 
virus stocks (149). Infected cell foci represent infected cells that express immediate-early 
proteins (149). Pfu quantification reveals how many of these foci progress to productive 
infection, i.e. late gene expression and infectious progeny production (149). Infections were 
based on U2OS titres because the pfu-to-virus particle and pfu-to-infected cell foci ratios of 
wild-type and ∆ICP0 viruses are comparable in U2OS, but not HFFF2 and Vero, cells (149). 
Importantly, U2OS titres correlate with the number of infectious particles in a sample (149). 
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To begin with, confluent HFFF2 cells were infected with the wild-type HSV-1 strain 17+ or the 
∆ICP0 mutant at a multiplicity of ten according to U2OS titres. Total virus harvested at the 
indicated times was then titrated on U2OS cells. The ∆ICP0 mutant exhibited a two-log 
growth defect compared with wild-type HSV-1 at 8 hpi (figure 7.1A). By 24 hpi this deficit had 
reduced to just over one-log. The discrepancy in titres 4 hpi, at which point only inoculum is 
present, suggests multiplicities of infection for the wild-type and ∆ICP0 viruses were not quite 
equally matched. Nevertheless, even at 24 hpi the ICP0-null mutant did not equal wild-type 
levels of infectious progeny production, indicating that this mutant exhibits a real defect under 
these conditions. The same argument applies to figures 7.2A and 7.4B. 
To test whether these findings were due to an early defect, HFFF2 cells infected as before 
were fixed 6 hpi and immunofluorescence staining performed for the immediate-early 
proteins ICP4 (figure 7.1B) and ICP27 (figure 7.1C). While protein expression may be greater 
at later times of infection, Everett et al. and Cai and Schaffer validated this approach for 
measuring the number of infected cells in a monolayer (60, 149). Virtually every cell stained 
positive for ICP4 and ICP27 in wild-type virus-infected cells (figures 7.1B and C). Fewer cells 
infected with the ∆ICP0 virus expressed these proteins. Neither antibody reacted 
nonspecifically with mock treated cells. At least 400 cells were scored for each condition to 
quantify these observations. While 93% and 81% of wild-type virus-infected cells stained 
positive for ICP4 and ICP27 respectively, just 72% and 52% of ∆ICP0 mutant-infected cells 
did (figure 7.1D). These data show that the ∆ICP0 virus initiated immediate-early gene 
expression less efficiently than wild-type HSV-1 in HFFF2 cells. This likely explains the 
growth defect of the ∆ICP0 virus (figure 7.1A). Therefore this experiment gives no insight into 
the importance of ICP0 late in infection. 
7.3 ICP0 IS REQUIRED FOR OPTIMAL LATE GENE EXPRESSION IN VERO CELLS 
The experiment was repeated in Vero cells. Confluent Vero cells were infected with the wild-
type HSV-1 strain 17+ or the ∆ICP0 mutant at a multiplicity of ten based on U2OS titres. 
Total virus was collected at the indicated times and titrated on U2OS cells. Again, the ∆ICP0 
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Figure 7.1: ICP0 deletion impairs HSV-1 infectivity in fibroblasts. Confluent HFFF2 cells 
were infected with the wild-type HSV-1 strain 17+ (wt) or the ∆ICP0 mutant at a multiplicity of 
ten according to U2OS titres. (A) Total infectious progeny was collected at the times 
indicated and titrated on U2OS cells. (B) Infected fibroblasts were fixed 6 hpi in 4% 
paraformaldehyde and immunofluorescence staining performed for ICP4 (red), shown 
individually and superimposed on corresponding brightfield images. Images were captured 
using a Zeiss Axiovert S100 TV inverted fluorescence microscope at 4X magnification. (C) 
As for (B) except cells were stained for ICP27. (D) Quantification of ICP4 and ICP27 
expression in at least 400 of the cells shown in (B) and (C). 
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virus displayed a two-log replication defect compared to wild-type HSV-1 between 8 hpi and 
16 hpi, though this defect was less pronounced by 24 hpi (figure 7.2A). 
As for HFFF2 cells, Vero cells were also fixed 6 hpi and immunofluorescence staining 
performed for ICP4 (figure 7.2B) and ICP27 (figure 7.2C). Both proteins were detected in the 
majority of cells infected with either virus (figures 7.2B and C). When immunofluorescence 
staining was quantified, 93% and 92% of wild-type virus-infected cells respectively stained 
positive for ICP4 and ICP27 (figure 7.2D). This compared with 88% and 83% of cells infected 
with the ∆ICP0 mutant. Unlike in HFFF2 cells, levels of ICP4 and ICP27 staining were similar 
for both viruses (compare figures 7.1D and 7.2D), hinting at cell type-specific differences in 
the expression pattern of these proteins. Based on these immediate-early markers the ∆ICP0 
virus displayed a negligible defect in initiation of infection (figure 7.2A). 
Concurrently with the growth curve shown in figure 7.2A, infected cells were harvested in 
SDS-PAGE loading dye for western blot analysis. ICP4 and ICP27 expression was 
equivalent in Vero cells infected with wild-type HSV-1 or the ∆ICP0 mutant (figure 7.3). 
Priscilla Schaffer and coworkers also observed similar levels of ICP4 in Vero cells infected at 
a multiplicity of one with their ∆ICP0 mutant or its wild-type parent (256, 583). On the other 
hand, late gene expression was impaired in the ICP0-null virus (figure 7.3). While VP22, 
VP16, UL42 and VP13/14 were detectable from 8 hpi in cells infected with wild-type virus, 
expression of these proteins was delayed by four hours in the ∆ICP0 mutant. It is unclear 
whether this resulted from a reduced number of cells progressing to late gene expression or 
from reduced levels of these proteins per cell. ICP0 was detectable as early as 4 hpi, and 
maximum ICP0 levels were observed from 12 hpi in wild-type virus-infected cells. Equivalent 
gel loading was verified by probing blots for the cellular protein GAPDH. 
In summary, while ICP0 deletion did not affect infectivity or immediate-early gene expression 
in Vero cells (figures 7.2B, C and D and 7.3), late gene expression was delayed (figure 7.3). 
This might account for the ICP0-dependent growth defect in this cell type (figure 7.2A). 
Again, these experiments do not shed light on the importance of ICP0 late in infection. 
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7.4 IN U2OS CELLS ICP0 ENHANCES LATE STAGES OF INFECTION 
It was reasoned that U2OS cells might be more suitable for assessing ICP0’s importance late 
in infection, since ICP0-null mutants establish productive infection as efficiently as wild-type 
HSV-1 in this cell type (149, 583). U2OS cells were infected with the wild-type strain 17+ or 
the ∆ICP0 virus at a multiplicity of ten according to U2OS titres. Total virus was harvested at 
the indicated times and titrated on U2OS cells. In line with previous reports (149, 583), the 
∆ICP0 virus replicated as efficiently as wild-type virus in this cell type (figure 7.4A). However, 
when the experiment was repeated at a multiplicity of infection of one, the ∆ICP0 virus 
exhibited a modest but reproducible one-log replication deficiency (figure 7.4B). 
Next, U2OS cells infected at a multiplicity of one were fixed 6 hpi and immunofluorescence 
staining performed for ICP4 (figure 7.4C) and ICP27 (figure 7.4D). The number of cells 
expressing these proteins appeared similar for the ∆ICP0 and wild-type viruses (figures 7.4C 
and D). ICP4 and ICP27 expression was respectively detected in 73% and 79% of wild-type 
virus-infected cells, and 68% and 69% of ∆ICP0 virus-infected cells (figure 7.4E). Viral gene 
expression was also assessed by western blot in cells harvested in SDS-PAGE loading dye 
concurrently with the growth curve (multiplicity of infection of one) shown in figure 7.4B. ICP0 
was detected from 12 hpi in cells infected with wild-type HSV-1 (figure 7.5). ICP4 expression 
was delayed by four hours in cells infected with the ∆ICP0 mutant. Since ICP4 is essential for 
late gene expression (277), and there was no difference in VP22, UL42 or VP13/14 
expression between the two viruses, this is likely a quirk of this particular western blot. 
GAPDH served as a loading control. Since gene expression was unaffected by ICP0 deletion 
in U2OS cells (figures 7.4C to E and 7.5), the multiplicity-dependent growth defect of the 
∆ICP0 mutant (figures 7.4A and B) suggests ICP0 augments a late stage of virus infection. 
ICP27 was more cytoplasmic at 6 hpi in HFFF2 cells compared with U2OS and Vero cells 
(figures 7.1C, 7.2C and 7.4D). A similar trend was noted for ICP0 by others (266), and in our 
own unpublished observations (data not shown). These findings may be linked to the 
observation that infection proceeds more rapidly in HFFF2 cells than other cell types (149). 
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Figure 7.2: ICP0 deletion impairs HSV-1 replication, but not infectivity, in Vero cells. 
Confluent Vero cells were infected with the wild-type HSV-1 strain 17+ (wt) or the ∆ICP0 
mutant at a multiplicity of ten according to U2OS titres. (A) Total infectious progeny was 
collected at the times indicated and titrated on U2OS cells. (B) Infected Vero cells were fixed 
6 hpi in 4% paraformaldehyde and immunofluorescence staining performed for ICP4 (red), 
shown individually and superimposed on corresponding brightfield images. Images were 
captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope at 4X 
magnification. (C) As for (B) except cells were stained for ICP27. (D) Quantification of ICP4 
and ICP27 expression in at least 400 of the cells depicted in (B) and (C). 
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Figure 7.3: ICP0 deletion impairs late gene expression in Vero cells. Confluent Vero cells 
were infected with the wild-type HSV-1 strain 17+ (wt) or the ∆ICP0 mutant at a multiplicity of 
ten according to U2OS cell titres. Cells were harvested in SDS-PAGE loading dye at the 
times shown and samples analysed by western blot with antibodies as annotated. 
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Figure 7.4: ICP0 deletion impairs HSV-1 replication, but not infectivity, in U2OS cells. 
Confluent U2OS cells were infected with the wild-type HSV-1 strain 17+ (wt) or the ∆ICP0 
mutant at a multiplicity of ten (A) or one (B) according to U2OS titres. Total infectious 
progeny was collected at the times indicated and titrated on U2OS cells. (C) U2OS cells 
infected at a multiplicity of one with the wild-type or ∆ICP0 viruses were fixed 6 hpi in 4% 
paraformaldehyde and immunofluorescence staining performed for ICP4 (red), shown 
individually and superimposed on corresponding brightfield images. Images were captured 
using a Zeiss Axiovert S100 TV inverted fluorescence microscope at 4X magnification. (D) 
As for (C) except cells were stained for ICP27. (E) Quantification of ICP4 and ICP27 
expression in at least 400 of the cells depicted in (C) and (D). 
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Figure 7.4 
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Figure 7.5: ICP0 deletion does not affect late gene expression in U2OS cells. Confluent 
U2OS cells were infected with the wild-type HSV-1 strain 17+ (wt) or the ∆ICP0 mutant at a 
multiplicity of one according to U2OS titres. Cells were harvested in SDS-PAGE loading 
buffer at the times indicated and samples analysed by western blot using antibodies as 
annotated. # Denotes nonspecific band. 
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Figure 7.5 
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7.5 VP22-POSITIVE CYTOPLASMIC DOMAINS CONTAIN POLYUBIQUITIN CHAINS 
It was of interest to investigate how ICP0 enhances late infectious processes. At late times of 
infection ICP0 colocalises with VP22 in cytoplasmic domains thought to contribute to HSV-1 
morphogenesis (chapter 5), where it is likely incorporated into glycoprotein-tegument 
assemblies (chapter 4). It was therefore hypothesised that ICP0 might play a role in HSV-1 
maturation. Since different types of ubiquitin modification direct different cellular functions 
(table 1.1) (221, 316), it was reasoned that investigating ubiquitination within the cytoplasmic 
puncta might reveal the origin and/or function of these domains. Conjugated ubiquitin has 
already been shown to accumulate at these sites in an ICP0-dependent manner (figure 5.9). 
Making use of the FK1 antibody that specifically recognises conjugated polyubiquitin chains, 
but not conjugated monoubiquitin (table 2.2) (185), the nature of ubiquitin conjugates within 
cytoplasmic puncta was characterised further. 
Subconfluent Vero cells were infected at a multiplicity of ten with the wild-type HSV-1 strain 
17+, the GFP-22 virus (figure 2.1) or the catalytically inactive ∆RING mutant (figure 2.2). 
Cells were fixed 6 hpi and immunofluorescence staining performed using the FK1 antibody. 
ICP0-specific accumulation of polyubiquitin within cytoplasmic puncta was observed in cells 
infected with wild-type HSV-1, but not in mock treated or ∆RING virus-infected cells (figure 
7.6). Polyubiquitin colocalised with a subset of the large VP22-positive cytoplasmic domains 
in cells infected with our GFP-22 virus, verifying the identity of these domains. These 
observations are similar to results obtained with the FK2 antibody that recognises all types of 
conjugated ubiquitin (compare figures 5.9 and 7.6). Therefore at least a proportion of 
ubiquitin conjugated at cytoplasmic puncta represents polyubiquitination, although the 
presence of monoubiquitin conjugates cannot be excluded. 
7.6 EXPRESSION OF HA-TAGGED UBIQUITIN MUTANTS 
Ubiquitin mutants that only allow polymerisation at certain lysine residues are established 
tools for characterising chain linkages within ubiquitinated targets (11, 13, 20, 68, 188, 189, 
227, 233, 236, 246, 323, 402, 488, 509, 510, 574). The constructs used here were generated 
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by Lim et al. (table 2.1) (323). In the K0 mutant, all seven conserved lysine residues are 
replaced with arginine, abrogating polyubiquitination. In a further three constructs, chain 
formation is only allowed at K33, K48 or K63 respectively, as the remaining lysines have 
been substituted with arginine. The K48R mutation prohibits only K48 polyubiquitination. 
These mutants were chosen since the functions of K48 and K63 polyubiquitination are well 
characterised, and because Livingston et al. observed the K33 construct within cytoplasmic 
puncta reminiscent of our VP22-containing domains in HSV-1-infected cells (316, 330). A 
plasmid expressing HA-tagged wild-type ubiquitin served as a control. 
Subconfluent HFFF2 cells were mock treated or transiently transfected with the HA-tagged 
ubiquitin expression vectors, fixed 30 hours posttransfection and immunofluorescence 
staining performed using a HA-specific antibody (table 2.2). HFFF2 cells were chosen 
empirically from a panel of cell types as they provided a good balance between transfection 
and infection efficiencies (data not shown), and because cytoplasmic puncta are clearly 
visible in HFFF2 cells infected with the GFP-22 virus (figure 5.2). The HA-specific antibody 
did not cross-react with cellular proteins (figure 7.7A). Furthermore, expression of each HA-
tagged ubiquitin construct was confirmed (figure 7.7B). Importantly, the wild-type construct 
behaved similarly to endogenous ubiquitin (compare figure 7.7B with the mock in figures 5.9 
and 7.6), although the mutants formed cytoplasmic aggregates in some cells. 
7.7 CHARACTERISATION OF POLYUBIQUITIN CHAINS WITHIN CYTOPLASMIC VP22-
CONTAINING PUNCTA 
Cells expressing the HA-tagged ubiquitin mutants were infected 24 hours posttransfection 
with our GFP-22 virus at a multiplicity of ten. Cells were fixed 6 hpi and immunofluorescence 
staining performed for the HA tag. Several staining patterns were noted in cells that 
expressed HA-tagged ubiquitin and also exhibited GFP-tagged VP22 within cytoplasmic 
domains (figure 7.8A). In a proportion of cells, more than half of the HA-positive and GFP-
positive cytoplasmic puncta colocalised (> 50%). In some cells, less than half (< 50%) or 
none of the HA-positive and GFP-positive cytoplasmic domains exhibited colocalisation. In a 
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Figure 7.6: Conjugated polyubiquitin chains are present in a subset of cytoplasmic VP22-
containing puncta. Subconfluent Vero cells were mock treated or infected at a multiplicity of 
ten with the wild-type HSV-1 strain 17+ (wt) or the GFP-22 or ∆RING mutants. Cells were 
fixed in 4% paraformaldehyde 6 hpi and immunofluorescence staining performed using the 
FK1 antibody that only recognises conjugated polyubiquitin (185). Images were captured 
using a confocal Zeiss LSM510 inverted laser scanning microscope. Red, conjugated 
polyubiquitin (poly-ub); green, GFP; blue, DAPI. 
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Figure 7.6 
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Figure 7.7: Expression of HA-tagged ubiquitin mutants in human fibroblasts. Subconfluent 
HFFF2 cells cultured in 12-well plates were mock treated (A) or transfected with 0.1 µg per 
well of plasmids encoding HA-tagged ubiquitin mutants (B). These constructs can either 
conjugate polyubiquitin chains at any lysine residue (wild-type, wt), any lysine apart from 
residue 48 (K48R), only at positions 48 (K48), 33 (K33) or 63 (K63), or not at all (K0) (323). 
Cells were fixed in 4% paraformaldehyde 30 hours posttransfection and immunofluorescence 
staining performed using a HA-specific antibody. Images were captured using a confocal 
Zeiss LSM510 inverted laser scanning microscope. (A) Red, HA; blue, DAPI. 
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Figure 7.7 
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Figure 7.8: Colocalisation between VP22 and ubiquitin mutants within cytoplasmic puncta. 
Subconfluent HFFF2 cells cultured in 12-well plates were transfected with 0.1 µg per well of 
plasmids encoding HA-tagged wild-type ubiquitin (wt) or the K0, K48, K48R, K33 or K63 
mutants. Cells were infected 24 hours posttransfection with our GFP-22 virus and fixed after 
a further 6 hours in 4% paraformaldehyde. Immunofluorescence staining was performed 
using a HA-specific antibody. Images were captured on a confocal Zeiss LSM510 inverted 
laser scanning microscope. (A) Representative images showing HA-tagged ubiquitin-
expressing cells in which GFP-tagged VP22 was present within cytoplasmic domains. Cells 
were categorised according to whether GFP and HA-tagged ubiquitin colocalised in the 
majority (> 50%), a minority (< 50%) or none of the cytoplasmic puncta. In some cells a 
minority of GFP-positive puncta contained HA-tagged ubiquitin, while the majority of HA-
positive puncta contained GFP (GFP < 50%, ub > 50%), or vice versa (GFP > 50%, ub < 
50%). Green, GFP; red, HA; blue, DAPI. (B) For each ubiquitin construct, 100 cells were 
scored as to whether the majority (> 50%), a minority (< 50%) or none of the GFP-positive 
cytoplasmic domains contained HA-tagged ubiquitin. (C) As for (B) except HA-tagged 
ubiquitin-containing cytoplasmic puncta were scored as to whether they also contained GFP. 
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Figure 7.8 
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subset of cells, although most HA-positive cytoplasmic puncta also contained GFP-tagged 
VP22, less than half of the GFP-positive cytoplasmic domains stained positive for HA (GFP < 
50%, ub > 50%). The converse was also observed (GFP > 50%, ub < 50%). The latter two 
patterns are important because if ubiquitin were recruited to pre-existing VP22-containing 
puncta, the majority of HA-tagged ubiquitin-positive domains would be expected to colocalise 
with GFP, whereas not all VP22-containing cytoplasmic dots would contain ubiquitin. The 
converse applies if VP22 were recruited to existing ubiquitin aggregates. 
The presence of HA-tagged ubiquitin within GFP-positive (figure 7.8B) and GFP-tagged 
VP22 within HA-positive (figure 7.8C) cytoplasmic domains was assessed in 100 cells for 
each ubiquitin construct. In every case, a greater number of cells exhibited GFP within the 
majority (> 50%) of HA-positive cytoplasmic puncta (figure 7.8C) than vice versa (figure 
7.8B). As explained above, this might indicate that ubiquitin is recruited to pre-existing VP22-
containing domains. Compared with wild-type ubiquitin, the K48, K48R, K33 and K63 
mutants localised to GFP-positive cytoplasmic puncta to equally reduced levels (figure 7.8B). 
Localisation of GFP to HA-positive cytoplasmic puncta was also reduced in cells transfected 
with these mutants, although the K48R construct behaved similarly to HA-tagged wild-type 
ubiquitin (figure 7.8C). Livingston et al. also observed reduced accumulation of several types 
of ubiquitin within virus-induced chaperone-enriched (VICE) domains that form adjacent to 
the replication compartment, and inferred that mixed ubiquitin chains are conjugated at these 
sites (330). This may also apply here. The K0 mutant exhibited a greater degree of 
colocalisation with GFP-positive cytoplasmic domains than HA-tagged wild-type ubiquitin 
(figure 7.8B). This likely reflects an increased availability of free ubiquitin when ubiquitin 
polymerisation is disrupted. Although endogenous ubiquitin may have caused some 
variability in colocalisation between GFP-tagged VP22 and exogenously expressed HA-
tagged ubiquitin, the overriding trends observed here are still likely to be relevant. 
While counting the 100 cells scored for figures 7.8B and C, a record was made of any HA-
positive cells that did not exhibit GFP-tagged VP22 within punctate cytoplasmic domains. In 
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these cells GFP-tagged VP22 was undetectable, nuclear or (rarely) diffuse within the 
cytoplasm (figure 7.9A). The number of GFP-positive cells lacking VP22-containing 
cytoplasmic puncta was similar for all ubiquitin mutants (figure 7.9B, GFP +ve), suggesting 
none of the constructs inhibited localisation of VP22 to cytoplasmic puncta. However, 
compared to wild-type ubiquitin, transfection with each of the mutants increased the number 
of GFP-negative cells recorded (figure 7.9B, GFP -ve). The K0 construct had the greatest 
effect, with four-fold more GFP-negative cells observed. While endogenous ubiquitin is likely 
still present, this mutant probably disrupts ubiquitin polymerisation. The greater number of 
GFP-negative cells observed could indicate that HSV-1 infection and/or VP22 expression is 
impaired in the presence of the K0 mutant. However, since the ubiquitin mutants might 
disrupt critical cellular processes, their effect on cell viability should be evaluated. 
These data imply that ubiquitin chains are conjugated to pre-existing VP22-containing 
cytoplasmic puncta, and that polyubiquitination is required at early stages of infection. 
7.8 CHAPTER DISCUSSION 
This chapter begins to address the role of ICP0 late in infection. While a proportion of ICP0 is 
complexed with VP22 at this time, experiments described here do not specifically address 
the function of VP22-associated ICP0. Experiments would have to be repeated with a panel 
of mutants in which VP22-ICP0 complex formation is disrupted (table 4.1) to tease apart the 
respective contributions of VP22-ICP0 and VP22-glycoprotein interactions late in infection. 
Nevertheless, the data provide the first direct evidence that ICP0 contributes to late stages of 
HSV-1 replication. These observations may explain the small plaque phenotype of the ∆ICP0 
virus (figure 6.2), although ICP0 might also enhance cell-to-cell spread. 
7.8.1 THE ICP0-NULL PHENOTYPE IN DIFFERENT CELL TYPES 
In HFFF2 cells impaired initiation of immediate-early gene expression contributed to a two-
log growth defect in the ∆ICP0 virus relative to its wild-type parent (figure 7.1). In Vero cells 
the ICP0-null mutant initiated immediate-early gene expression as efficiently as wild-type 
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Figure 7.9: Effect of ubiquitin mutant expression on VP22 localisation. Subconfluent HFFF2 
cells cultured in 12-well plates were transiently transfected with 0.1 µg per well of plasmids 
encoding HA-tagged wild-type ubiquitin (wt) or the K0, K48, K48R, K33 or K63 mutants. Cells 
were infected 24 hours posttransfection with our GFP-22 virus, and fixed after a further 6 
hours in 4% paraformaldehyde. Immunofluorescence staining was performed using a HA-
specific antibody. Images were captured on a confocal Zeiss LSM510 inverted laser 
scanning microscope. (A) Representative images showing HA-tagged ubiquitin-expressing 
cells in which GFP-tagged VP22 is not detectable (top panel), predominantly nuclear (middle 
panel) or present in a diffuse cytoplasmic pattern (lower panel). (B) For each ubiquitin 
construct, the number of HA-tagged ubiquitin-positive cells in which GFP-tagged VP22 was 
not detectable (GFP –ve) or detectable but not localised to cytoplasmic puncta (GFP +ve) 
was counted until the 100 cells depicted in figures 7.8B and C had been scored. 
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virus, although a two-log replication deficiency likely resulted from delayed late gene 
expression (figures 7.2 and 7.3). Neither experiment sheds light on the importance of ICP0 
late in infection. Interestingly, ICP0 deletion resulted in a modest one-log replication defect in 
U2OS cells infected at a multiplicity of one, but not ten (figures 7.4A and B). In agreement 
with the literature (149), at a multiplicity of infection of one the ∆ICP0 virus was not deficient 
in late gene expression or the number of U2OS cells synthesising immediate-early proteins 
(figures 7.4C to E and 7.5). These data demonstrate that ICP0 augments late stages of virus 
replication under conditions in which it is dispensable for establishing productive infection. 
ICP0 is considered dispensable during high multiplicity infection in all cell types (145, 209). 
Although many reports address the cell type-specific phenotype of ICP0-null HSV-1 (60, 142, 
144, 149, 232, 256, 470, 514, 583), only one describes high multiplicity growth curves based 
on U2OS titres in cells relevant to this study (149). Everett et al. observed a negligible growth 
defect in HFFF2 cells infected at a multiplicity of five with the ∆ICP0 virus used here, and no 
defect in U2OS cells at any multiplicity of infection (149). The authors harvested virus at just 
one time point, and may have missed defects described here, while differences in tissue 
culture conditions and virus stock preparation might also have played a part (149). Other 
groups also report small plaque phenotypes in independent ICP0-null mutants, confirming 
that ICP0 is important under the high multiplicity conditions present in a plaque (470, 514). 
The rationale for experiments described in sections 7.2 to 7.4 was based on work by Everett 
et al. (149). Since the ICP0-null phenotype is more pronounced in Vero and HFFF2 than 
U2OS cells (149, 583), it may be worthwhile repeating these experiments in Vero and HFFF2 
cells using titres calculated on these respective cell lines. Using these modified titres should 
overcome the requirement for ICP0 early in infection, and the modest late defect observed in 
U2OS cells at a multiplicity of one may be more pronounced in these cell types. 
7.8.2 UBIQUITINATION AT VP22- AND ICP0-CONTAINING CYTOPLASMIC DOMAINS 
Experiments characterising ubiquitin chains in VP22-containing cytoplasmic domains did not 
reveal the origin or function of these sites. Although these sites were shown to contain 
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polyubiquitin (figure 7.6), the presence of monoubiquitin conjugates cannot be excluded. In 
line with conclusions drawn by Livingston et al. in analogous experiments (330), VP22-
positive cytoplasmic puncta may contain mixed-chain polymers, as accumulation of all tested 
types of ubiquitin in these domains was reduced (figure 7.8). However, mixed polyubiquitin 
chains are thought to occur rarely in vivo (433). It is possible that other types of chain not 
tested here accumulate in these domains. Mutant ubiquitin tended to aggregate in the 
cytoplasm (figure 7.7B), suggesting proteins modified with mutant ubiquitin are not correctly 
processed. Furthermore, in a large proportion of cells expressing the ubiquitin constructs, 
VP22 exhibited an unusual nuclear distribution (figure 7.9) not normally observed (134). 
Recently developed antibodies specific for K11-, K48- or K63-linked polyubiquitin could be 
used to characterise endogenous ubiquitin within cytoplasmic puncta (349, 398, 553). 
The atypical aggregates formed by mutant ubiquitin (figure 7.7B) made the two types of 
VP22-containing domains difficult to distinguish. Subtle differences in accumulation of mutant 
ubiquitin at large cytoplasmic puncta (of interest here) may become more pronounced after 
treating cells with brefeldin A. This drug blocks protein transit from the ER to Golgi, and 
therefore inhibits secondary envelopment because viral glycoproteins are no longer recruited 
to internal membranes involved in herpesvirus maturation. As a consequence, brefeldin A 
enhances the appearance of the large static tegument accumulations, and induces the 
disappearance of the smaller mobile puncta that likely represent mature intracellular virus 
particles (data not shown). Alternatively, the experiment could be repeated using the wild-
type HSV-1 strain F. Our preliminary observations indicate that cytoplasmic accumulation of 
ICP0 and its localisation to cytoplasmic puncta is more clear-cut in strain F than in our VP22 
mutants derived from strain 17+ (data not shown). 
Nevertheless, the data imply that ICP0 conjugates ubiquitin to pre-existing VP22-containing 
cytoplasmic puncta. This could be confirmed by tracking ubiquitin accumulation in live cells 
using functionally verified GFP-tagged ubiquitin constructs (93, 448). 
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The K0 ubiquitin mutant, which likely disrupts polyubiquitination, impaired HSV-1 infection 
and/or VP22 expression (figure 7.9B). This may be due to the established importance of 
polyubiquitin in signalling ICP0-mediated ND10 disruption (145, 209), or the recently reported 
role of the ubiquitin-proteasome system in facilitating capsid transport to the nucleus (103). 
7.8.3 FUNCTIONS FOR CYTOPLASMIC ICP0 LATE IN INFECTION 
Any of ICP0’s reported cytoplasmic activities could be important for late stages of infection. 
The hypothesised modulation of translation is unlikely to play a part since late genes were 
expressed normally in U2OS cells infected at a multiplicity of one with the ∆ICP0 virus, which 
exhibited a growth defect under these conditions (figures 7.4B and 7.5). Others have noted 
that cytoplasmic, but not nuclear, ICP0 inhibits interferon production (419). Inhibition of 
cytokine induction is unlikely to be relevant to this study, since Mossman et al. showed that 
∆ICP0 mutants are as sensitive to interferon in U2OS cells as wild-type HSV-1 (379). 
It remains feasible that ICP0 is required late in infection for virus maturation. Electron 
microscopy studies into the effects of ICP0 deletion on HSV-1 morphogenesis were initiated, 
but data were not available during the preparation of this manuscript. The localisation of 
virion components in U2OS cells infected with the ∆ICP0 virus could also be assessed. 
Growth curves should be repeated with the ∆RING virus to confirm the requirement for 
ICP0’s E3 ubiquitin ligase activity late in infection. The putative roles of ICP0-dependent 
ubiquitination in herpesvirus morphogenesis, and precedents from other viral systems, are 
considered in detail in section 8.3. 
Given the small plaque phenotype of the ∆ICP0 virus, it will be important to differentiate 
between requirements for ICP0 in virus maturation, release and intercellular spread. 
Nevertheless, ICP0 plays at most an accessory role in virus assembly, since even the 
modest ICP0-dependent growth defect in U2OS cells disappeared at higher multiplicities 
(figures 7.4A and B). 
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7.8.4 CONCLUDING REMARKS 
This chapter provides the first direct evidence for a role for ICP0 late in infection. It will be 
important to build on these preliminary observations and clarify the importance of VP22-
associated ICP0 to HSV-1 replication. Furthermore, expanding on the initial characterisation 
of ubiquitin chains conjugated at VP22-containing cytoplasmic domains might help elucidate 
the nature of these sites. These observations open exciting future research directions. 
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8.1 THE INTERPLAY BETWEEN VP22 AND ICP0 THROUGHOUT INFECTION 
This thesis tested the hypothesis that VP22 mediates virion incorporation of ICP0 via a direct 
interaction, and that VP22 also modulates ICP0 function. While VP22 did prove to be the 
major determinant for ICP0 assembly, gE and gM also contribute to VP22-ICP0 complex 
formation, and VP22 and ICP0 packaging. VP22 was shown to modulate ICP0 localisation, 
but had no discernable impact on the ability of ICP0 to conjugate ubiquitin and disrupt ND10. 
Figure 8.1 summarises the major findings in the context of the existing literature and relates 
results to different stages of the HSV-1 lytic replication cycle. 
The localisation of ICP0 to ND10 and subsequent ND10 dispersal early in infection has been 
characterised by Roger Everett and coworkers (145, 209). Our NLS-22 virus, which 
expresses GFP-tagged VP22 targeted to the nucleus with the SV40 NLS (figure 2.1), exhibits 
increased virion ICP0 levels and enhanced replication kinetics (chapter 6). Furthermore, we 
previously described mutants that fail to assemble ICP0 and replicate poorly in tissue culture 
(129, 443, 518). ICP0 is tightly capsid-associated (chapter 4), and might thus enter the 
nucleus following viral entry. This circumstantial evidence implies that virion ICP0 augments 
HSV-1 replication, possibly by kick-starting ND10 dispersal prior to viral gene expression 
(figure 8.1A). 
Our group previously reported that a subpopulation of VP22 is juxtaposed with ICP0 in the 
nucleus (235). As discussed in chapter 5, the unidentified VP22-containing nuclear domains 
may be linked to the novel observation that VP22 suppresses gene expression (figure 8.1B). 
Since a subpopulation of virion VP22 is tightly capsid-associated (chapter 4), virion VP22 
may also enter the nucleus to modulate early stages of infection. VP22 does not modulate 
ICP0’s nuclear activities, although ICP0-mediated HDAC1/2-CoREST-REST complex 
disruption was not assessed (chapter 5). Nevertheless, increasing the nuclear VP22 
subpopulation enhances ICP0 virion incorporation without affecting VP22 assembly, ICP0 
localisation or VP22-ICP0 association (chapter 6) (figure 8.1B). 
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Late in infection VP22 and ICP0 colocalise in punctate cytoplasmic domains (129). 
Cytoplasmic accumulation of ICP0 is dependent upon ICP27, but not VP22 (129, 486, 592), 
and is essential, but not sufficient, for ICP0 virion incorporation (chapter 5). Nevertheless, 
VP22 modulates ICP0 localisation in infected cells (chapter 5). VP22 and ICP0 assembly is 
mediated by a complex incorporating VP22, gE, gM and ICP0 (chapters 3 and 4) (figure 
8.1C). The conserved region of VP22, required for VP22-glycoprotein interaction, and N-
terminal sequences that enhance VP22-glycoprotein binding are important for VP22-ICP0 
association. ICP0’s RING finger is essential for VP22-ICP0 complex formation, while C-
terminal sequences also contribute to ICP0 assembly. The glycoproteins are redundant for 
VP22, but not ICP0, packaging. These data give important insights into the formation of 
glycoprotein-tegument assemblies involved in secondary envelopment. Interestingly, ICP0 
was shown for the first time to enhance late stages of HSV-1 replication (chapter 7). 
8.2 SIGNIFICANCE OF THE VP22-gE-gM-ICP0 COMPLEX TO HERPESVIRUS 
REPLICATION 
The conservation of the glycoprotein-binding domain among VP22 homologues (381) implies 
that the VP22-gE-gM complex performs an important function during alphaherpesvirus 
infection. The VP22-binding domain within the gE tail is known to contribute to secondary 
envelopment during HSV-1 maturation, and Chi et al. proposed that VP22 acts as a link 
between the viral envelope and capsid (75, 172). Furthermore, although nonessential for 
HSV-1 replication and assembly (54, 304), gE and gM contribute redundantly to PRV 
secondary envelopment (49, 50, 184). VP22 on the other hand is dispensable for secondary 
envelopment in HSV-1 and PRV (124, 129, 184), indicating that the VP22-glycoprotein 
complex, while important for VP22 assembly, is not essential for herpesvirus maturation. 
Farnsworth et al. note that, in addition to VP22, gE binds the tegument protein UL11 (172), 
which is known to contribute to secondary envelopment in PRV (24, 284). There are also 
conflicting reports regarding redundancy between the gE-gI complex and gD in HSV-1 
assembly (170, 304). Therefore, redundancy in glycoprotein-tegument interactions may 
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Figure 8.1: Summary of findings presented in this thesis. (A) Following uncoating, ICP0 
likely remains tightly capsid-associated and may thus enter the nucleus prior to immediate-
early gene expression. Circumstantial evidence suggests virion ICP0 may augment early 
stages of HSV-1 replication, possibly by disrupting ND10 along with newly expressed ICP0. 
(B) VP22, once expressed, localises to unidentified nuclear domains juxtaposed with ICP0-
containing ND10 (235). The ability of VP22 to nonspecifically suppress gene expression (1) 
may be linked to these sites. Nuclear VP22 also performs unknown functions that later 
preferentially select ICP0-bound VP22 for virion incorporation (2), but does not modulate 
ICP0’s biological activities. (C) In the cytoplasm, VP22 and ICP0 are recruited into an 
assembly complex by gE and gM, presumably at membranous sites of secondary 
envelopment. ? Indicates speculative processes or unidentified nuclear domains. 
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account for some of the difficulties in assigning definitive functions for specific proteins in 
virus maturation (172). Since VP22 is only conserved among the alphaherpesviruses (381), it 
is conceivable that the VP22-gE-gM complex plays a more pronounced role in virus 
maturation in neurones, the site of latency for the alpha-, but not beta- or 
gammaherpesviruses (277). 
It remains to be seen whether the ICP0 homologues of other alphaherpesviruses are 
recruited into the complex. While Fossum et al. confirmed binding between HSV-1 VP22 and 
ICP0 in a yeast-two-hybrid screen, no interaction between the VZV homologues was 
observed (178). On the other hand, PRV ICP0 is incorporated into virions (415), and the 
RING finger required for VP22-ICP0 association (chapter 4) and ICP0 function in HSV-1 is 
conserved in all ICP0 homologues (139, 142, 147, 148, 155, 421, 422). It would therefore be 
pertinent to assess VP22-ICP0 complex formation and ICP0 assembly in other 
alphaherpesviruses. 
Apart from a putative role in secondary envelopment, the VP22-gE-gM-ICP0 complex may 
contribute to other aspects of HSV-1 replication. Interestingly, gE binds and is 
phosphorylated by the conserved viral serine/threonine kinase UL13 (70, 399, 500), which 
also targets VP22 and ICP0 and is itself tegument-associated (16, 87, 411, 418). It is unlikely 
that gE facilitates correct VP22 phosphorylation by bringing VP22 in close proximity with 
UL13, because VP22 packaged by the glycoprotein complex is nonphosphorylated (136). 
However, Morrison et al. demonstrated that dissociation of tegument VP22 during viral entry 
is specifically impaired in the absence of functional UL13 (377). Therefore, if UL13 is present, 
the VP22-gE-gM-ICP0 complex may play some role in tegument disassembly during viral 
entry. Furthermore, cytoplasmic accumulation of ICP0 depends upon late gene expression 
and may be linked to ICP0 phosphorylation (5, 335). It is feasible that phosphorylation-
dependent cytoplasmic accumulation of ICP0 and/or VP22-ICP0 association may be 
facilitated by gE bringing ICP0 into close proximity with UL13 within the VP22-gE-gM-ICP0 
complex. It would be interesting to determine whether UL13 is included in the complex, 
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whether UL13 virion incorporation is gE-dependent, and whether UL13 deletion affects VP22-
gE-gM-ICP0 complex formation and VP22 and/or ICP0 assembly. 
The role of the gE-gI complex in direct cell-to-cell spread of HSV-1, PRV, MDV and VZV is 
well characterised (26, 82, 96, 112-114, 252, 291, 384, 480, 535), and VP22 has also been 
implicated in efficient spread of HSV-1, BHV-1 and MDV (119, 124, 261). Tirabassi et al. 
reported that the gE population mediating intercellular PRV spread is not virion-associated 
(535). Furthermore, the VP22 homologues of HSV-1, BHV-1 and MDV are known to traffic 
between cells in the absence of other viral proteins (8, 9, 52, 73, 118, 133, 310, 589). It is 
therefore plausible that, in addition to facilitating VP22 and ICP0 assembly, the VP22-gE-gM-
ICP0 complex may perform a virion-independent function that contributes to efficient in vivo 
herpesvirus spread. One interesting scenario involves ICP0 spreading between cells in a 
complex with VP22. Viral entry is dependent upon gH, and gH-null mutants cultured in 
complementing cells only enter a single round of replication (177). By performing low 
multiplicity infections with one such mutant, Gill Elliott previously demonstrated spread of 
VP22 to adjacent cells (133), and it would be highly interesting to repeat this experiment to 
assess cell-to-cell spread of ICP0. 
8.3 PUTATIVE FUNCTIONS FOR ICP0 IN HERPESVIRUS ASSEMBLY 
An important finding of this work is that ICP0 contributes to late stages of HSV-1 infection, 
when ICP0 and VP22 accumulate in punctate cytoplasmic domains (chapters 5 and 7). 
Although localisation to cytoplasmic puncta is not sufficient for ICP0 virion incorporation, 
these sites likely contribute to tegument assembly (chapter 5). ICP0 catalyses the formation 
of ubiquitin conjugates within these domains (144 and chapters 5 and 7). Considering the 
various functions of ubiquitination (summarised in table 1.1) provides several, not necessarily 
mutually exclusive, putative explanations for recruitment of ICP0 to these sites. 
Plasma membrane-associated herpesvirus glycoproteins are internalised via endocytosis for 
recruitment to assembly sites (169, 359), which might be mediated by monoubiquitination or 
K63-linked polyubiquitination. Trafficking of other viral proteins to these sites might also be 
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facilitated by ubiquitination, which mediates cargo sorting within the endocytic pathway and 
can redirect TGN proteins from the secretory to the late endocytic pathway (68, 188, 222, 
236, 383, 435, 453, 504). Interestingly, ubiquitination reportedly targets the matrix protein of 
the paramyxovirus Nipah virus to the plasma membrane for viral budding (556). It has also 
been suggested that K63-linked polyubiquitination sorts gB to multivesicular bodies for HSV-
1 secondary envelopment (62). It might therefore be interesting to reassess recruitment of 
viral proteins to cytoplasmic domains in the absence of ICP0. 
Several viruses, including retroviruses and hepatitis B virus, subvert cellular endosomal 
sorting pathways for virus assembly (300, 348). Retrovirus envelopment is analogous to 
vesicle budding into multivesicular bodies, requiring ubiquitination of viral Gag proteins and 
the cellular endosomal sorting complex required for transport (ESCRT) machinery (348). If 
VP22-containing cytoplasmic puncta are sites of tegument assembly, ICP0-dependent 
ubiquitination may similarly facilitate HSV-1 envelopment. This hypothesis is appealing since 
unpublished data from our group indicates that HSV-1 secondary envelopment occurs at 
endocytic tubules (data not shown), exhibiting a budding topology similar to retrovirus 
maturation at the plasma membrane. 
ICP0 might also regulate the stability and/or activity of proteins involved in herpesvirus 
assembly by catalysing their conjugation with K6-, K29- or K33-linked ubiquitin chains. In a 
similar manner, monoubiquitination of the influenza virus nucleoprotein alters its interaction 
with RNA and enhances viral genome replication (319). 
K6-, K27- and K63-linked ubiquitin polymers form scaffolds for the assembly of 
multicomponent protein complexes involved in IKK activation and recruitment of 
transcriptional coregulators around androgen receptor (4, 383, 562, 574). Furthermore, in 
line with a report by Loret et al. (336), we detected ubiquitin within extracellular virions (data 
not shown). An intriguing proposition is that polyubiquitin chains might form a scaffold for the 
formation of multicomponent tegument assemblies during HSV-1 maturation. This hypothesis 
could be tested by assessing virion production in the presence of the HA-tagged K0 ubiquitin 
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mutant (chapter 7), which would be expected to disrupt ubiquitin chain elongation. However, 
ubiquitin appears to be recruited to pre-existing VP22-containing cytoplasmic sites rather 
than vice versa (chapter 7), although newly synthesised ubiquitin scaffolds might fall below 
the detection limit of our immunofluorescence assay. 
It remains plausible that the cytoplasmic puncta represent viral protein aggregates targeted 
for proteasomal degradation via K48- or K11-linked polyubiquitin chains, or for lysosomal 
degradation via monoubiquitination and/or K27- or K29-linked ubiquitin polymers. In fact, all 
types of ubiquitin chain can reportedly signal proteasomal degradation (21, 230, 316, 472, 
575), which might explain why no single linkage preferentially accumulated within VP22-
positive cytoplasmic puncta (chapter 7). Therefore, ICP0 might counteract excessive viral 
protein production to prevent stimulation of immune responses and/or cellular stress 
pathways such as the unfolded protein response. Regulated ubiquitin-dependent degradation 
of the human immunodeficiency virus type 1 (HIV-1) protein Vpu reduces virus release to 
balance HIV-1 dissemination and preservation of an infected-cell reservoir (138), setting a 
precedent for virus-induced degradation of viral gene products. It might therefore be 
worthwhile assessing the impact ICP0 has on the stability of VP22 and other HSV-1 proteins. 
While the role of ICP0-dependent ubiquitination at cytoplasmic domains warrants further 
investigation, ICP0 is not required for HSV-1 virion formation and is not conserved in the 
beta- or gammaherpesviruses (277, 514). Therefore, either other herpesvirus gene products 
compensate in the absence of ICP0, or ICP0 merely performs an accessory role in 
herpesvirus maturation. 
8.4 IMMEDIATE-EARLY PROTEINS AS TEGUMENT COMPONENTS 
As well as confirming the specificity of ICP0 assembly, this thesis identified ICP27 as a novel 
component of HSV-1 particles (chapter 4), contributing to an emerging theme of immediate-
early protein virion incorporation. ICP4 is also an established tegument protein (336, 581). 
While ICP22 was not detected in HSV-1 virions, the VZV and EHV-1 homologues are 
assembled (231, 273, 336, 416). Since, unlike HSV-1 ICP0, VZV ICP0 is reportedly not a 
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virion component, these discrepancies may reflect variability in alphaherpesvirus immediate-
early protein assembly, although experimental differences may also play a part (273, 416). 
To date ICP47 and US1.5 have not been detected in purified HSV-1 virions (336). 
Assembly of ICP4 and ICP0 is dependent upon VP22 (129 and chapter 4). However, ICP4 is 
still packaged in the absence of ICP0 (104). While ICP27 is required for ICP0 virion 
incorporation (486), ICP27 assembly is independent of VP22 and ICP0 (chapter 4). 
Furthermore, ICP22 is not required for ICP0 virion incorporation (416). Therefore the 
assembly pathways of each immediate-early protein are likely to be distinct. 
The roles of virion-associated immediate-early proteins are unknown, though data presented 
here suggest virion ICP0 may augment HSV-1 replication (chapter 6). Assembly of these key 
proteins is unlikely to be coincidental and it would be interesting to identify additional mutants 
that fail to package various immediate-early proteins in order to assess their replication. 
8.5 FUTURE DIRECTIONS 
An obvious next step is to further define the role virion ICP0 plays early in infection. While 
packaging ICP0 from complementing cell lines into ICP0-null viruses has proven difficult (103 
and personal communication, Chris Boutell), our mutant viruses that fail to assemble ICP0 
represent unique tools that could be used to the same effect. Infecting cells with UV-
inactivated virus or treating infected cells with cycloheximide to block viral protein synthesis 
would also reveal the impact virion ICP0 has on early events. It would be prudent to reassess 
the replication of our NLS-22 mutant in PML-/- cell lines to explore the links between 
increased ICP0 assembly, ND10 disruption and enhanced virus replication. 
It may also be worthwhile further investigating the importance of the VP22-gE-gM-ICP0 
complex to HSV-1 replication. For instance, whether UL13 is recruited into the complex to 
modulate the behaviour of complex components during virion assembly or viral entry should 
be addressed. Whether gE and/or gM modulate ICP0 function could also be explored using 
the ND10 disruption and ubiquitin conjugation assays already employed within this thesis. 
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While obtaining a crystal structure of the complex would advance our understanding of how 
this glycoprotein-tegument structure assembles, this would not be a trivial task, especially 
given that the complex was not easily reconstituted in the absence of other viral proteins. 
Given the relationship between VP22 and ICP0, it would be pertinent to assess the impact 
VP22 has on additional ICP0 activities, including disruption of immune signalling and the 
HDAC1/2-CoREST-REST complex. The effect ICP0 has on the localisation, stability and 
known activities of VP22 should also be tested, for instance by expressing GFP-tagged full-
length VP22 in the background of an ICP0-null virus. Eventually it might be interesting to 
explore the VP22-ICP0 relationship, and ICP0 virion incorporation, in other 
alphaherpesviruses. Furthermore, the role VP22 plays in ICP4 packaging should be 
readdressed, and the mechanisms of ICP27 assembly could also be investigated. 
Whether ICP0 and VP22 shuttle dynamically between the nucleus and cytoplasm, or whether 
newly expressed populations of these proteins are simply retained in the cytoplasm at late 
stages of infection, should also be investigated. This could be easily established by 
fluorescence loss in photobleaching (FLIP) studies using existing double-labelled fluorescent 
viruses, and might ease interpretation of the impact VP22 mutation has on ICP0 localisation. 
The mechanism by which ICP0 augments HSV-1 replication at late times may become clear 
once the nature of the cytoplasmic puncta incorporating VP22 and ICP0 is elucidated. 
Existing double-labelled fluorescent viruses and GFP-tagged ubiquitin constructs allow the 
dynamic association of VP22, ICP0 and ubiquitin at these sites to be explored in live cells. 
Recently developed antibodies could also be used to characterise endogenous K11-, K48- 
and K63-linked ubiquitin chains within these domains (349, 398, 553). The origin of these 
sites might also be revealed by identifying resident cellular proteins by immunofluorescence 
microscopy. Since others have suggested that similar cytoplasmic puncta represent sites of 
secondary envelopment (99, 519), it would be interesting to assess ICP0-null HSV-1 
morphogenesis by electron microscopy. It will also be important to distinguish between roles 
for ICP0 in enhancing virus maturation, release and/or cell-to-cell spread. 
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Another question arising from this work regards the mechanism by which VP22 suppresses 
gene expression. VP22 has been shown to bind splice factors and nucleic acids (117, 315, 
339, 406, 484). As discussed in chapter 5, it would therefore be worthwhile assessing 
whether VP22 localises to interchromatin granule clusters or cajal bodies, which are thought 
to function in mRNA processing (88). In addition, whether VP22 acts at the level of 
transcription initiation, mRNA processing and/or stability or translation should be 
investigated. To begin with, it would be pertinent to replicate work by Yu et al. that indicates 
VP22 reduces reporter transcript levels in transfected cells. It would also be interesting to 
further explore the functional relationship between VP22 and the viral endoribonuclease vhs. 
8.6 CONCLUDING REMARKS 
This thesis characterised the mechanisms of VP22 and ICP0 virion incorporation, and has 
provided valuable insights into the hierarchical interactions contributing to the formation of 
higher-order glycoprotein-tegument assemblies involved in herpesvirus morphogenesis. 
Novel functions for ICP0 late in infection and VP22 in regulating gene expression were 
identified. Importantly, this work indicates that virion ICP0 may play a role in augmenting 
early stages of HSV-1 replication. 
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APPENDIX 1: Reagent Details 
Unless stated the solvent for all solutions was reverse-osmosis water. 
A1.1 TISSUE CULTURE 
All reagents from Invitrogen; details as stated at www.invitrogen.com (accessed 25/7/2011). 
A1.1.1 DMEM 
Glycine (0.4 mM), L-arginine hydrochloride (0.298 mM), L-cystine 2HCl (0.201 mM), L-
glutamine (4 mM), L-histidine hydrochloride-H2O (0.2 mM), L-isoleucine (0.802 mM), L-
leucine (0.802 mM), L-lysine hydrochloride (0.798 mM), L-methionine (0.201 mM), L-
phenylalanine (0.4 mM), L-serine (0.4 mM), L-threonine (0.798 mM), L-tryptophan (0.0784 
mM), L-tyrosine disodium salt dihydrate (0.398 mM), L-valine (0.803 mM), choline chloride 
(0.0286 mM), D-calcium pantothenate (0.00839 mM), folic acid (0.00907 mM), niacinamide 
(0.0328 mM), pyridoxine hydrochloride (0.0194 mM), riboflavin (0.00106 mM), thiamine 
hydrochloride (0.0119 mM), i-inositol (0.04 mM), anhydrous calcium chloride (CaCl2) (1.8 
mM), ferric nitrate (Fe(NO3)3•9H2O) (0.000248 mM), anhydrous magnesium sulphate 
(MgSO4) (0.814 mM), potassium chloride (KCl) (5.33 mM), sodium bicarbonate (NaHCO3) 
(44.05 mM), sodium chloride (NaCl) (81.9 mM), sodium phosphate monobasic 
(NaH2PO4•H2O) (0.906 mM), D-glucose (dextrose) (25 mM), sodium pyruvate (1 mM), phenol 
red (0.0399 mM). 
A1.1.2 TRYPSIN-EDTA IN HANKS’ BALANCED SALT SOLUTION WITHOUT CaCl2, 
MgCl2•6H2O and MgSO4•7H2O 
Potassium chloride (KCl) (5.33 mM), potassium phosphate monobasic (KH2PO4) (0.441 mM), 
sodium bicarbonate (NaHCO3) (4.17 mM), sodium chloride (NaCl) (137.93 mM), sodium 
phosphate dibasic (Na2HPO4•7H2O) (0.336 mM), D-glucose (dextrose) (5.56 mM), phenol 
red (0.0251 mM), sodium EDTA (Na2•EDTA) (0.481 mM), trypsin (0.021 mM). 
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A1.2 VIRUS TECHNIQUES 
A1.2.1 2X FORMAL SALINE SOLUTION 
Formaldehyde (8% v/v) (Thermo Fisher Scientific Inc.), NaCl (0.291 M) (Sigma-Aldrich). 
A1.2.2 0.1% CRYSTAL VIOLET SOLUTION 
Crystal violet (2.45 mM) (Sigma-Aldrich), ethanol (15% v/v) (VWR). 
A1.3 BACTERIA TECHNIQUES 
All reagents from Sigma-Aldrich; details as stated at www.sigmaaldrich.com (accessed 
26/7/2011). 
A1.3.1 LB AGAR 
Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L), agar (15 g/L). 
A1.3.2 LB MEDIA 
Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L). 
A1.4 QIAGEN PLASMID MAXI KIT REAGENTS (QIAGEN) 
Buffer compositions as outlined in manufacturer protocol (08/2003). 
A1.4.1 BUFFER P1 (pH 8.0) (RESUSPENSION BUFFER) 
Tris-HCl (50 mM), EDTA (10 mM), RNase A (100 µg/ml). 
A1.4.2 BUFFER P2 (LYSIS BUFFER) 
NaOH (200 mM), sodium dodecyl sulphate (SDS) (1% w/v). 
A1.4.3 BUFFER P3 (pH 5.5) (NEUTRALISATION BUFFER) 
Potassium acetate (3.0 M). 
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A1.4.4 BUFFER QBT (pH 7.0) (EQUILIBRATION BUFFER) 
NaCl (750 mM), MOPS (50 mM), isopropanol (15% v/v), Triton® X-100 (0.15% v/v). 
A1.4.5 BUFFER QC (pH 7.0) (WASH BUFFER) 
NaCl (1 M), MOPS (50 mM), isopropanol (15% v/v). 
A1.4.6 BUFFER QF (pH 8.5) (ELUTION BUFFER) 
NaCl (1.25 M), Tris-HCl (50 mM), isopropanol (15% v/v). 
A1.4.7 BUFFER TE (pH 8.0) 
Tris-HCl (10 mM), EDTA (1 mM). 
A1.5 PROTEIN TECHNIQUES 
A1.5.1 2X SDS-PAGE LOADING DYE 
Tris-HCl (100 mM) (pH 7.0), SDS (4% w/v), beta-mercaptoethanol (10% v/v), glycerol (20% 
w/v), bromophenol blue (0.2% w/v) (all reagents Sigma-Aldrich). 
A1.5.2 10% POLYACRYLAMIDE RESOLVING GEL 
Acrylamide/bis-acrylamide (37.5:1) (10% w/v) (Bio-Rad Laboratories), tris-HCl (0.375 M) (pH 
8.8) (Bio-Rad Laboratories), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.05% 
v/v) (Sigma-Aldrich), ammonium persulphate (0.1% w/v) (Sigma-Aldrich). 
A1.5.3 12% POLYACRYLAMIDE RESOLVING GEL 
Acrylamide/bis-acrylamide (37.5:1) (12% w/v), tris-HCl (0.375 M) (pH 8.8), SDS (0.1% w/v), 
N,N,N’,N’-tetramethylethylenediamine (0.05% v/v), ammonium persulphate (0.1% w/v). 
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A1.5.4 SDS-PAGE STACKING GEL 
Acrylamide/bis-acrylamide (37.5:1) (4% w/v), tris-HCl (0.13 M) (pH 6.8) (Bio-Rad 
Laboratories), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.1% v/v), ammonium 
persulphate (0.1% w/v). 
A1.5.5 SDS-PAGE RUNNING BUFFER 
Glycine (192 mM), tris base (25 mM), SDS (1% w/v) (all reagents Sigma-Aldrich). 
A1.5.6 SDS-PAGE GEL TRANSFER BUFFER 
Glycine (192 mM), tris base (25 mM), methanol (20% v/v) (VWR). 
A1.5.7 RIPA BUFFER (pH 7.5) 
Tris-HCl (50 mM), NaCl (150 mM), SDS (0.1% w/v), sodium deoxycholate (1% w/v) (Sigma-
Aldrich), Triton® X-100 (0.2% v/v) (Sigma-Aldrich), 1X complete ULTRA Mini protease 
inhibitors (Roche Applied Science, Penzberg, Germany). 
A1.6 MICROSCOPY 
A1.6.1 MOWIOL® 4-88 MOUNTING MEDIUM WITH DAPI 
Mowiol® 4-88 (10% w/v) (Sigma-Aldrich), tris-HCl (0.1 M) (pH 8.5), glycerol (25% w/v), DAPI 
dihydrochloride (0.1 µg/ml) (Sigma-Aldrich). 
A1.7 ASSAY REAGENTS 
A1.7.1 RENILLA LUCIFERASE SUBSTRATE 
Coelenterazine (LUX Innovate, Edinburgh, UK) stock was dissolved at 1 mg/ml concentration 
in 100% ethanol and stored at -20˚C. Coelenterazine stock was diluted to 2 µg/ml in room 
temperature PBS before use. 
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A1.7.2 FIREFLY LUCIFERASE SUBSTRATE 
Tricine (20 mM), MgSO4•7H2O (2.67 mM), EDTA (0.1 mM) (pH 8.0), dithiothreitol (33.3 mM), 
adenosine triphosphate (ATP) (530 µM), acetyl coenzyme A (270 µM) (LUX Innovate), firefly 
luciferin (sodium salt) (0.41 mM) (Gold Biotechnology, St. Louis, MO USA), NaOH (5 mM), 
magnesium carbonate hydroxide ((MgCO3)4Mg(OH)2•5H2O) (265 mM) (pH 5.5 – 6.0). Unless 
specified all reagents from Sigma-Aldrich. 
A1.8 GENERAL LABORATORY SOLUTIONS 
A1.8.1 PBS (pH 7.2) (VWR) 
NaCl (8.77 g/L), Na2HPO4•12H2O (19.2 g/L), NaH2PO4•2H2O (6.55 g/L). As detailed at 
www.vwr.com (accessed 27/07/2011). 
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APPENDIX 2: Statistical Analysis 
A2.1 DESCRIPTION OF STATISTICAL METHODS USED 
As detailed in materials and methods, all data were analysed by two-tailed Student’s t test in 
Microsoft® Excel® 2008 for Mac with Welch’s correction applied to account for unequal 
variances among the data (heteroscedasticity). Samples were considered to be independent. 
These options were input as pictured in the screen shot below. 
 
In this way each test condition was compared to the relevant control. Results of t test 
analyses are summarised below. Raw data used in these analyses are also shown. 
Whenever multiple means were compared to one-another or a common control (sections 
A2.2.1, A2.2.2, A2.2.3, A2.2.5 and A2.3.1), the sequentially rejective Bonferroni adjustment 
was subsequently applied. This adjustment protects the significance level in multiple testing, 
since the probability of type I errors (false rejection of the null hypothesis) increases for 
multiple comparisons (195). Therefore this correction prevents differences from appearing 
significant when they are not. 
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The sequentially rejective Bonferroni adjustment is performed as outlined below (refer to 
section A2.2.1 for a step-by-step example) (195): 
(1) k number of hypotheses are ranked according to their P value. 
(2) The first null hypothesis (with the lowest P value) is rejected (i.e. the difference in 
means is considered significant) if P < α/k (where α is the level of significance, e.g. 
0.05 for a 95% confidence level). If P < α/k does not hold true, all other hypotheses 
are rejected without further testing. 
(3) This process is repeated sequentially through the ranked hypotheses, reducing the k 
value by one each time to account for previously confirmed hypotheses, until P < α/k 
no longer holds true. At this point all further hypotheses are rejected. 
The sequentially rejective Bonferroni correction was first applied for α = 0.01 (99% 
confidence) and then repeated for α = 0.05 (95% confidence). 
A2.2 ANALYSIS RELATING TO CHAPTER 5 
A2.2.1 ANALYSIS FOR FIGURE 5.5A 
This analysis also acts as an example of the application of the sequentially rejective 
Bonferroni correction. Results of initial t test analysis are shown below. Data were compared 
to the control situation in the absence of VP22, in the presence or absence of ICP0 as 
appropriate. RLU, relative light units; P(T<=t) two-tail, P value returned by t test analysis. 
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In both cases (‘+ ICP0’ and ‘- ICP0’) the hypotheses are already ranked according to their P 
values. To calculate the Bonferroni adjustment (below), k = 5 (five null hypotheses were 
tested, i.e. five sample means were compared to the control mean). Sequential α/k 
calculations (starting with the lowest P value, with k reduced by one each time) are detailed 
to the left of the corresponding result for 99% confidence (0.01 cut-off) and 95% confidence 
(0.05 cut-off). Grey shading highlights data for which P < α/k holds true, signifying that the 
sample mean is significantly different from the control mean at the given confidence limit. 
 
A2.2.2 ANALYSIS FOR FIGURE 5.5B 
Data were compared to the control situation in the absence of VP22 or β-galactosidase as 
appropriate. Note that β-galactosidase data has been ranked according to the calculated P 
value. Significance at the given confidence level (0.01 or 0.05) following calculation of the 
sequentially rejective Bonferroni correction is highlighted in grey. RLU, relative light units; 
P(T<=t) two-tail, P value returned by t test analysis. 
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A2.2.3 ANALYSIS FOR FIGURE 5.5E 
Data were compared to the control situation in the absence of plasmids expressing ICP0 and 
VP22. Note that data are ranked according to P value. All data are nonsignificant at the given 
confidence level (0.01 or 0.05) following calculation of the sequentially rejective Bonferroni 
correction. P(T<=t) two-tail, P value returned by t test analysis. 
 
A2.2.4 ANALYSIS FOR FIGURE 5.6C 
Data were compared to the control situation in the absence of VP22 for each promoter. The 
sequentially rejective Bonferroni correction was not applied as only one null hypothesis was 
tested for each promoter. RLU, relative light units; P(T<=t) two-tail, P value returned by t test 
analysis. 
 
A2.2.5 ANALYSIS FOR FIGURE 5.4A 
Data were compared to the control situation in the absence of the vector pCMV-SV5α. Note 
that data are ranked according to P value. Significance at the given confidence level (0.01 or 
0.05) following calculation of the sequentially rejective Bonferroni correction is highlighted in 
grey. RLU, relative light units; P(T<=t) two-tail, P value returned by t test analysis. 
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A2.3 ANALYSIS RELATING TO CHAPTER 6 
A2.3.1 ANALYSIS FOR FIGURE 6.2B 
The size of plaques formed by the wild-type HSV-1 strain 17+ (wt) or the ∆22 or ∆ICP0 
mutants was compared separately in U2OS and Vero cells. Comparisons are shown ranked 
according to their P value. Significance at the given confidence level (0.01 or 0.05) following 
calculation of the sequentially rejective Bonferroni correction is highlighted in grey. P(T<=t) 
two-tail, P value returned by t test analysis. 
 
Raw data used in the statistical analysis are shown below; plaque size is measured in mm2. 
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